BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87. [PMID: 25069599 DOI: 10.1002/hep.27259] [Cited by in Crossref: 957] [Cited by in F6Publishing: 866] [Article Influence: 119.6] [Reference Citation Analysis]
Number Citing Articles
1 Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother 2018;62:e01249-18. [PMID: 30061289 DOI: 10.1128/AAC.01249-18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
2 Spearman CW, Dusheiko GM, Hellard M, Sonderup M. Hepatitis C. Lancet. 2019;394:1451-1466. [PMID: 31 DOI: 10.1016/s0140-6736(19)32320-7] [Cited by in Crossref: 108] [Cited by in F6Publishing: 56] [Article Influence: 2.3] [Reference Citation Analysis]
3 Kouyoumjian SP, Chemaitelly H, Abu-Raddad LJ. Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions. Sci Rep. 2018;8:1661. [PMID: 29374178 DOI: 10.1038/s41598-017-17936-4] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 17.3] [Reference Citation Analysis]
4 Jakobsen JC, Nielsen EE, Feinberg J, Fobian K, Katakam KK, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C, Jakobsen JC. Direct-acting antivirals for chronic hepatitis C. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd012143] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
5 Desombere I, Fafi-Kremer S, Van Houtte F, Pessaux P, Farhoudi A, Heydmann L, Verhoye L, Cole S, McKeating JA, Leroux-Roels G, Baumert TF, Patel AH, Meuleman P. Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. Hepatology 2016;63:1120-34. [PMID: 26710081 DOI: 10.1002/hep.28428] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
6 Wu Q, Li Z, Mellor P, Zhou Y, Anderson DH, Liu Q. The role of PTEN - HCV core interaction in hepatitis C virus replication. Sci Rep 2017;7:3695. [PMID: 28623358 DOI: 10.1038/s41598-017-03052-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
7 Ward JC, Bowyer S, Chen S, Fernandes Campos GR, Ramirez S, Bukh J, Harris M. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon. J Gen Virol 2020;101:1182-90. [PMID: 32897181 DOI: 10.1099/jgv.0.001486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Mahmud S, Akbarzadeh V, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Iran: Systematic review and meta-analyses. Sci Rep. 2018;8:150. [PMID: 29317673 DOI: 10.1038/s41598-017-18296-9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 13.3] [Reference Citation Analysis]
9 Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14:122-132. [PMID: 27924080 DOI: 10.1038/nrgastro.2016.176] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 32.7] [Reference Citation Analysis]
10 Estefan S, Brandão-Melo CE, Dos Santos Silva CM, Gomes DCK, Cardoso P, Costa MHS. Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents. Front Med (Lausanne) 2021;8:631600. [PMID: 34136497 DOI: 10.3389/fmed.2021.631600] [Reference Citation Analysis]
11 Margusino-Framiñán L, Cid-Silva P, Rotea-Salvo S, Mena-de-Cea Á, Suárez-López F, Vázquez-Rodríguez P, Delgado-Blanco M, Sanclaudio-Luhia AI, Martín-Herranz I, Castro-Iglesias Á. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Eur J Hosp Pharm 2020;27:e41-7. [PMID: 32296504 DOI: 10.1136/ejhpharm-2019-002060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Sidhu SS, Malhi NS, Goyal O, Singh R, Dutta U, Grover R, Sidhu JS, Nanda V, Saluja H, Bansal A, Singh G, Sehgal A, Kishore H, Sidhu S. Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study. Hepatol Int 2017;11:277-85. [PMID: 28361300 DOI: 10.1007/s12072-017-9794-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Karabulut N, Alacam S, Yolcu A, Onel M, Agacfidan A. Distribution of hepatitis C virus genotypes in Istanbul, Turkey. Indian J Med Microbiol 2018;36:192-6. [PMID: 30084409 DOI: 10.4103/ijmm.IJMM_17_381] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Huang QT, Hang LL, Zhong M, Gao YF, Luo ML, Yu YH. Maternal HCV infection is associated with intrauterine fetal growth disturbance: A meta-analysis of observational studies. Medicine (Baltimore) 2016;95:e4777. [PMID: 27583932 DOI: 10.1097/MD.0000000000004777] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mignogna MD, Leuci S. Interface Between Oral and Systemic Disease. In: Farah CS, Balasubramaniam R, Mccullough MJ, editors. Contemporary Oral Medicine. Cham: Springer International Publishing; 2019. pp. 67-136. [DOI: 10.1007/978-3-319-72303-7_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Klenerman P, Fitzmaurice K. An update on hepatitis C virus. Clin Med (Lond) 2015;15 Suppl 6:s33-6. [PMID: 26634679 DOI: 10.7861/clinmedicine.15-6-s33] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ikram S, Ahmad J, Rehman IU, Durdagi S. Potent novel inhibitors against hepatitis C virus NS3 (HCV NS3 GT-3a) protease domain. J Mol Graph Model 2020;101:107727. [PMID: 33027738 DOI: 10.1016/j.jmgm.2020.107727] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Faisal N, Mumtaz K, Marquez M, Renner EL, Lilly LB. High sustained virological response to pegylated interferon and ribavirin for recurrent genotype 3 hepatitis C infection post-liver transplantation. Hepatol Int. 2015;9:76-83. [PMID: 25788382 DOI: 10.1007/s12072-014-9589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
19 Gummow J, Li Y, Yu W, Garrod T, Wijesundara D, Brennan AJ, Mullick R, Voskoboinik I, Grubor-Bauk B, Gowans EJ. A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice. J Virol 2015;89:7991-8002. [PMID: 26018154 DOI: 10.1128/JVI.00803-15] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
20 Schnell G, Tripathi R, Krishnan P, Beyer J, Reisch T, Irvin M, Dekhtyar T, Setze C, Rodrigues L, Alves K, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir. J Med Virol. 2018;90:109-119. [PMID: 28842997 DOI: 10.1002/jmv.24923] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
21 Tsukiyama-Kohara K, Kohara M. Hepatitis C Virus: Viral Quasispecies and Genotypes. Int J Mol Sci 2017;19:E23. [PMID: 29271914 DOI: 10.3390/ijms19010023] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
22 Li CW, Yang CJ, Sun HY, Tsai MS, Lin SP, Lin TY, Cheng CY, Lee YC, Huang YS, Liu CE, Lee YT, Tang HJ, Wang NC, Cheng SH, Ko WC, Hung CC; Taiwan HIV Study Group. Changing seroprevalence of hepatitis C virus infection among HIV-positive patients in Taiwan. PLoS One 2018;13:e0194149. [PMID: 29547628 DOI: 10.1371/journal.pone.0194149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Xie Z, Li Y, Long L, Liang H, Cai W, Shen T. Polymorphisms in the Th17 cell-related RORC gene are associated with spontaneous clearance of HCV in Chinese women. BMC Infect Dis 2018;18:254. [PMID: 29866105 DOI: 10.1186/s12879-018-3153-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Mattar EH, Almehdar HA, Uversky VN, Redwan EM. Virucidal activity of human α- and β-defensins against hepatitis C virus genotype 4. Mol Biosyst 2016;12:2785-97. [PMID: 27327492 DOI: 10.1039/c6mb00283h] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
25 Kelly L, Badhan A, Roberts GC, Mbisa JL, Harris M. Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon. J Gen Virol 2017;98:2495-506. [PMID: 28984238 DOI: 10.1099/jgv.0.000932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
26 Saha B, Kodys K, Adejumo A, Szabo G. Circulating and Exosome-Packaged Hepatitis C Single-Stranded RNA Induce Monocyte Differentiation via TLR7/8 to Polarized Macrophages and Fibrocytes. J Immunol 2017;198:1974-84. [PMID: 28122964 DOI: 10.4049/jimmunol.1600797] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
27 Di Stefano M, Ismail MH, Leitner T, Faleo G, Elmnan Adem SA, Elamin MOME, Eltreifi O, Alwazzeh MJ, Fiore JR, Santantonio TA. Genetic Subtypes and Natural Resistance Mutations in HCV Genotype 4 Infected Saudi Arabian Patients. Viruses 2021;13:1832. [PMID: 34578414 DOI: 10.3390/v13091832] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Salas-villalobos T, Lozano-sepúlveda S, Rincón-sánchez A, Govea-salas M, Rivas-estilla A. Mechanisms involved in liver damage resolution after hepatitis C virus clearance. Medicina Universitaria 2017;19:100-7. [DOI: 10.1016/j.rmu.2017.05.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
29 Lu NT, Liu NM, Patel D, Vu JQ, Liu L, Kim CY, Cho P, Khachatoorian R, Patel N, Magyar CE, Ganapathy E, Arumugaswami V, Dasgupta A, French SW. Oncoprotein Stathmin Modulates Sensitivity to Apoptosis in Hepatocellular Carcinoma Cells During Hepatitis C Viral Replication. J Cell Death 2018;11:1179066018785141. [PMID: 30034249 DOI: 10.1177/1179066018785141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 El-Bendary M, Neamatallah M, Elalfy H, Besheer T, Kamel E, Mousa H, Eladl AH, El-Setouhy M, El-Gilany AH, El-Waseef A, Esmat G. HLA Class II-DRB1 Alleles with Hepatitis C Virus Infection Outcome in Egypt: A Multicentre Family-based Study. Ann Hepatol. 2019;18:68-77. [PMID: 31113612 DOI: 10.5604/01.3001.0012.7864] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
31 Bailey H, Nizova N, Martsynovska V, Volokha A, Malyuta R, Cortina-Borja M, Thorne C; Ukraine European Collaborative Study in EuroCoord. HCV co-infection and markers of liver injury and fibrosis among HIV-positive childbearing women in Ukraine: results from a cohort study. BMC Infect Dis 2016;16:755. [PMID: 27955711 DOI: 10.1186/s12879-016-2089-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
32 Lozano-sepulveda S, Bryan-marrugo O, Merino-mascorro J, Rivas-estilla AM. Approachability to the new anti-HCV direct acting antiviral agents in the Latin American context. Future Virology 2016;11:39-46. [DOI: 10.2217/fvl.15.97] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Hongjaisee S, Doungjinda N, Khamduang W, Carraway TS, Wipasa J, Debes JD, Supparatpinyo K. Rapid visual detection of hepatitis C virus using a reverse transcription loop-mediated isothermal amplification assay. Int J Infect Dis 2021;102:440-5. [PMID: 33130211 DOI: 10.1016/j.ijid.2020.10.082] [Reference Citation Analysis]
34 O'Brien TR, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. Gastroenterology 2019;156:400-17. [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
35 Maaroufi A, Vince A, Himatt SM, Mohamed R, Fung J, Opare-Sem O, Workneh A, Njouom R, Al Ghazzawi I, Abdulla M, Kaliaskarova KS, Owusu-Ofori S, Abdelmageed MK, Adda D, Akin O, Al Baqali A, Al Dweik N, Al Ejji K, Al Kaabi S, Al Naamani K, Al Qamish J, Al Sadadi M, Al Salman J, AlBadri M, Al-Busafi SA, Al-Romaihi HE, Ampofo W, Antonov K, Anyaike C, Arome F, Bane A, Blach S, Borodo MM, Brandon SM, Bright B, Butt MT, Cardenas I, Chan HLY, Chen CJ, Chen DS, Chen PJ, Chien RN, Chuang WL, Cuellar D, Derbala M, Elbardiny AA, Estes C, Farag E, Gamkrelidze I, Garcia V, Genov J, Ghandour Z, Ghuloom M, Gomez B, Gunter J, Habeeb J, Hajelssedig O, Hamoudi W, Hrstic I, Hu CC, Huang CF, Hui YT, Jahis R, Jelev D, John AK, Kamel Y, Kao JH, Khamis J, Khattabi H, Khoudri I, Konysbekova A, Kotzev I, Lai MS, Lao WC, Layden J, Lee MH, Lesi O, Li M, Lo A, Loo CK, Lukšić B, Malu AO, Mateva L, Mitova R, Morović M, Murphy K, Mustapha B, Nde H, Nersesov A, Ngige E, Njoya O, Nonković D, Obekpa S, Oguche S, Okolo EE, Omede O, Omuemu C, Ondoa P, Phillips RO, Prokopenko YN, Razavi H, Razavi-Shearer D, Redae B, Reic T, Rinke de Wit T, Rios C, Robbins S, Roberts LR, Sanad SJ, Schmelzer JD, Sharma M, Simonova M, Su TH, Sultan K, Tan SS, Tchernev K, Tsang OTY, Tsang S, Tzeuton C, Ugoeze S, Uzochukwu B, Vi R, Wani HU, Wong VWS, Yacoub R, Yesmembetov KI, Youbi M, Yuen MF, Razavi-Shearer K. Historical epidemiology of hepatitis C virus in select countries-volume 4. J Viral Hepat 2017;24 Suppl 2:8-24. [PMID: 29105285 DOI: 10.1111/jvh.12762] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
36 Lozano-Sepulveda SA, Bryan-Marrugo OL, Cordova-Fletes C, Gutierrez-Ruiz MC, Rivas-Estilla AM. Oxidative stress modulation in hepatitis C virus infected cells. World J Hepatol 2015; 7(29): 2880-2889 [PMID: 26692473 DOI: 10.4254/wjh.v7.i29.2880] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 3.7] [Reference Citation Analysis]
37 Walker MR, Li H, Teutsch S, Betz-Stablein B, Luciani F, Lloyd AR, Bull RA. Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. J Clin Microbiol 2016;54:1855-61. [PMID: 27170021 DOI: 10.1128/JCM.00287-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
38 Aguilera A, Navarro D, Rodríguez-Frias F, Viciana I, Martínez-Sapiña AM, Rodríguez MJ, Martró E, Lozano MC, Coletta E, Cardeñoso L, Suárez A, Trigo M, Rodríguez-Granjer J, Montiel N, de la Iglesia A, Alados JC, Vegas C, Bernal S, Fernández-Cuenca F, Pena MJ, Reina G, García-Bujalance S, Echevarria MJ, Benítez L, Pérez-Castro S, Ocete D, García-Arata I, Guerrero C, Rodríguez-Iglesias M, Casas P, García F. Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (the GEHEP 005 study). J Viral Hepat 2017;24:725-32. [PMID: 28248445 DOI: 10.1111/jvh.12700] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
39 Pollmann J, Rölle A, Hofmann M, Cerwenka A. Hepatitis C Virus and Human Cytomegalovirus-Natural Killer Cell Subsets in Persistent Viral Infections. Front Immunol 2017;8:566. [PMID: 28567042 DOI: 10.3389/fimmu.2017.00566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
40 Huang YC, Huang CF, Liu SF, Liu HY, Yeh ML, Huang CI, Hsieh MH, Dai CY, Chen SC, Yu ML, Chuang WL, Huang JF. The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. PLoS One 2021;16:e0246376. [PMID: 33513184 DOI: 10.1371/journal.pone.0246376] [Reference Citation Analysis]
41 Lee MH, Hsiao TI, Subramaniam SR, Le AK, Vu VD, Trinh HN, Zhang J, Jin M, Wong VW, Wong GL, Nguyen MH. HCV Genotype 6 Increased the Risk for Hepatocellular Carcinoma Among Asian Patients With Liver Cirrhosis. Am J Gastroenterol. 2017;112:1111-1119. [PMID: 28440303 DOI: 10.1038/ajg.2017.123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
42 Ahmadi-Ghezeldasht S, Badiei Z, Sima HR, Hedayati-Moghaddam MR, Habibi M, Khamooshi M, Azimi A. Distribution of Hepatitis C Virus Genotypes in Patients with Major β-Thalassemia in Mashhad, Northeast Iran. Middle East J Dig Dis 2018;10:35-9. [PMID: 29682246 DOI: 10.15171/mejdd.2017.88] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Thézé J, Lowes S, Parker J, Pybus OG. Evolutionary and Phylogenetic Analysis of the Hepaciviruses and Pegiviruses. Genome Biol Evol 2015;7:2996-3008. [PMID: 26494702 DOI: 10.1093/gbe/evv202] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 6.0] [Reference Citation Analysis]
44 Nakayama M, Kobayashi H, Fukushima K, Ishido M, Komada Y, Yoshizawa K. Predictive factors for 24 weeks sustained virologic response (SVR24) and viral relapse in patients treated with simeprevir plus peginterferon and ribavirin. Hepatol Int 2016;10:158-68. [PMID: 26264253 DOI: 10.1007/s12072-015-9654-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
45 Janardhan SV, Reau NS. Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies? Hepat Med 2015;7:11-20. [PMID: 25926761 DOI: 10.2147/HMER.S79584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Palladino C, Ezeonwumelu IJ, Marcelino R, Briz V, Moranguinho I, Serejo F, Velosa JF, Marinho RT, Borrego P, Taveira N. Epidemic history of hepatitis C virus genotypes and subtypes in Portugal. Sci Rep. 2018;8:12266. [PMID: 30116054 DOI: 10.1038/s41598-018-30528-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
47 Matthew AN, Leidner F, Newton A, Petropoulos CJ, Huang W, Ali A, KurtYilmaz N, Schiffer CA. Molecular Mechanism of Resistance in a Clinically Significant Double-Mutant Variant of HCV NS3/4A Protease. Structure 2018;26:1360-1372.e5. [PMID: 30146168 DOI: 10.1016/j.str.2018.07.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
48 Hampton H, Farrington E, Ellery A, Mckenna M, Stableforth W, Hussaini H. Community hepatitis C treatment in Cornwall: a model to improve care. Gastrointestinal Nursing 2015;13:S17-21. [DOI: 10.12968/gasn.2015.13.sup5.s17] [Cited by in Crossref: 4] [Article Influence: 0.6] [Reference Citation Analysis]
49 Younossi ZM, Chan HLY, Dan YY, Lee MH, Lim YS, Kruger E, Tan SC. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat. 2018;25:228-235. [PMID: 29053909 DOI: 10.1111/jvh.12808] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
50 Manuel Sousa J, Vergara M, Pulido F, Sánchez Antolín G, Hijona L, Carnicer F, Rincón D, Salmerón J, Mateos-Muñoz B, Jou A, Polo-Lorduy B, Rubín Á, Escarda A, Aguilar P, Aldámiz-Echevarría T, García-Buey L, Carrión JA, Hernández-Guerra M, Chimeno-Hernández S, Espinosa N, Morillas RM, Andrade RJ, Delgado M, Gallego A, Magaz M, Moreno-Planas JM, Estébanez Á, Rico M, Menéndez F, Sampedro B, Morano L, Izquierdo S, Zozaya JM, Rodríguez M, Morán-Sánchez S, Lorente S, Martín-Granizo I, Von-Wichmann MÁ, Delgado M, Manzanares A. Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain. PLoS One 2019;14:e0225061. [PMID: 31714950 DOI: 10.1371/journal.pone.0225061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Omar H, El Akel W, Elbaz T, El Kassas M, Elsaeed K, El Shazly H, Said M, Yousif M, Gomaa AA, Nasr A, AbdAllah M, Korany M, Ismail SA, Shaker MK, Doss W, Esmat G, Waked I, El Shazly Y. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018;47:421-431. [PMID: 29193226 DOI: 10.1111/apt.14428] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 10.6] [Reference Citation Analysis]
52 Schnell G, Tripathi R, Beyer J, Reisch T, Krishnan P, Dekhtyar T, Irvin M, Hall C, Yu Y, Mobashery N, Redman R, Pilot-Matias T, Collins C. Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir. J Viral Hepat 2018;25:1078-88. [PMID: 29624809 DOI: 10.1111/jvh.12906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
53 Chen M, Ma Y, Chen H, Dai J, Luo H, Jia M, Song Z. Complete genome sequencing and evolutionary analysis of HCV subtype 6xg from IDUs in Yunnan, China. PLoS One 2019;14:e0217010. [PMID: 31095618 DOI: 10.1371/journal.pone.0217010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Bartolini B, Giombini E, Taibi C, Lionetti R, Montalbano M, Visco-Comandini U, D'Offizi G, Capobianchi MR, McPhee F, Garbuglia AR. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents. Viruses 2017;9:E212. [PMID: 28783119 DOI: 10.3390/v9080212] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
55 Kati W, Koev G, Irvin M, Beyer J, Liu Y, Krishnan P, Reisch T, Mondal R, Wagner R, Molla A. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015;59:1505-1511. [PMID: 25534735 DOI: 10.1128/aac.04619-14] [Cited by in Crossref: 79] [Cited by in F6Publishing: 42] [Article Influence: 9.9] [Reference Citation Analysis]
56 Palenzuela Gardón D, Guillen IA, Fernández JR, Camacho H, Estevez ZC, Dueñas S, Alvares-Lajonchere L, Amador Y, Martinez-Donato G, Han J, Zhang Z, Zhang X, Gao Y, Campaña JR, Novoa LI. Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. J Biomol Tech 2017;28:80-6. [PMID: 28058039 DOI: 10.7171/jbt.17-2801-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
57 Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral therapy in patients with recurrent HCV infection after liver transplant: A real-life experience. Ann Hepatol 2019;18:450-5. [PMID: 31028014 DOI: 10.1016/j.aohep.2018.09.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
58 Mensa FJ, Lovell S, Pilot-Matias T, Liu W. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection. Future Microbiol 2019;14:89-110. [PMID: 30499343 DOI: 10.2217/fmb-2018-0233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
59 Younossi ZM, Park H, Dieterich D, Saab S, Ahmed A, Gordon SC. The value of cure associated with treating treatment-naïve chronic hepatitis C genotype 1: Are the new all-oral regimens good value to society? Liver Int 2017;37:662-8. [PMID: 27804195 DOI: 10.1111/liv.13298] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
60 Vermehren J, Stelzl E, Maasoumy B, Michel-Treil V, Berkowski C, Marins EG, Paxinos EE, Marino E, Wedemeyer H, Sarrazin C, Kessler HH. Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms. J Clin Microbiol 2017;55:1131-9. [PMID: 28122870 DOI: 10.1128/JCM.02193-16] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
61 Ryder S, Pett S, Cooke GS. Genotype 4 and the global challenge of hepatitis C treatment. Lancet Gastroenterol Hepatol 2016;1:3-4. [PMID: 28404109 DOI: 10.1016/S2468-1253(16)30006-1] [Reference Citation Analysis]
62 Dussaq AM, Soni A, Willey C, Park SL, Harada S. Hepatitis C Virus Genie: A Web 2.0 Interpretation and Analytics Platform for the Versant Hepatitis C Virus Genotype Line Probe Assay Version 2.0. J Pathol Inform 2017;8:41. [PMID: 29114435 DOI: 10.4103/jpi.jpi_44_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
63 Pan YF, Zheng Y, Qin T, Feng L, Zhang Q, Ping XG, Pan YT, Wang XP, Bai L, Li HH. Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion. Exp Ther Med. 2016;12:3476-3484. [PMID: 27882182 DOI: 10.3892/etm.2016.3792] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
64 Stepanova M, Younossi ZM. Economic Burden of Hepatitis C Infection. Clin Liver Dis. 2017;21:579-594. [PMID: 28689595 DOI: 10.1016/j.cld.2017.03.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
65 Plissonnier ML, Lahlali T, Raab M, Michelet M, Romero-López C, Rivoire M, Strebhardt K, Durantel D, Levrero M, Mehlen P, Zoulim F, Parent R. Reciprocal antagonism between the netrin-1 receptor uncoordinated-phenotype-5A (UNC5A) and the hepatitis C virus. Oncogene 2017;36:6712-24. [PMID: 28783179 DOI: 10.1038/onc.2017.271] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
66 Séron K, Sahuc M, Rouillé Y. Natural Products and Hepatitis C Virus. In: Mérillon J, Riviere C, editors. Natural Antimicrobial Agents. Cham: Springer International Publishing; 2018. pp. 289-327. [DOI: 10.1007/978-3-319-67045-4_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Mohammed AS, Balapure A, Khan AA, Khaja MN, Ganesan R, Dutta JR. Genotyping simplified: rationally designed antisense oligonucleotide-mediated PCR amplification-free colorimetric sensing of viral RNA in HCV genotypes 1 and 3. Analyst 2021;146:4767-74. [PMID: 34231566 DOI: 10.1039/d1an00590a] [Reference Citation Analysis]
68 Danilau D, Litvinchuk D, Solovey N, Krasko O, Karpov I. Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype. Clin Exp Hepatol 2017;3:16-22. [PMID: 28856285 DOI: 10.5114/ceh.2017.65279] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
69 Steinebrunner N, Stein K, Sandig C, Bruckner T, Stremmel W, Pathil A. Predictors of functional benefit of hepatitis C therapy in a ‘real-life’ cohort. World J Gastroenterol 2018; 24(7): 852-861 [PMID: 29467555 DOI: 10.3748/wjg.v24.i7.852] [Reference Citation Analysis]
70 Aziz H, Fatima S, Faheem M. Indeterminate Prediction of Hepatitis C Virus Genotype by Commercial Real-Time Polymerase Chain Reaction Assay Resolving by Sequencing to Avoid the Consequence of Inaccurate Typing. Viral Immunol 2020;33:507-13. [PMID: 32429831 DOI: 10.1089/vim.2019.0162] [Reference Citation Analysis]
71 Ulveling D, Le Clerc S, Cobat A, Labib T, Noirel J, Laville V, Coulonges C, Carpentier W, Nalpas B, Heim MH, Poynard T, Cerny A, Pol S, Bochud PY, Dabis F, Theodorou I, Lévy Y, Salmon D, Abel L, Dominguez S, Zagury JF; HEPAVIH ANRS CO13 Cohort Study Group., Swiss Hepatitis C Cohort Study Group., French ANRS HC EP 26 Genoscan Study Group. A new 3p25 locus is associated with liver fibrosis progression in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2016;64:1462-72. [PMID: 27339598 DOI: 10.1002/hep.28695] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
72 Behzadi MA, Alborzi A, Pouladfar G, Dianatpour M, Ziyaeyan M. Expression of NS3/NS4A Proteins of Hepatitis C Virus in Huh7 Cells Following Engineering Its Eukaryotic Expression Vector. Jundishapur J Microbiol 2015;8:e27355. [PMID: 26862385 DOI: 10.5812/jjm.27355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
73 Barros MMO, Ronchini KROM, Soares RLS. HEPATITIS B AND C IN PREGNANT WOMEN ATTENDED BY A PRENATAL PROGRAM IN AN UNIVERSITARY HOSPITAL IN RIO DE JANEIRO, BRAZIL: RETROSPECTIVE STUDY OF SEROPREVALENCE SCREENING. Arq Gastroenterol 2018;55:267-73. [PMID: 30540090 DOI: 10.1590/S0004-2803.201800000-68] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
74 Abou Rached A, Yaghi C, Khalil L, Saba J, Ammar W. Prevalence of hepatitis C virus genotypes and subtypes in Lebanese population and major high risk groups. Arab J Gastroenterol 2017;18:114-7. [PMID: 28579342 DOI: 10.1016/j.ajg.2017.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
75 Hai T, Zou LQ. Clinical management and susceptibility of primary hepatic lymphoma: A cases-based retrospective study. World J Clin Cases 2021; 9(31): 9417-9430 [PMID: 34877277 DOI: 10.12998/wjcc.v9.i31.9417] [Reference Citation Analysis]
76 Jamil Z, Waheed Y, Malik M, Durrani AA. Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study. PeerJ 2018;6:e4853. [PMID: 29844992 DOI: 10.7717/peerj.4853] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
77 Walker A, Kaiser R, Bartenschlager R, Timm J. Genotypic resistance testing of HCV - is there a clinical need? GMS Infect Dis 2016;4:Doc05. [PMID: 30671319 DOI: 10.3205/id000023] [Reference Citation Analysis]
78 Salemovic D, Pesic-Pavlovic I, Jevtovic D, Bojovic K, Ranin J, Brmbolic B, Stanojevic M. Intravenous drug use - an independent predictor for HCV genotypes 3 and 4 infection among HIV/HCV co-infected patients. Arch Med Sci. 2017;13:652-658. [PMID: 28507583 DOI: 10.5114/aoms.2017.66022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
79 Wadood M, Usman M. Comparative Analysis of Electrochemiluminescence Assay and Chemiluminescent Microparticle Immunoassay for the Screening of Hepatitis C. Indian J Hematol Blood Transfus 2019;35:131-6. [PMID: 30828160 DOI: 10.1007/s12288-018-0968-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
80 Esteban R, Buti M. Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp? Gastroenterology 2015;149:1326-30. [PMID: 26416329 DOI: 10.1053/j.gastro.2015.09.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
81 Nguyen LT, Van Nguyen D, Carr MJ, Hall WW, Nguyen LA. Association of interferon lambda polymorphisms with elevated baseline viral loads in chronic hepatitis C virus genotype 6 infection. Arch Virol 2018;163:115-24. [PMID: 29022122 DOI: 10.1007/s00705-017-3583-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
82 Thomson E, Ip CL, Badhan A, Christiansen MT, Adamson W, Ansari MA, Bibby D, Breuer J, Brown A, Bowden R, Bryant J, Bonsall D, Da Silva Filipe A, Hinds C, Hudson E, Klenerman P, Lythgow K, Mbisa JL, McLauchlan J, Myers R, Piazza P, Roy S, Trebes A, Sreenu VB, Witteveldt J, Barnes E, Simmonds P; STOP-HCV Consortium. Comparison of Next-Generation Sequencing Technologies for Comprehensive Assessment of Full-Length Hepatitis C Viral Genomes. J Clin Microbiol 2016;54:2470-84. [PMID: 27385709 DOI: 10.1128/JCM.00330-16] [Cited by in Crossref: 79] [Cited by in F6Publishing: 44] [Article Influence: 13.2] [Reference Citation Analysis]
83 Sokal E, Nannini P. Hepatitis C virus in children: the global picture. Arch Dis Child. 2017;102:668-671. [PMID: 28473309 DOI: 10.1136/archdischild-2017-312708] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
84 Sedeño-Monge V, Laguna-Meraz S, Santos-López G, Panduro A, Sosa-Jurado F, Jose-Abrego A, Meléndez-Mena D, Muñoz-Ramírez MA, Cosme-Chávez M, Roman S. A comprehensive update of the status of hepatitis C virus (HCV) infection in Mexico-A systematic review and meta-analysis (2008-2019). Ann Hepatol 2021;20:100292. [PMID: 33259949 DOI: 10.1016/j.aohep.2020.100292] [Reference Citation Analysis]
85 McGowan DC, Khamlichi MD, De Groot A, Pauwels F, Delouvroy F, Van Emelen K, Simmen K, Raboisson P. Synthesis and evaluation of novel HCV replication inhibitors. Mol Divers 2017;21:475-81. [PMID: 28293834 DOI: 10.1007/s11030-017-9733-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
86 Gentile I, Maraolo AE, Niola M, Graziano V, Borgia G, Paternoster M. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma. Expert Review of Gastroenterology & Hepatology 2016;10:1227-34. [DOI: 10.1080/17474124.2016.1234375] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
87 Ng TI, Tripathi R, Reisch T, Lu L, Middleton T, Hopkins TA, Pithawalla R, Irvin M, Dekhtyar T, Krishnan P, Schnell G, Beyer J, McDaniel KF, Ma J, Wang G, Jiang LJ, Or YS, Kempf D, Pilot-Matias T, Collins C. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother 2018;62:e01620-17. [PMID: 29084747 DOI: 10.1128/AAC.01620-17] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
88 Flisiak R, Kawazoe S, Znoyko O, Assy N, Gadano A, Kao J, Lee K, Zwirtes R, Portsmouth S, Dong Y, Xu D, Kumada H, Srinivasan S. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b. Journal of Interferon & Cytokine Research 2016;36:635-43. [DOI: 10.1089/jir.2015.0173] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
89 Oluremi AS, Opaleye OO, Ogbolu DO, Alli OAT, Adeola O, Alaka O, Ogunleke OA, Ojo A, Bello MD, Enitan SS, Adediji IO, Adelakun AA, Suleiman IE. High Viral Hepatitis Infection among Pregnant Women Attending Antenatal Clinic in Adeoyo Maternity Teaching Hospital Ibadan (AMTHI) Oyo State, Nigeria. J Immunoassay Immunochem 2020;41:913-23. [PMID: 32835616 DOI: 10.1080/15321819.2020.1807358] [Reference Citation Analysis]
90 Xiao S, Tian Z, Wang Y, Si L, Zhang L, Zhou D. Recent progress in the antiviral activity and mechanism study of pentacyclic triterpenoids and their derivatives. Med Res Rev 2018;38:951-76. [PMID: 29350407 DOI: 10.1002/med.21484] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 15.5] [Reference Citation Analysis]
91 Baumert TF, Berg T, Lim JK, Nelson DR. Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges. Gastroenterology 2019;156:431-45. [PMID: 30342035 DOI: 10.1053/j.gastro.2018.10.024] [Cited by in Crossref: 60] [Cited by in F6Publishing: 56] [Article Influence: 15.0] [Reference Citation Analysis]
92 Naz Z, Wahid B, Usman S, Saleem K, Rafique S, Ali A, Idrees M. Expression of SOCS1 and SOCS3 Genes in Interferon-Treated and Direct-Acting Antiviral Drugs-Treated Hepatitis C Patients. J Interferon Cytokine Res 2018;38:255-60. [PMID: 29920131 DOI: 10.1089/jir.2017.0138] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
93 Poordad F, Landis CS, Asatryan A, Jackson DF 3rd, Ng TI, Fu B, Lin CW, Yao B, Kort J. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int 2016;36:1125-32. [PMID: 26778412 DOI: 10.1111/liv.13067] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
94 Patra T, Sasaki R, Meyer K, Ray RB, Ray R. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections. J Virol 2019;93:e00811-19. [PMID: 31243135 DOI: 10.1128/JVI.00811-19] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
95 Giannakopoulou E, Pardali V, Frakolaki E, Siozos V, Myrianthopoulos V, Mikros E, Taylor MC, Kelly JM, Vassilaki N, Zoidis G. Scaffold hybridization strategy towards potent hydroxamate-based inhibitors of Flaviviridae viruses and Trypanosoma species. Medchemcomm 2019;10:991-1006. [PMID: 31303998 DOI: 10.1039/c9md00200f] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Colomba GME, Urone N, Marco VD, Ferraro D. Phylodynamic Analysis and Implication of HCV Genotype 4 Variability on Antiviral Drug Response and T-Cell Recognition. Viruses 2020;12:E1363. [PMID: 33260596 DOI: 10.3390/v12121363] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Nouroz F, Shaheen S, Mujtaba G, Noreen S. An overview on hepatitis C virus genotypes and its control. Egyptian Journal of Medical Human Genetics 2015;16:291-8. [DOI: 10.1016/j.ejmhg.2015.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.1] [Reference Citation Analysis]
98 Moosavy SH, Davoodian P, Nazarnezhad MA, Nejatizaheh A, Eftekhar E, Mahboobi H. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician 2017;9:5646-56. [PMID: 29238510 DOI: 10.19082/5646] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
99 Yu ML, Tsai WL, Chu CJ, Kao JH. Characteristics of patients with hepatitis C virus infection and antiviral treatment initiation in Taiwan: The MOSAIC study. Kaohsiung J Med Sci 2021;37:245-52. [PMID: 33089964 DOI: 10.1002/kjm2.12317] [Reference Citation Analysis]
100 Tang Q, Wei L, Liu X, Hu P. Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience. Infect Drug Resist 2021;14:2297-307. [PMID: 34188496 DOI: 10.2147/IDR.S312902] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Wyles DL. Resistance to DAAs: When to Look and When It Matters. Curr HIV/AIDS Rep. 2017;14:229-237. [PMID: 29116550 DOI: 10.1007/s11904-017-0369-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
102 Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L; ANRS HC32 QUATTRO study group. Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study. Eur J Gastroenterol Hepatol 2018;30:302-9. [PMID: 29271782 DOI: 10.1097/MEG.0000000000001035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, Awni WM, Menon RM, Dutta S. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol 2017;83:527-39. [PMID: 27662429 DOI: 10.1111/bcp.13138] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
104 Prakash S, Shukla S, Ramakrishna V, Jain A. Distribution of hepatitis C genotypes in Uttar Pradesh, India; rare genotype 4 detected. J Med Virol 2018;90:1875-81. [PMID: 30085356 DOI: 10.1002/jmv.25277] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
105 Spitz N, Barros JJ, do Ó KM, Brandão-Mello CE, Araujo NM. The First Complete Genome Sequences of Hepatitis C Virus Subtype 2b from Latin America: Molecular Characterization and Phylogeographic Analysis. Viruses 2019;11:E1000. [PMID: 31683566 DOI: 10.3390/v11111000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
106 Kao CC, Yi G, Huang HC. The core of hepatitis C virus pathogenesis. Curr Opin Virol. 2016;17:66-73. [PMID: 26851516 DOI: 10.1016/j.coviro.2016.01.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
107 Irekeola AA, Malek NA, Wada Y, Mustaffa N, Muhamad NI, Shueb RH. Prevalence of HCV genotypes and subtypes in Southeast Asia: A systematic review and meta-analysis. PLoS One 2021;16:e0251673. [PMID: 34014997 DOI: 10.1371/journal.pone.0251673] [Reference Citation Analysis]
108 Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis 2016;16:459-64. [PMID: 26803446 DOI: 10.1016/S1473-3099(15)00529-0] [Cited by in Crossref: 71] [Cited by in F6Publishing: 26] [Article Influence: 11.8] [Reference Citation Analysis]
109 Chirikov VV, Marx SE, Manthena SR, Strezewski JP, Saab S. Development of a Comprehensive Dataset of Hepatitis C Patients and Examination of Disease Epidemiology in the United States, 2013–2016. Adv Ther 2018;35:1087-102. [DOI: 10.1007/s12325-018-0721-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
110 Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon KG, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 2018;90:304-12. [PMID: 28710853 DOI: 10.1002/jmv.24903] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
111 Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389-397. [PMID: 28128852 DOI: 10.1002/hep.29081] [Cited by in Crossref: 135] [Cited by in F6Publishing: 116] [Article Influence: 27.0] [Reference Citation Analysis]
112 Brieva T, Rivero A, Rivero-Juarez A. Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol. 2017;13:483-490. [PMID: 28165830 DOI: 10.1080/17425255.2017.1292253] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
113 El-Shabrawi M, Baroudy S, Hassanin F, Behairy AS, Yakoot M, Ahmed A. Follow-up of chronic paediatric hepatitis C virus in a low-/middle-income country. Acta Paediatr 2020;109:2699-705. [PMID: 32358871 DOI: 10.1111/apa.15333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, Hill A. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology. 2015;61:1174-1182. [PMID: 25482139 DOI: 10.1002/hep.27641] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
115 Alghamdi AS, Alghamdi M, Sanai FM, Alghamdi H, Aba-Alkhail F, Alswat K, Babatin M, Alqutub A, Altraif I, Alfaleh F. SASLT guidelines: Update in treatment of Hepatitis C virus infection. Saudi J Gastroenterol 2016;22 Suppl:S25-57. [PMID: 27538727 DOI: 10.4103/1319-3767.188067] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
116 Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol 2016;64:301-7. [PMID: 26476290 DOI: 10.1016/j.jhep.2015.10.005] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 16.0] [Reference Citation Analysis]
117 Kaddah MMY, Talaat W, El Demellawy MA. Determination and structural characterization of ravidasvir metabolites by LC coupled to triple quadrupole linear ion trap MS: Application to pharmacokinetics and phase I metabolism in rats. Biomed Chromatogr 2021;35:e5146. [PMID: 33893663 DOI: 10.1002/bmc.5146] [Reference Citation Analysis]
118 Hua R, Jiang X, Qi L, Guan S, Kuai Z, Qiao Y, Xu Y, Gong X, Shi Y, Kong W, Niu J, Zhang H, Shan Y. Screening HCV genotype-specific epitope peptides based on conserved sequence analysis and B cell epitope prediction in HCV E2 region. Immunol Res 2018;66:67-73. [PMID: 29151181 DOI: 10.1007/s12026-017-8962-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Garagiola E, Ferrario L, Croce D, Menzaghi B, Quirino T, Rizzardini G, Foglia E. HCV novel therapeutic regimens in Wonderland: A budget impact analysis in the Lombardy Region. Digestive and Liver Disease 2016;48:1200-7. [DOI: 10.1016/j.dld.2016.06.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
120 Wedemeyer H. Towards interferon-free treatment for all HCV genotypes. Lancet 2015;385:2443-5. [PMID: 25837828 DOI: 10.1016/S0140-6736(15)60605-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
121 Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol 2016;13:11-35. [PMID: 25544499 DOI: 10.1038/cmi.2014.127] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 7.6] [Reference Citation Analysis]
122 Balaraju T, Konreddy AK, Parveen A, Toyama M, Ito W, Karampuri S, Baba M, Sharon A, Bal C. Synthesis and anti-HCV determinant motif identification in pyranone carboxamide scaffold. Bioorganic & Medicinal Chemistry Letters 2015;25:5224-7. [DOI: 10.1016/j.bmcl.2015.09.060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
123 Roger S, Ducancelle A, Le Guillou-Guillemette H, Gaudy C, Lunel F. HCV virology and diagnosis. Clin Res Hepatol Gastroenterol 2021;45:101626. [PMID: 33636428 DOI: 10.1016/j.clinre.2021.101626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
124 Zhang X, Zhu C, Wang T, Jiang H, Ren Y, Zhang Q, Wu K, Liu F, Liu Y, Wu J. GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation. PLoS Pathog 2017;13:e1006321. [PMID: 28394926 DOI: 10.1371/journal.ppat.1006321] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
125 Yang L, Jiang C, Hu S, Diao Q, Li J, Si W, Chen M, Zhao RY. Evolving Diversity of Hepatitis C Viruses in Yunnan Honghe, China. Int J Mol Sci 2016;17:403. [PMID: 26999127 DOI: 10.3390/ijms17030403] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
126 Saludes V, Quer J, Gregori J, Bascuñana E, García-Cehic D, Esteban JI, Ausina V, Martró E. Identification of hepatitis C virus genotype 3 by a commercial assay challenged by natural polymorphisms detected in Spain from patients with diverse origins. J Clin Virol 2016;78:14-9. [PMID: 26946155 DOI: 10.1016/j.jcv.2016.02.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
127 Mukherjee TI, Pillai V, Ali SH, Altice FL, Kamarulzaman A, Wickersham JA. Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. Int J Drug Policy 2017;47:144-52. [PMID: 28652072 DOI: 10.1016/j.drugpo.2017.05.041] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
128 Lin SK, De Maio N, Pedergnana V, Wu CH, Thézé J, Wilson DJ, Barnes E, Ansari MA. Using host genetics to infer the global spread and evolutionary history of HCV subtype 3a. Virus Evol 2021;7:veab065. [PMID: 34532064 DOI: 10.1093/ve/veab065] [Reference Citation Analysis]
129 Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Marenco S, Nosotti L, Giannelli V, Siciliano M, Romagnoli D, Pellicelli A, Vecchiet J, Magni CF, Babudieri S, Mura MS, Taliani G, Mastroianni C, Vespasiani-gentilucci U, Romano M, Morisco F, Gasbarrini A, Vullo V, Bruno S, Baiguera C, Pasquazzi C, Tisone G, Picciotto A, Andreoni M, Parruti G, Rizzardini G, Angelico M, Perno CF, Ceccherini-silberstein F. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. J Antimicrob Chemother 2016;71:739-50. [DOI: 10.1093/jac/dkv403] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
130 Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol. 2014;Epub ahead of print. [PMID: 25544499 DOI: 10.1038/cmi.2014.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
131 Mandoh SS, Ayman K, Elbardakheny A, Raaft H, Ibrahim AA, Alshaikh RA, Mansour FR. A cross sectional study of the risk factors of hepatitis C infection in North Egypt. Virusdisease 2021;32:22-8. [PMID: 33969153 DOI: 10.1007/s13337-020-00639-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
132 Warkad SD, Nimse SB, Song KS, Kim T. Development of a Method for Screening and Genotyping of HCV 1a, 1b, 2, 3, 4, and 6 Genotypes. ACS Omega 2020;5:10794-9. [PMID: 32455199 DOI: 10.1021/acsomega.0c00386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
133 Nguyen DT, Tran TTT, Nghiem NM, Le PT, Vo QM, Day J, Rahman M, Le HM. Effectiveness of sofosbuvir based direct-acting antiviral regimens for chronic hepatitis C virus genotype 6 patients: Real-world experience in Vietnam. PLoS One 2020;15:e0233446. [PMID: 32433676 DOI: 10.1371/journal.pone.0233446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Yasseen AS 3rd, Kwong JC, Feld JJ, Janjua NZ, Greenaway C, Lapointe-Shaw L, Sherman M, Mazzulli T, Kustra R, MacDonald L, Sander B, Crowcroft NS. Viral hepatitis C cascade of care: A population-level comparison of immigrant and long-term residents. Liver Int 2021;41:1775-88. [PMID: 33655665 DOI: 10.1111/liv.14840] [Reference Citation Analysis]
135 Mokhtari C, Ebel A, Reinhardt B, Merlin S, Proust S, Roque-Afonso AM. Characterization of Samples Identified as Hepatitis C Virus Genotype 1 without Subtype by Abbott RealTime HCV Genotype II Assay Using the New Abbott HCV Genotype Plus RUO Test. J Clin Microbiol 2016;54:296-9. [PMID: 26582834 DOI: 10.1128/JCM.02264-15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
136 Tzarum N, Wilson IA, Law M. The Neutralizing Face of Hepatitis C Virus E2 Envelope Glycoprotein. Front Immunol 2018;9:1315. [PMID: 29951061 DOI: 10.3389/fimmu.2018.01315] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 6.8] [Reference Citation Analysis]
137 Tavares RCF, Feldner ACCA, Pinho JRR, Uehara SNO, Emori CT, Carvalho-Filho RJ, Silva ISS, Santana RAF, de Castro VFD, Castoli GTF, Cristovão CU, Ferraz MLCG. Prevalence of naturally occurring protease inhibitor resistance-associated variants in hemodialysis and renal transplant patients with hepatitis C virus infection. Eur J Gastroenterol Hepatol 2017;29:754-8. [PMID: 28234637 DOI: 10.1097/MEG.0000000000000866] [Reference Citation Analysis]
138 de Bruijn W, Ibáñez C, Frisk P, Bak Pedersen H, Alkan A, Vella Bonanno P, Brkičić LS, Bucsics A, Dedet G, Eriksen J, Fadare JO, Fürst J, Gallego G, Godói IP, Guerra Júnior AA, Gürsöz H, Jan S, Jones J, Joppi R, Kerman S, Laius O, Madzikwa N, Magnússon E, Maticic M, Markovic-Pekovic V, Massele A, Ogunleye O, O'Leary A, Piessnegger J, Sermet C, Simoens S, Tiroyakgosi C, Truter I, Thyberg M, Tomekova K, Wladysiuk M, Vandoros S, Vural EH, Zara C, Godman B. Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Front Pharmacol 2016;7:197. [PMID: 27516740 DOI: 10.3389/fphar.2016.00197] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
139 Kammarabutr J, Mahalapbutr P, Nutho B, Kungwan N, Rungrotmongkol T. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. J Mol Graph Model 2019;89:122-30. [PMID: 30884449 DOI: 10.1016/j.jmgm.2019.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
140 Zhu DY, Deng XZ, Zhu YM, Li GT, Zhang GQ, Wang LJ, Zhang JH, Xiao W, Zhou ZX, Ding WL. Association of IL-28B, TBX21 gene polymorphisms and predictors of virological response for chronic hepatitis C. Arch Virol 2018;163:1253-62. [PMID: 29399747 DOI: 10.1007/s00705-018-3750-9] [Reference Citation Analysis]
141 Abaalkhail F, Elsiesy H, Elbeshbeshy H, Shawkat M, Yousif S, Ullah W, Alabbad S, Al-Jedai A, Ajlan A, Broering D, Saab S, Al Sebayel M, Al-Hamoudi W. Treatment of Patients With Hepatitis C Virus Infection With Ledipasvir-Sofosbuvir in the Liver Transplant Setting. Transplantation 2017;101:2739-45. [PMID: 28795982 DOI: 10.1097/TP.0000000000001907] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.6] [Reference Citation Analysis]
142 Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-tack K, Murray J, Birnkrant D, Struble K. HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens. J Viral Hepat 2018;25:969-75. [DOI: 10.1111/jvh.12896] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
143 Chan A, Patel K, Naggie S. Genotype 3 Infection: The Last Stand of Hepatitis C Virus. Drugs 2017;77:131-44. [PMID: 28074358 DOI: 10.1007/s40265-016-0685-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
144 Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis. Liver Int. 2018; Epub ahead of print. [PMID: 29461687 DOI: 10.1111/liv.13727] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
145 Zarębska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, Janczewska E, Dybowska D, Pawłowska M, Halota W, Mazur W, Lorenc B, Janocha-Litwin J, Simon K, Piekarska A, Berak H, Klapaczyński J, Stępień P, Sobala-Szczygieł B, Citko J, Socha Ł, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Dobracka B, Krygier R, Białkowska-Warzecha J, Laurans Ł, Flisiak R. Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics. J Clin Med 2021;10:3280. [PMID: 34362064 DOI: 10.3390/jcm10153280] [Reference Citation Analysis]
146 Saga R, Fujimoto A, Watanabe N, Matsuda M, Hasegawa M, Watashi K, Aizaki H, Nakamura N, Tajima S, Takasaki T, Konishi E, Kato T, Kohara M, Takeyama H, Wakita T, Suzuki R. Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus. Sci Rep 2016;6:28688. [PMID: 27345289 DOI: 10.1038/srep28688] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
147 Ogishi M, Yotsuyanagi H, Tsutsumi T, Gatanaga H, Ode H, Sugiura W, Moriya K, Oka S, Kimura S, Koike K. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. PLoS One. 2015;10:e0119145. [PMID: 25748426 DOI: 10.1371/journal.pone.0119145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
148 ElDeeb MK, Ghazal AA, Metwally DE, Elghlied LA. Possible roles of methylenetetrahydrofolate reductase polymorphism and folate status in patients with early hepatitis C virus genotype 4. Arab J Gastroenterol 2021;22:121-6. [PMID: 33664006 DOI: 10.1016/j.ajg.2020.12.001] [Reference Citation Analysis]
149 Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:36-44. [PMID: 28404110 DOI: 10.1016/S2468-1253(16)30002-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
150 Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An experience of tertiary care hospital in Karachi. Pak J Med Sci 2021;37:2014-9. [PMID: 34912436 DOI: 10.12669/pjms.37.7.4627] [Reference Citation Analysis]
151 Gallardo-Flores CE, Colpitts CC. Cyclophilins and Their Roles in Hepatitis C Virus and Flavivirus Infections: Perspectives for Novel Antiviral Approaches. Pathogens 2021;10:902. [PMID: 34358052 DOI: 10.3390/pathogens10070902] [Reference Citation Analysis]
152 Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea. J Korean Med Sci 2021;36:e308. [PMID: 34845874 DOI: 10.3346/jkms.2021.36.e308] [Reference Citation Analysis]
153 Naz A, Mukry SN, Naseer I, Shamsi TS. Evaluation of efficacy of serological methods for detection of HCV infection in blood donors: A single centre experience. Pak J Med Sci 2018;34:1204-8. [PMID: 30344577 DOI: 10.12669/pjms.345.15707] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
154 Li C, Hu J. A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Medicine (Baltimore) 2018;97:e0416. [PMID: 29642211 DOI: 10.1097/MD.0000000000010416] [Reference Citation Analysis]
155 Rid A, Johansson MA, Leung G, Valantine H, Burchard EG, Oh SS, Zimmerman C; PLOS Medicine Editors. Towards Equity in Health: Researchers Take Stock. PLoS Med 2016;13:e1002186. [PMID: 27898673 DOI: 10.1371/journal.pmed.1002186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
156 Seifert LL, Perumpail RB, Ahmed A. Update on hepatitis C: Direct-acting antivirals. World J Hepatol 2015; 7(28): 2829-2833 [PMID: 26668694 DOI: 10.4254/wjh.v7.i28.2829] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
157 Fouad M, El Kassas M, Ahmed E, El Sheemy R. Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients. World J Hepatol 2021; 13(11): 1743-1752 [PMID: 34904042 DOI: 10.4254/wjh.v13.i11.1743] [Reference Citation Analysis]
158 Chaabna K, Dashzeveg D, Shagdarsuren T, Al-Rifai RH. Prevalence and genotype distribution of hepatitis C virus in Mongolia: Systematic review and meta-analysis. Int J Infect Dis 2021;105:377-88. [PMID: 33601031 DOI: 10.1016/j.ijid.2021.02.040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
159 Tsai FJ, Cheng CF, Chen CJ, Lin CY, Wu YF, Li TM, Chuang PH, Wu YC, Lai CH, Liu X, Tsang H, Lin TH, Liao CC, Huang SM, Li JP, Lin JC, Lin CC, Liang WM, Lin YJ. Effects of Chinese herbal medicine therapy on survival and hepatic outcomes in patients with hepatitis C virus infection in Taiwan. Phytomedicine 2019;57:30-8. [PMID: 30668320 DOI: 10.1016/j.phymed.2018.09.237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
160 Gentile I, Maraolo AE, Buonomo AR, Zappulo E, Borgia G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin Drug Discov. 2015;10:1363-1377. [PMID: 26563720 DOI: 10.1517/17460441.2015.1094051] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
161 Cunningham EB, Applegate TL, Lloyd AR, Dore GJ, Grebely J. Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nat Rev Gastroenterol Hepatol 2015;12:218-30. [DOI: 10.1038/nrgastro.2015.36] [Cited by in Crossref: 68] [Cited by in F6Publishing: 68] [Article Influence: 9.7] [Reference Citation Analysis]
162 Kapur S, Kalra N, Bhatia A, Duseja A, Das A, Dhiman RK, Chawla Y, Sandhu MS. Comparison of Elastography Point Quantification with Transient Elastography in Patients with Chronic Viral Hepatitis and Nonalcoholic Fatty Liver Disease: A Pilot Study. J Clin Exp Hepatol 2021;11:21-9. [PMID: 33679045 DOI: 10.1016/j.jceh.2020.06.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
163 McPhee F. Developments in the treatment of HCV genotype 3 infection. Expert Rev Anti Infect Ther 2019;17:775-85. [PMID: 31584833 DOI: 10.1080/14787210.2019.1676730] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
164 Zeuzem S, Hézode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourlière M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S; LEAGUE-1 Study Team. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. J Hepatol 2016;64:292-300. [PMID: 26453968 DOI: 10.1016/j.jhep.2015.09.024] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
165 Tsai SM, Kao JT, Tsai YF. Illness trajectory of initial infection for patients with hepatitis C: A qualitative study. Nurs Health Sci 2019;21:112-8. [PMID: 30251452 DOI: 10.1111/nhs.12568] [Reference Citation Analysis]
166 Mariño Z, Lens S, Gambato M, Forns X. Advances in hepatitis C therapies. Expert Opin Pharmacother 2015;16:1929-43. [PMID: 26219918 DOI: 10.1517/14656566.2015.1070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
167 Ghazy AA, Osman EM, Rashwan EA, Gaballah AH, Mostafa H, Tawfik S. Relation between microRNA-21, transforming growth factor β and response to treatment among chronic hepatitis C patients. J Med Virol 2019;91:2166-73. [PMID: 31368531 DOI: 10.1002/jmv.25559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
168 Schwarzkopf R, Novikov D, Anoushiravani AA, Feng JE, Vigdorchik J, Schurko B, Dwyer MK, Bedair HS. The preoperative management of Hepatitis C may improve the outcome after total knee arthroplasty. Bone Joint J 2019;101-B:667-74. [PMID: 31154838 DOI: 10.1302/0301-620X.101B6.BJJ-2018-0723.R3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
169 Cink RD, Lukin KA, Bishop RD, Zhao G, Pelc MJ, Towne TB, Gates BD, Ravn MM, Hill DR, Ding C, Cullen SC, Mei J, Leanna MR, Henle J, Napolitano JG, Nere NK, Chen S, Sheikh A, Kallemeyn JM. Development of the Enabling Route for Glecaprevir via Ring-Closing Metathesis. Org Process Res Dev 2020;24:183-200. [DOI: 10.1021/acs.oprd.9b00469] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
170 Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infect Dis Ther 2017;6:423-33. [PMID: 28677020 DOI: 10.1007/s40121-017-0163-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
171 Valkov I, Ivanova R, Alexiev A, Antonov K, Mateva L. Association of Serum Lipids with Hepatic Steatosis, Stage of Liver Fibrosis and Viral Load in Chronic Hepatitis C. J Clin Diagn Res 2017;11:OC15-20. [PMID: 28969178 DOI: 10.7860/JCDR/2017/28609.10459] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
172 Patiño-Galindo JÁ, González-Candelas F. Comparative analysis of variation and selection in the HCV genome. Infect Genet Evol 2017;49:104-10. [PMID: 28087495 DOI: 10.1016/j.meegid.2017.01.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
173 Shenge JA, Odaibo GN, Olaleye DO. Phylogenetic analysis of hepatitis C virus among HIV/ HCV co-infected patients in Nigeria. PLoS One 2019;14:e0210724. [PMID: 30726229 DOI: 10.1371/journal.pone.0210724] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
174 Hernández-Vásquez A, Rosselli D. A bibliometric analysis of the global research on sofosbuvir. F1000Res 2017;6:1536. [PMID: 29259762 DOI: 10.12688/f1000research.12314.1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
175 Alhaddad O, Wahb A, Sabry A, Khalil F, Elsabaawy D, Elshazly H, Shebl N, Rady M, Elsabaawy M. Role of Ribavirin in the Era of Direct-Acting Antiviral Therapies of Chronic Hepatitis C. Expert Rev Anti Infect Ther 2020;18:817-22. [PMID: 32397842 DOI: 10.1080/14787210.2020.1758557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
176 Riaz S, Bashir MF, Haider S, Rahid N. Association of genotypes with viral load and biochemical markers in HCV-infected Sindhi patients. Braz J Microbiol 2016;47:980-6. [PMID: 27528079 DOI: 10.1016/j.bjm.2016.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
177 Alberti A, Lacoin L, Morais E, Lefevre C, Abogunrin S, Iheanacho I. Literature review of the distribution of hepatitis C virus genotypes across Europe: HCV Genotype Distribution in Europe Review. J Med Virol 2016;88:2157-69. [DOI: 10.1002/jmv.24573] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
178 Mohamed AA, Elbedewy TA, El-Serafy M, El-Toukhy N, Ahmed W, Ali El Din Z. Hepatitis C virus: A global view. World J Hepatol 2015; 7(26): 2676-2680 [PMID: 26609344 DOI: 10.4254/wjh.v7.i26.2676] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 8.9] [Reference Citation Analysis]
179 Kao JH, Ahn SH, Chien RN, Cho M, Chuang WL, Jeong SH, Liu CH, Paik SW. Urgency to treat patients with chronic hepatitis C in Asia. J Gastroenterol Hepatol 2017;32:966-74. [PMID: 28005275 DOI: 10.1111/jgh.13709] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
180 Trifan A, Stanciu C, Gheorghe L, Iacob S, Curescu M, Cijevschi Prelipcean C, Stefanescu G, Girleanu I, Chiriac S, Mihai C, Brisc C, Goldis A, Sporea I, Miftode E, Bataga S, Rogoveanu I, Preda C, Caruntu FA, Singeap AM. Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Medicine (Baltimore) 2017;96:e9271. [PMID: 29390377 DOI: 10.1097/MD.0000000000009271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 2.8] [Reference Citation Analysis]
181 Wasitthankasem R, Vongpunsawad S, Siripon N, Suya C, Chulothok P, Chaiear K, Rujirojindakul P, Kanjana S, Theamboonlers A, Tangkijvanich P. Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia. PLoS One. 2015;10:e0126764. [PMID: 25962112 DOI: 10.1371/journal.pone.0126764] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 7.3] [Reference Citation Analysis]
182 Barclay ST, Cooke GS, Holtham E, Gauthier A, Schwarzbard J, Atanasov P, Irving WL; HCV Research UK. A new paradigm evaluating cost per cure of HCV infection in the UK. Hepatol Med Policy 2016;1:2. [PMID: 30288304 DOI: 10.1186/s41124-016-0002-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
183 Welzel TM, Bhardwaj N, Hedskog C, Chodavarapu K, Camus G, Mcnally J, Brainard D, Miller MD, Mo H, Svarovskaia E, Jacobson I, Zeuzem S, Agarwal K. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. Journal of Hepatology 2017;67:224-36. [DOI: 10.1016/j.jhep.2017.03.014] [Cited by in Crossref: 85] [Cited by in F6Publishing: 81] [Article Influence: 17.0] [Reference Citation Analysis]
184 Petruzziello A, Sabatino R, Loquercio G, Guzzo A, Di Capua L, Labonia F, Cozzolino A, Azzaro R, Botti G. Nine-year distribution pattern of hepatitis C virus (HCV) genotypes in Southern Italy. PLoS One 2019;14:e0212033. [PMID: 30785909 DOI: 10.1371/journal.pone.0212033] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
185 Ceccherini-Silberstein F, Cento V, Di Maio VC, Perno CF, Craxì A. Viral resistance in HCV infection. Curr Opin Virol 2018;32:115-27. [PMID: 30439589 DOI: 10.1016/j.coviro.2018.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
186 Hernandez D, Yu F, Huang X, Kirov S, Pant S, Mcphee F. Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir. Adv Ther 2016;33:1169-79. [DOI: 10.1007/s12325-016-0354-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
187 Ploen D, Hildt E. Hepatitis C virus comes for dinner: How the hepatitis C virus interferes with autophagy. World J Gastroenterol 2015; 21(28): 8492-8507 [PMID: 26229393 DOI: 10.3748/wjg.v21.i28.8492] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
188 Shafran SD. HIV Coinfected Have Similar SVR Rates as HCV Monoinfected With DAAs: It's Time to End Segregation and Integrate HIV Patients Into HCV Trials. Clin Infect Dis 2015;61:1127-34. [DOI: 10.1093/cid/civ438] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
189 Tong L, Yu W, Coburn CA, Meinke PT, Nair AG, Dwyer MP, Chen L, Selyutin O, Rosenblum SB, Jiang Y, Fells J, Hu B, Zhong B, Soll RM, Liu R, Agrawal S, Xia E, Zhai Y, Kong R, Ingravallo P, Nomeir A, Asante-Appiah E, Kozlowski JA. Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors. Bioorg Med Chem Lett 2016;26:5132-7. [PMID: 27634194 DOI: 10.1016/j.bmcl.2016.07.057] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
190 Kao JH, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhore R. All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. Liver Int. 2016;36:1433-1441. [PMID: 27009831 DOI: 10.1111/liv.13128] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
191 Nieto-Aponte L, Quer J, Ruiz-Ripa A, Tabernero D, Gonzalez C, Gregori J, Vila M, Asensio M, Garcia-Cehic D, Ruiz G, Chen Q, Ordeig L, Llorens M, Saez M, Esteban JI, Esteban R, Buti M, Pumarola T, Rodriguez-Frias F. Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. J Clin Microbiol 2017;55:504-9. [PMID: 27927921 DOI: 10.1128/JCM.01960-16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
192 Kirdar S, Sener AG, Cengİz M, Aydin N. The prevalence of autoantibody and its relationship with genotypes of hepatitis C virus in patients with chronic hepatitis C virus infection. APMIS 2016;124:979-84. [PMID: 27670736 DOI: 10.1111/apm.12593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
193 Kelly C, Swadling L, Capone S, Brown A, Richardson R, Halliday J, von Delft A, Oo Y, Mutimer D, Kurioka A, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Grazioli F, Esposito ML, Di Marco S, Siani L, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Folgori A, Klenerman P, Barnes E. Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 2016;63:1455-70. [PMID: 26474390 DOI: 10.1002/hep.28294] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
194 Zhang X, Wang T, Dai X, Zhang Y, Jiang H, Zhang Q, Liu F, Wu K, Liu Y, Zhou H, Wu J. Golgi protein 73 facilitates the interaction of hepatitis C virus NS5A with apolipoprotein E to promote viral particle secretion. Biochem Biophys Res Commun. 2016;479:683-689. [PMID: 27697522 DOI: 10.1016/j.bbrc.2016.09.152] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
195 El-ansary MR, Asaad A, Khalifa R, Abdel Rahman AT, Abd Elsalam AE. Antiviral and immunomodulatory effects of oral bovine lactoferrin therapy among patients with chronic hepatitis C: . Egyptian Liver Journal 2016;6:81-8. [DOI: 10.1097/01.elx.0000522249.08166.ef] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
196 Hopcraft SE, Evans MJ. Selection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudins. Hepatology 2015;62:1059-69. [PMID: 25820616 DOI: 10.1002/hep.27815] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
197 Quadeer AA, Louie RHY, McKay MR. Identifying immunologically-vulnerable regions of the HCV E2 glycoprotein and broadly neutralizing antibodies that target them. Nat Commun 2019;10:2073. [PMID: 31061402 DOI: 10.1038/s41467-019-09819-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
198 Menon RM, Klein CE, Podsadecki TJ, Chiu YL, Dutta S, Awni WM. Pharmacokinetics and tolerability of paritaprevir, a direct acting antiviral agent for hepatitis C virus treatment, with and without ritonavir in healthy volunteers. Br J Clin Pharmacol 2016;81:929-40. [PMID: 26710243 DOI: 10.1111/bcp.12873] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 4.3] [Reference Citation Analysis]
199 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
200 Morisco F, Granata R, Camera S, Ippolito A, Milella M, Conti F, Masetti C, Smedile A, Tundo P, Santantonio T, Valvano MR, Termite A, Gatti P, Messina V, Iacobellis A, Librandi M, Caporaso N, Andriulli A; ITAL-C consortium. Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. United European Gastroenterol J 2018;6:225-37. [PMID: 29511552 DOI: 10.1177/2050640617717158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
201 Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader AG. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. Virol J 2017;14:208. [PMID: 29096662 DOI: 10.1186/s12985-017-0873-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
202 Adhoute X, Penaranda G, Raoul JL, Sellier F, Castellani P, Oules V, Perrier H, Lefolgoc G, Pol B, Campanile M. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study. Eur J Gastroenterol Hepatol. 2018;30:368-375. [PMID: 29384796 DOI: 10.1097/meg.0000000000001082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
203 El Kassas M, Elbaz T, Salaheldin M, Abdelsalam L, Kaseb A, Esmat G. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues - A mini-review. J Adv Res 2019;17:43-8. [PMID: 31193326 DOI: 10.1016/j.jare.2019.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
204 Quer J, Rodríguez-Frias F, Gregori J, Tabernero D, Soria ME, García-Cehic D, Homs M, Bosch A, Pintó RM, Esteban JI, Domingo E, Perales C. Deep sequencing in the management of hepatitis virus infections. Virus Res 2017;239:115-25. [PMID: 28040474 DOI: 10.1016/j.virusres.2016.12.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
205 Omran D, Alboraie M, Zayed RA, Wifi MN, Naguib M, Eltabbakh M, Abdellah M, Sherief AF, Maklad S, Eldemellawy HH, Saad OK, Khamiss DM, El Kassas M. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations. World J Gastroenterol 2018; 24(38): 4330-4340 [PMID: 30344418 DOI: 10.3748/wjg.v24.i38.4330] [Cited by in CrossRef: 60] [Cited by in F6Publishing: 45] [Article Influence: 15.0] [Reference Citation Analysis]
206 European Paediatric HIVHCV Co-infection Study Group in the European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord. Coinfection with HIV and hepatitis C virus in 229 children and young adults living in Europe. AIDS 2017;31:127-35. [PMID: 27898593 DOI: 10.1097/QAD.0000000000001285] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
207 Pecoraro V, Banzi R, Cariani E, Chester J, Villa E, D'Amico R, Bertele' V, Trenti T. New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials. J Clin Exp Hepatol 2019;9:522-38. [PMID: 31516269 DOI: 10.1016/j.jceh.2018.07.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
208 Kang IJ, Hsu SJ, Yang HY, Yeh TK, Lee CC, Lee YC, Tian YW, Song JS, Hsu TA, Chao YS, Yueh A, Chern JH. A Potent, Selective, and Orally Bioavailable HCV NS5A Inhibitor for Treatment of Hepatitis C Virus: (S)-1-((R)-2-(Cyclopropanecarboxamido)-2-phenylacetyl)-N-(4-phenylthiazol-2-yl)pyrrolidine-2-carboxamide. J Med Chem 2017;60:228-47. [PMID: 27966956 DOI: 10.1021/acs.jmedchem.6b00962] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
209 Chemaitelly H, Chaabna K, Abu-Raddad LJ. The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis. PLoS One. 2015;10:e0135281. [PMID: 26296200 DOI: 10.1371/journal.pone.0135281] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 5.9] [Reference Citation Analysis]
210 Pedergnana V, Irving WL, Barnes E, McLauchlan J, Spencer CCA. Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients. J Interferon Cytokine Res 2019;39:642-9. [PMID: 31260374 DOI: 10.1089/jir.2019.0013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Buti M, Riveiro-Barciela M, Esteban R. Management of direct-acting antiviral agent failures. J Hepatol. 2015;63:1511-1522. [PMID: 26299621 DOI: 10.1016/j.jhep.2015.08.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 50] [Article Influence: 7.6] [Reference Citation Analysis]
212 Luxenburger H, Graß F, Baermann J, Boettler T, Marget M, Emmerich F, Panning M, Thimme R, Nitschke K, Neumann-Haefelin C. Differential virus-specific CD8+ T-cell epitope repertoire in hepatitis C virus genotype 1 versus 4. J Viral Hepat 2018;25:779-90. [PMID: 29397015 DOI: 10.1111/jvh.12874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
213 Asselah T, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Sci Rep 2019;2:e92. [PMID: 30937389 DOI: 10.1002/hsr2.92] [Reference Citation Analysis]
214 Cuypers L, Ceccherini-Silberstein F, Van Laethem K, Li G, Vandamme AM, Rockstroh JK. Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time. Rev Med Virol 2016;26:408-34. [PMID: 27401933 DOI: 10.1002/rmv.1895] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
215 Asselah T, Hézode C, Qaqish RB, ElKhashab M, Hassanein T, Papatheodoridis G, Feld JJ, Moreno C, Zeuzem S, Ferenci P, Yu Y, Redman R, Pilot-Matias T, Mobashery N. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:25-35. [PMID: 28404108 DOI: 10.1016/S2468-1253(16)30001-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
216 Puri P, Anand AC, Saraswat VA, Acharya SK, Dhiman RK, Sarin SK, Singh SP, Chawla YK, Aggarwal R, Amarapurkar D, Arora A, Dixit VK, Sood A, Shah S, Duseja A, Kapoor D, Shalimar, Madan K, Pande G, Nagral A, Kar P, Koshy A, Puri AS, Eapen CE, Thareja S. Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015. J Clin Exp Hepatol 2015;5:221-38. [PMID: 26628840 DOI: 10.1016/j.jceh.2015.09.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
217 El Kassas M, Elbaz T, Hafez E, Esmat G. Safety of direct antiviral agents in the management of hepatitis C. Expert Opin Drug Saf. 2016;15:1643-1652. [PMID: 27661100 DOI: 10.1080/14740338.2017.1240781] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
218 Akhil MS, Kirushnan B, Martin M, Arumugam K, Ganesh Prasad NK, Ravichandran R. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Nephrology (Carlton) 2018;23:446-52. [PMID: 28339162 DOI: 10.1111/nep.13050] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
219 Gantumur G, Batsaikhan B, Huang CI, Yeh ML, Huang CF, Lin YH, Lin TC, Liang PC, Liu TW, Lee JJ, Lin YC, Lin IL, Huang JF, Chuang WL, Yu ML, Tu HP, Dai CY. The association between hepatitis C virus infection and renal function. J Chin Med Assoc 2021;84:757-65. [PMID: 34074934 DOI: 10.1097/JCMA.0000000000000561] [Reference Citation Analysis]
220 Crespo J, Calleja JL, Fernández I, Sacristan B, Ruiz-Antorán B, Ampuero J, Hernández-Conde M, García-Samaniego J, Gea F, Buti M, Cabezas J, Lens S, Morillas RM, Salcines JR, Pascasio JM, Turnes J, Sáez-Royuela F, Arenas J, Rincón D, Prieto M, Jorquera F, Sanchez Ruano JJ, Navascués CA, Molina E, Moya AG, Moreno-Planas JM; Spanish Group for the Study of the Use of Direct-acting Drugs Hepatitis C Collaborating Group. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection. Clin Gastroenterol Hepatol 2017;15:945-949.e1. [PMID: 28238958 DOI: 10.1016/j.cgh.2017.02.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
221 Patel S. In silico analysis of Hepatitis C virus (HCV) polyprotein domains and their comparison with other pathogens and allergens to gain insight on pathogenicity mechanisms. Computational Biology and Chemistry 2016;65:91-102. [DOI: 10.1016/j.compbiolchem.2016.10.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
222 Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M, Rossi F, Capuano A. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opinion on Drug Safety 2016;15:85-100. [DOI: 10.1080/14740338.2016.1221396] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
223 Fung J. Era of direct acting antivirals in chronic hepatitis C: Who will benefit? World J Hepatol 2015; 7(24): 2543-2550 [PMID: 26523206 DOI: 10.4254/wjh.v7.i24.2543] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
224 Qi M, Yang M, Xu L, Ma C, Huang P, Sun J, Shi J, Hu Y. Complete genome analysis identifies recombinant events and positive selection sites of hepatitis C virus from mainland China during 2010-2019. Virus Res 2021;296:198354. [PMID: 33639223 DOI: 10.1016/j.virusres.2021.198354] [Reference Citation Analysis]
225 Chen XF, Zhao X, Yang Z. Aptamer-Based Antibacterial and Antiviral Therapy against Infectious Diseases. J Med Chem 2021;64:17601-26. [PMID: 34854680 DOI: 10.1021/acs.jmedchem.1c01567] [Reference Citation Analysis]
226 Sirinawasatien A, Techasirioangkun T. Sofosbuvir-based regimens in the treatment of patients with chronic hepatitis C virus infection: Real-world efficacy in Thailand. PLoS One 2020;15:e0229517. [PMID: 32106270 DOI: 10.1371/journal.pone.0229517] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
227 Shridhar Gulati R, Wimalanathan T, Norheim Andersen S, Isaksen K, Lagging M, Midgard H, Moghaddam A, Dalgard O. The relationship between IFNL4 genotype and the rate of fibrosis in hepatitis C patients. Scand J Gastroenterol 2019;54:1172-5. [PMID: 31479286 DOI: 10.1080/00365521.2019.1643403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
228 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;9:CD012143. [PMID: 28922704 DOI: 10.1002/14651858.CD012143.pub3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
229 Orkin C, Jeffery-Smith A, Foster GR, Tong CY. Retrospective hepatitis C seroprevalence screening in the antenatal setting-should we be screening antenatal women? BMJ Open 2016;6:e010661. [PMID: 27231001 DOI: 10.1136/bmjopen-2015-010661] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
230 Wilson EM, Rosenthal ES, Kattakuzhy S, Tang L, Kottilil S. Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C. Clin Microbiol Rev 2017;30:23-42. [PMID: 27795306 DOI: 10.1128/CMR.00037-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
231 Nováková L, Pavlík J, Chrenková L, Martinec O, Červený L. Current antiviral drugs and their analysis in biological materials - Part II: Antivirals against hepatitis and HIV viruses. J Pharm Biomed Anal 2018;147:378-99. [PMID: 29031512 DOI: 10.1016/j.jpba.2017.07.003] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 5.2] [Reference Citation Analysis]
232 Zhang C, Wang XM, Li SR, Twelkmeyer T, Wang WH, Zhang SY, Wang SF, Chen JZ, Jin X, Wu YZ, Chen XW, Wang SD, Niu JQ, Chen HR, Tang H. NKG2A is a NK cell exhaustion checkpoint for HCV persistence. Nat Commun 2019;10:1507. [PMID: 30944315 DOI: 10.1038/s41467-019-09212-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 15.7] [Reference Citation Analysis]
233 Gonzalez-miro M, Chen S, Gonzaga ZJ, Evert B, Wibowo D, Rehm BHA. Polyester as Antigen Carrier toward Particulate Vaccines. Biomacromolecules 2019;20:3213-32. [DOI: 10.1021/acs.biomac.9b00509] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
234 Howell J, Pedrana A, Cowie BC, Doyle J, Getahun A, Ward J, Gane E, Cunningham C, Wallace J, Lee A, Malani J, Thompson A, Hellard ME. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. J Gastroenterol Hepatol. 2019;34:40-48. [PMID: 30151932 DOI: 10.1111/jgh.14457] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
235 Florian J, Mishra P, Arya V, Harrington P, Connelly S, Reynolds K, Sinha V. Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now. Clin Pharmacol Ther 2015;98:394-402. [DOI: 10.1002/cpt.185] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
236 Chen M, Ma Y, Chen H, Luo H, Dai J, Song L, Yang C, Mei J, Yang L, Dong L, Jia M, Lu L. Multiple Introduction and Naturally Occuring Drug Resistance of HCV among HIV-Infected Intravenous Drug Users in Yunnan: An Origin of China's HIV/HCV Epidemics. PLoS One 2015;10:e0142543. [PMID: 26562015 DOI: 10.1371/journal.pone.0142543] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
237 Craxì A, Perno CF, Viganò M, Ceccherini-silberstein F, Petta S, Aghemo A, Alberti A, Andreone P, Andreoni M, Bonora S, Brunetto MR, Bruno S, Caporaso N, Chirianni A, Ciancio A, Degasperi E, Di Perri G, Fagiuoli S, Ferrari C, Gaeta GB, Pellicelli A, Puoti M, Raimondo G, Taliani G, Villa E, Zignego AL. From current status to optimization of HCV treatment: Recommendations from an expert panel. Digestive and Liver Disease 2016;48:995-1005. [DOI: 10.1016/j.dld.2016.06.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
238 Khedhiri M, Ghedira K, Chouikha A, Touzi H, Sadraoui A, Hammemi W, Triki H. Tracing the epidemic history of hepatitis C virus genotype 1b in Tunisia and in the world, using a Bayesian coalescent approach. Infect Genet Evol 2019;75:103944. [PMID: 31260787 DOI: 10.1016/j.meegid.2019.103944] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
239 McCormack PL. Daclatasvir: a review of its use in adult patients with chronic hepatitis C virus infection. Drugs. 2015;75:515-524. [PMID: 25721433 DOI: 10.1007/s40265-015-0362-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
240 Lau G, Benhamou Y, Chen G, Li J, Shao Q, Ji D, Li F, Li B, Liu J, Hou J, Sun J, Wang C, Chen J, Wu V, Wong A, Wong CL, Tsang ST, Wang Y, Bassit L, Tao S, Jiang Y, Hsiao HM, Ke R, Perelson AS, Schinazi RF. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. Lancet Gastroenterol Hepatol 2016;1:97-104. [PMID: 27917405 DOI: 10.1016/S2468-1253(16)30015-2] [Cited by in Crossref: 64] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
241 Li X, Li J, Feng Y, Cai H, Li YP, Peng T. Long-chain fatty acyl-coenzyme A suppresses hepatitis C virus infection by targeting virion-bound lipoproteins. Antiviral Res. 2020;177:104734. [PMID: 32057770 DOI: 10.1016/j.antiviral.2020.104734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
242 He L, Cheng Y, Kong L, Azadnia P, Giang E, Kim J, Wood MR, Wilson IA, Law M, Zhu J. Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep 2015;5:12501. [PMID: 26238798 DOI: 10.1038/srep12501] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
243 Matthew AN, Zephyr J, Hill CJ, Jahangir M, Newton A, Petropoulos CJ, Huang W, Kurt-Yilmaz N, Schiffer CA, Ali A. Hepatitis C Virus NS3/4A Protease Inhibitors Incorporating Flexible P2 Quinoxalines Target Drug Resistant Viral Variants. J Med Chem 2017;60:5699-716. [PMID: 28594175 DOI: 10.1021/acs.jmedchem.7b00426] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
244 Asselah T, Hassanein T, Waked I, Mansouri A, Dusheiko G, Gane E. Eliminating hepatitis C within low-income countries - The need to cure genotypes 4, 5, 6. J Hepatol 2018;68:814-26. [PMID: 29229584 DOI: 10.1016/j.jhep.2017.11.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
245 Caspi DD, Cink RD, Clyne D, Diwan M, Engstrom KM, Grieme T, Mei J, Miller RW, Mitchell C, Napolitano JG, Nere N, Ravn MM, Sheikh A, Wagaw S, Zhang H. Process development of ABT-450 – A first generation NS3/4A protease inhibitor for HCV. Tetrahedron 2019;75:4271-86. [DOI: 10.1016/j.tet.2019.05.064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
246 Ishikawa T, Imai M, Owaki T, Sato H, Nozawa Y, Sano T, Iwanaga A, Seki K, Honma T, Yoshida T. Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment. Intern Med 2018;57:2843-5. [PMID: 29780129 DOI: 10.2169/internalmedicine.0621-17] [Reference Citation Analysis]
247 Venables BL, Sin N, Wang AX, Sun LQ, Tu Y, Hernandez D, Sheaffer A, Lee M, Dunaj C, Zhai G, Barry D, Friborg J, Yu F, Knipe J, Sandquist J, Falk P, Parker D, Good AC, Rajamani R, McPhee F, Meanwell NA, Scola PM. P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor. Bioorg Med Chem Lett 2018;28:1853-9. [PMID: 29650290 DOI: 10.1016/j.bmcl.2018.04.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
248 Chang C, Hung CH, Wang JH, Lu SN. Hepatitis C core antigen highly correlated to HCV RNA. Kaohsiung J Med Sci 2018;34:684-8. [PMID: 30527202 DOI: 10.1016/j.kjms.2018.08.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
249 Salum GM, Bader El Din NG, Ibrahim MK, Anany MA, Dawood RM, Khairy A, El Awady MK. Vascular Endothelial Growth Factor Expression in Hepatitis C Virus-Induced Liver Fibrosis: A Potential Biomarker. J Interferon Cytokine Res 2017;37:310-6. [PMID: 28472595 DOI: 10.1089/jir.2016.0127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
250 Ekstrom V, Kumar R, Zhao Y, Yee ML, Sung C, Toh D, Loh PY, Tan J, Teo EK, Chow WC. Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourable IL28B polymorphism. Gastroenterol Rep (Oxf) 2017;5:208-12. [PMID: 28852525 DOI: 10.1093/gastro/gow033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
251 Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J. Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies. Virology 2018;522:177-92. [PMID: 30032031 DOI: 10.1016/j.virol.2018.05.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
252 Mahmud S, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C Virus Infection in Populations With Liver-Related Diseases in the Middle East and North Africa. Hepatol Commun. 2020;4:577-587. [PMID: 32258952 DOI: 10.1002/hep4.1491] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
253 Rodrigo C, Eltahla AA, Bull RA, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins M, Estes C, Razavi H, Lloyd AR, Luciani F; International Collaborative of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study Group. Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. J Infect Dis 2016;214:1383-9. [PMID: 27571901 DOI: 10.1093/infdis/jiw389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
254 Holmes JA, Yu ML, Chung RT. Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals. Expert Opin Drug Saf. 2017;16:651-672. [PMID: 28471314 DOI: 10.1080/14740338.2017.1325869] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
255 Prud'homme S, Nevens F, Casteels I. Bilateral simultaneous anterior ischemic optic neuropathy, an extrahepatic manifestation of hepatitis C cured with direct acting antivirals. GMS Ophthalmol Cases 2016;6:Doc05. [PMID: 27625964 DOI: 10.3205/oc000042] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
256 El-Maraghy SA, Adel O, Zayed N, Yosry A, El-Nahaas SM, Gibriel AA. Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis. J Adv Res 2020;22:57-66. [PMID: 31956442 DOI: 10.1016/j.jare.2019.12.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
257 Pawlowska M, Sobolewska-Pilarczyk M, Domagalski K. Hepatitis C virus infection in children in the era of direct-acting antiviral. World J Gastroenterol 2018; 24(24): 2555-2566 [PMID: 29962813 DOI: 10.3748/wjg.v24.i24.2555] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
258 Hundie GB, Raj VS, GebreMichael D, Pas SD, Haagmans BL. Genetic diversity of hepatitis C virus in Ethiopia. PLoS One 2017;12:e0179064. [PMID: 28570623 DOI: 10.1371/journal.pone.0179064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
259 Bloom DE, Khoury A, Srinivasan V. Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India. PLoS One 2021;16:e0252764. [PMID: 34292958 DOI: 10.1371/journal.pone.0252764] [Reference Citation Analysis]
260 Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B. Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients. J Viral Hepat 2017;24:895-9. [PMID: 28470815 DOI: 10.1111/jvh.12719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
261 Manne V, Ryan J, Wong J, Vengayil G, Basit SA, Gish RG. Hepatitis C Vaccination: Where We Are and Where We Need to Be. Pathogens 2021;10:1619. [PMID: 34959574 DOI: 10.3390/pathogens10121619] [Reference Citation Analysis]
262 El Serafy MA, Kassem AM, Omar H, Mahfouz MS, El Said El Raziky M. APRI test and hyaluronic acid as non-invasive diagnostic tools for post HCV liver fibrosis: Systematic review and meta-analysis. Arab J Gastroenterol 2017;18:51-7. [PMID: 28579340 DOI: 10.1016/j.ajg.2017.05.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
263 Naseem S, Manzoor S, Javed A, Abbas S. Interleukin-6 Rescues Lymphocyte from Apoptosis and Exhaustion Induced by Chronic Hepatitis C Virus Infection. Viral Immunol 2018;31:624-31. [PMID: 30222516 DOI: 10.1089/vim.2018.0045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
264 Aboushady M, Alwassief A, Abdelrazik M, Ziada D, Shahba H, Elmestikawy A, Elbahrawy A. Retreatment of Egyptian Chronic Hepatitis C Patients Not Responding to Pegylated Interferon and Ribavirin Dual Therapy. J Interferon Cytokine Res 2019;39:539-46. [PMID: 31173550 DOI: 10.1089/jir.2019.0041] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
265 Indolfi G, Thorne C, El Sayed MH, Giaquinto C, Gonzalez-Peralta RP. The Challenge of Treating Children With Hepatitis C Virus Infection. J Pediatr Gastroenterol Nutr. 2017;64:851-854. [PMID: 28362694 DOI: 10.1097/mpg.0000000000001589] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 5.3] [Reference Citation Analysis]
266 Fujii H, Kimura H, Kurosaki M, Hasebe C, Akahane T, Yagisawa H, Kato K, Yoshida H, Itakura J, Sakita S, Satou T, Okada K, Kusakabe A, Kojima Y, Kondo M, Morita A, Nasu A, Tamada T, Okushin H, Kobashi H, Tsuji K, Joko K, Ogawa C, Uchida Y, Mitsuda A, Sohda T, Ide Y, Izumi N. Efficacy of daclatasvir plus asunaprevir in patients with hepatitis C virus infection undergoing and not undergoing hemodialysis: Daclatasvir plus asunaprevir in non-HD and HD patients. Hepatol Res 2018;48:746-56. [DOI: 10.1111/hepr.13070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
267 Mari PC, Gulati R, Fragassi P. Adolescent Hepatitis C: Prevalence, Impact, and Management Challenges. Adolesc Health Med Ther 2021;12:45-53. [PMID: 33994820 DOI: 10.2147/AHMT.S263864] [Reference Citation Analysis]
268 El-Sayed M, Abdellatif Z, Elsharkawy A, El Kassas M, Abd Elmoniem R, Marzouk A, Fouad R, Esmat G, Abdel Alem S. Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. Infection 2020;48:913-22. [PMID: 32816249 DOI: 10.1007/s15010-020-01505-5] [Reference Citation Analysis]
269 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
270 Wiznia DH, Morgan RC Jr, Gibson D. Movement is Life-Optimizing Patient Access to Total Joint Arthroplasty: HIV and Hepatitis C Disparities. J Am Acad Orthop Surg 2021. [PMID: 34723921 DOI: 10.5435/JAAOS-D-21-00427] [Reference Citation Analysis]
271 Saha B, Kodys K, Szabo G. Hepatitis C Virus-Induced Monocyte Differentiation Into Polarized M2 Macrophages Promotes Stellate Cell Activation via TGF-β. Cell Mol Gastroenterol Hepatol 2016;2:302-316.e8. [PMID: 28090562 DOI: 10.1016/j.jcmgh.2015.12.005] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
272 Palanisamy N, Lennerstrand J. Biophysical Studies on HCV 1a NS3/4A Protease and Its Catalytic Triad in Wild Type and Mutants by the In Silico Approach. Interdiscip Sci 2018;10:143-56. [PMID: 27311576 DOI: 10.1007/s12539-016-0177-4] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
273 Buivydiene A, Liakina V, Kashuba E, Norkuniene J, Jokubauskiene S, Gineikiene E, Valantinas J. Impact of the Uridine⁻Cytidine Kinase Like-1 Protein and IL28B rs12979860 and rs8099917 SNPs on the Development of Hepatocellular Carcinoma in Cirrhotic Chronic Hepatitis C Patients-A Pilot Study. Medicina (Kaunas) 2018;54:E67. [PMID: 30344298 DOI: 10.3390/medicina54050067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
274 Rashid M, Ismail H. HCV extinction analysis in district Gujrat, Pakistan by using SARIMA and linear regression models. Medicine (Baltimore) 2021;100:e28193. [PMID: 34889300 DOI: 10.1097/MD.0000000000028193] [Reference Citation Analysis]
275 Jiao X, Fan Z, Chen H, He P, Li Y, Zhang Q, Ke C. Serum and exosomal miR-122 and miR-199a as a biomarker to predict therapeutic efficacy of hepatitis C patients. J Med Virol 2017;89:1597-605. [DOI: 10.1002/jmv.24829] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
276 Ohmer S, Honegger J. New prospects for the treatment and prevention of hepatitis C in children. Curr Opin Pediatr. 2016;28:93-100. [PMID: 26709684 DOI: 10.1097/mop.0000000000000313] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
277 Soh BYM, Kumar R, Ekstrom VSM, Lin CYH, Thangaraju S, Tan HH, Chan KP, Choong LHL, Teo D, Chow WC. Prevalence of hepatitis C virus infection and the IL28B genotype polymorphism among blood donors and high-risk populations. Singapore Med J 2019;60:34-9. [PMID: 29926111 DOI: 10.11622/smedj.2018078] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
278 Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG. Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study. Clin Infect Dis 2017;65:13-9. [PMID: 28535298 DOI: 10.1093/cid/cix289] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
279 Bassig BA, Willhauck-fleckenstein M, Shu X, Koh W, Gao Y, Purdue MP, Xiang Y, Adams-haduch J, Wang R, Brenner N, Waterboer T, Michel A, Ji B, Hosgood HD, Rabkin CS, Yang G, Wong JY, Zhang J, Hu W, Seow WJ, Chow W, Pawlita M, Zheng W, Yuan J, Lan Q, Rothman N. Serologic markers of viral infection and risk of non-Hodgkin lymphoma: A pooled study of three prospective cohorts in China and Singapore: Serologic markers of viral infection and risk of non-Hodgkin lymphoma. Int J Cancer 2018;143:570-9. [DOI: 10.1002/ijc.31385] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
280 Babatin MA, AlGhamdi AS, Assiri AM, AlBiladi H, AlOthmani HS, Mogharbel MH, Mahallawi W, Asselah T, Sanai FM. Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patients. Saudi J Gastroenterol 2019;25:55-60. [PMID: 30117490 DOI: 10.4103/sjg.SJG_189_18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
281 Chopra D, Bhandari B. Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment? Infect Disord Drug Targets 2020;20:2-15. [PMID: 30113002 DOI: 10.2174/1871526518666180816101124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
282 Le Ngoc C, Tran Thi Thanh T, Tran Thi Lan P, Nguyen Mai T, Nguyen Hoa T, Nghiem My N, Le Van T, Le Manh H, Le Thanh P, Nguyen Van Vinh C, Thwaites G, Cooke G, Heilek GM, Shikuma C, Le T, Baker S, Rahman M; VIZIONS consortium. Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. PLoS One 2019;14:e0212734. [PMID: 30865664 DOI: 10.1371/journal.pone.0212734] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
283 Han Y, Niu J, Wang D, Li Y. Hepatitis C Virus Protein Interaction Network Analysis Based on Hepatocellular Carcinoma. PLoS One 2016;11:e0153882. [PMID: 27115606 DOI: 10.1371/journal.pone.0153882] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
284 Zhang H, Zhu X, Li Q, Lou J, Sun J, Shen Z, Chen H, Li X, Wu M, Li C, Liu J, Liu C, Hu Y, Wang J, Chen G, Ding Y, Niu J. Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus. J Pharm Pharmacol 2018;70:855-64. [PMID: 29630721 DOI: 10.1111/jphp.12916] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
285 Shah R, Ahovegbe L, Niebel M, Shepherd J, Thomson EC. Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens. J Hepatol 2021;75:462-73. [PMID: 33974951 DOI: 10.1016/j.jhep.2021.04.045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
286 Zhang Y, Jiang X, Zhao Y, Xu Y. Effect of baseline resistance-associated substitutions on the efficiency of glecaprevir/pibrentasvir in chronic hepatitis C subjects: A meta-analysis. J Viral Hepat 2021;28:177-85. [PMID: 32961624 DOI: 10.1111/jvh.13409] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
287 Nageswara Rao D, Zephyr J, Henes M, Chan ET, Matthew AN, Hedger AK, Conway HL, Saeed M, Newton A, Petropoulos CJ, Huang W, Kurt Yilmaz N, Schiffer CA, Ali A. Discovery of Quinoxaline-Based P1-P3 Macrocyclic NS3/4A Protease Inhibitors with Potent Activity against Drug-Resistant Hepatitis C Virus Variants. J Med Chem 2021;64:11972-89. [PMID: 34405680 DOI: 10.1021/acs.jmedchem.1c00554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
288 Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol. 2015;12:387-400. [PMID: 26055245 DOI: 10.1038/nrgastro.2015.94] [Cited by in Crossref: 270] [Cited by in F6Publishing: 262] [Article Influence: 38.6] [Reference Citation Analysis]
289 Maheden K, Todd B, Gordon CJ, Tchesnokov EP, Götte M. Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs. Enzymes 2021;49:315-54. [PMID: 34696837 DOI: 10.1016/bs.enz.2021.07.002] [Reference Citation Analysis]
290 Lee SS, Kim CY, Kim BR, Cha RR, Kim WS, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea. J Viral Hepat. 2019;26:459-465. [PMID: 30516858 DOI: 10.1111/jvh.13047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
291 Barathan M, Mohamed R, Yong YK, Kannan M, Vadivelu J, Saeidi A, Larsson M, Shankar EM. Viral Persistence and Chronicity in Hepatitis C Virus Infection: Role of T-Cell Apoptosis, Senescence and Exhaustion. Cells 2018;7:E165. [PMID: 30322028 DOI: 10.3390/cells7100165] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
292 Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H, Felizarta F, Hassanein T, Hinrichsen H, Rincon D, Morillas R, Zeuzem S, Horsmans Y, Nelson DR, Yu Y, Krishnan P, Lin CW, Kort JJ, Mensa FJ. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017;17:1062-8. [PMID: 28818546 DOI: 10.1016/S1473-3099(17)30496-6] [Cited by in Crossref: 217] [Cited by in F6Publishing: 87] [Article Influence: 43.4] [Reference Citation Analysis]
293 Tomer S, Chawla YK, Duseja A, Arora SK. Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infection. World J Gastroenterol 2016; 22(22): 5173-5182 [PMID: 27298560 DOI: 10.3748/wjg.v22.i22.5173] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
294 Pedersen MS, Fahnøe U, Hansen TA, Pedersen AG, Jenssen H, Bukh J, Schønning K. A near full-length open reading frame next generation sequencing assay for genotyping and identification of resistance-associated variants in hepatitis C virus. J Clin Virol 2018;105:49-56. [PMID: 29886373 DOI: 10.1016/j.jcv.2018.05.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
295 Montazerhodjat V, Weinstock DM, Lo AW. Buying cures versus renting health: Financing health care with consumer loans. Sci Transl Med 2016;8:327ps6. [PMID: 26912902 DOI: 10.1126/scitranslmed.aad6913] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
296 Jiang X, Kanda T, Wu S, Nakamoto S, Nakamura M, Sasaki R, Haga Y, Wakita T, Shirasawa H, Yokosuka O. Hepatitis C Virus Nonstructural Protein 5A Inhibits MG132-Induced Apoptosis of Hepatocytes in Line with NF-κB-Nuclear Translocation. PLoS One 2015;10:e0131973. [PMID: 26133378 DOI: 10.1371/journal.pone.0131973] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
297 Saeed N, Gurakar A. Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies. Euroasian J Hepatogastroenterol 2016;6:35-42. [PMID: 29201722 DOI: 10.5005/jp-journals-10018-1163] [Reference Citation Analysis]
298 Gupta V, Kumar A, Sharma P, Arora A. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India. Indian J Med Res 2017;146:23-33. [PMID: 29168457 DOI: 10.4103/ijmr.IJMR_679_15] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
299 Khalil AT, Ali M, Tanveer F, Ovais M, Idrees M, Shinwari ZK, Hollenbeck JE. Emerging Viral Infections in Pakistan: Issues, Concerns, and Future Prospects. Health Security 2017;15:268-81. [DOI: 10.1089/hs.2016.0072] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
300 Leila ARS, Mousa MHA, Frakolaki E, Vassilaki N, Bartenschlager R, Zoidis G, Abdel-Halim M, Abadi AH. Symmetric Anti-HCV Agents: Synthesis, Antiviral Properties, and Conformational Aspects of Core Scaffolds. ACS Omega 2019;4:11440-54. [PMID: 31460249 DOI: 10.1021/acsomega.9b01242] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
301 Mansoor S, Riaz S, Kausar S, Muhammad Din S, Javed A, Sultan A, Mansoor A. Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3? J Gen Virol 2016;97:2592-8. [PMID: 27498543 DOI: 10.1099/jgv.0.000572] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
302 Rodriguez-frias F, Nieto-aponte L, Gregori J, Garcia-cehic D, Casillas R, Tabernero D, Homs M, Blasi M, Vila M, Chen Q, Vargas V, Castells L, Viladomiu L, Genesca J, Minguez B, Augustin S, Riveiro-barciela M, Carbonell J, Perales C, Soria M, Asensio M, Llorens M, Ordeig L, Godoy C, Buti M, Esteban R, Pumarola T, Esteban J, Quer J. High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. Clinical Microbiology and Infection 2017;23:775.e1-6. [DOI: 10.1016/j.cmi.2017.02.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
303 Kattakuzhy S, Levy R, Rosenthal E, Tang L, Wilson E, Kottilil S. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70. [DOI: 10.1007/s12072-016-9748-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
304 Hussein NR, Mohammed Abdullah I, Mohammed Younus O, Taher AM, Salim AA, Shahab FI. Prevalence of HBV, HCV and HIV Infections Among Syrian Refugees in Kurdistan Region, Iraq. Int J Infect 2016;4. [DOI: 10.17795/iji-39420] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
305 Lin HM, Wu PS, Hu HS, Chang WC, Wu RH, Tian JN, Chern JH, Yueh A. Development of robust genotype 1a hepatitis C replicons harboring adaptive mutations for facilitating the antiviral drug discovery and study of virus replication. J Virol Methods 2018;259:10-7. [PMID: 29782889 DOI: 10.1016/j.jviromet.2018.05.010] [Reference Citation Analysis]
306 Li F, Feng Y, Ni N, Hu J, Ruan Y, Shao Y, Ma L. Five Near Full-Length Hepatitis C Virus Sequences Were Identified from HIV Coinfected Injection Drug Users of China. AIDS Res Hum Retroviruses 2017;33:496-9. [PMID: 28075146 DOI: 10.1089/AID.2016.0317] [Reference Citation Analysis]
307 Asselah T, Bourlière M. Hepatitis C Virus. Gastroenterology Clinics of North America 2015;44:859-70. [DOI: 10.1016/j.gtc.2015.07.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
308 Watanabe N, Suzuki T, Date T, Hussan HA, Hmwe SS, Aizaki H, Sugiyama M, Mizokami M, Delaney Iv W, Cheng G, Muramatsu M, Wakita T. Establishment of infectious genotype 4 cell culture-derived hepatitis C virus. J Gen Virol 2020;101:188-97. [PMID: 31859613 DOI: 10.1099/jgv.0.001378] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
309 Wahid B, Waqar M, Saleem K, Shafi F, Rehman Z, Hanif I, Ahmad HM, Wasim M, Sajjad, Wahid K, Idrees M. Poor response to direct-acting antiviral therapy in HCV-infected elderly population: a real-life cohort study based on GeneXpert ® technology. Future Virology 2018;13:467-74. [DOI: 10.2217/fvl-2017-0158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
310 Czarnota A, Offersgaard A, Pihl AF, Prentoe J, Bukh J, Gottwein JM, Bieńkowska-Szewczyk K, Grzyb K. Specific Antibodies Induced by Immunization with Hepatitis B Virus-Like Particles Carrying Hepatitis C Virus Envelope Glycoprotein 2 Epitopes Show Differential Neutralization Efficiency. Vaccines (Basel) 2020;8:E294. [PMID: 32532076 DOI: 10.3390/vaccines8020294] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
311 Hartlage AS, Cullen JM, Kapoor A. The Strange, Expanding World of Animal Hepaciviruses. Annu Rev Virol 2016;3:53-75. [PMID: 27741408 DOI: 10.1146/annurev-virology-100114-055104] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
312 Bartolini B, Lionetti R, Giombini E, Sias C, Taibi C, Montalbano M, D'Offizi G, McPhee F, Hughes EA, Zhou N, Ippolito G, Garbuglia AR, Capobianchi MR. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV+daclatasvir: a case study using ultra deep pyrosequencing. J Clin Virol 2015;66:38-43. [PMID: 25866334 DOI: 10.1016/j.jcv.2015.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
313 Asselah T, Lee SS, Yao BB, Nguyen T, Wong F, Mahomed A, Lim SG, Abergel A, Sasadeusz J, Gane E, Zadeikis N, Schnell G, Zhang Z, Porcalla A, Mensa FJ, Nguyen K. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4:45-51. [PMID: 30393106 DOI: 10.1016/s2468-1253(18)30341-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 13] [Article Influence: 8.5] [Reference Citation Analysis]
314 Lin WY, Lin MS, Weng YH, Yeh TH, Lin YS, Fong PY, Wu YR, Lu CS, Chen RS, Huang YZ. Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection. JAMA Neurol 2019;76:1019-27. [PMID: 31168563 DOI: 10.1001/jamaneurol.2019.1368] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
315 Ederth J, Jern C, Norder H, Magnius L, Alm E, Rognsvåg BK, Sundin CG, Brytting M, Esbjörnsson J, Mild M. Molecular characterization of HCV in a Swedish county over 8 years (2002-2009) reveals distinct transmission patterns. Infect Ecol Epidemiol 2016;6:30670. [PMID: 26854010 DOI: 10.3402/iee.v6.30670] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
316 Hayes CN, Imamura M, Chayama K. Management of HCV patients in cases of direct-acting antiviral failure. Expert Rev Gastroenterol Hepatol. 2019;13:839-848. [PMID: 31392907 DOI: 10.1080/17474124.2019.1651642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
317 Gordon SC, Trudeau S, Li J, Zhou Y, Rupp LB, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Boscarino JA, Daida YG, Schmidt MA, Lu M; CHeCS investigators. Race, Age, and Geography Impact Hepatitis C Genotype Distribution in the United States. J Clin Gastroenterol 2019;53:40-50. [PMID: 28737649 DOI: 10.1097/MCG.0000000000000872] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
318 Esposito I, Cicconi P, D'Alise AM, Brown A, Esposito M, Swadling L, Holst PJ, Bassi MR, Stornaiuolo M, Mori F, Vassilev V, Li W, Donnison T, Gentile C, Turner B, von Delft A, Del Sorbo M, Barra F, Contino AM, Abbate A, Novellino E, Thomsen AR, Christensen JP, Lahm A, Grazioli F, Ammendola V, Siani L, Colloca S, Klenerman P, Nicosia A, Dorrell L, Folgori A, Capone S, Barnes E; PEACHI Consortium. MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans. Sci Transl Med 2020;12:eaaz7715. [PMID: 32554708 DOI: 10.1126/scitranslmed.aaz7715] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
319 Hu P, Wilhelm J, Gerresheim GK, Shalamova LA, Niepmann M. Lnc-ITM2C-1 and GPR55 Are Proviral Host Factors for Hepatitis C Virus. Viruses 2019;11:E549. [PMID: 31200545 DOI: 10.3390/v11060549] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
320 Vine LJ, Sieberhagen C, Cramp ME. Diagnosis and management of hepatitis C. Br J Hosp Med (Lond) 2015;76:625-30. [PMID: 26551491 DOI: 10.12968/hmed.2015.76.11.625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
321 Corcorran MA, Scott JD. Treatment of DAA-Experienced Patients with Chronic Hepatitis C. Curr Hepatology Rep 2018;17:121-9. [DOI: 10.1007/s11901-018-0395-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
322 Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. Drug Resist Updat 2018;37:17-39. [PMID: 29525636 DOI: 10.1016/j.drup.2018.01.004] [Cited by in Crossref: 98] [Cited by in F6Publishing: 94] [Article Influence: 24.5] [Reference Citation Analysis]
323 Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int 2017;11:161-70. [PMID: 27928718 DOI: 10.1007/s12072-016-9776-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
324 Guo X, Zhong JY, Li JW. Hepatitis C Virus Infection and Vaccine Development. J Clin Exp Hepatol 2018;8:195-204. [PMID: 29892184 DOI: 10.1016/j.jceh.2018.02.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
325 Morgan JR, Kim AY, Naggie S, Linas BP. The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets. Open Forum Infect Dis 2018;5:ofx267. [PMID: 29354660 DOI: 10.1093/ofid/ofx267] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
326 Sagnelli E, Alessio L, Sagnelli C, Gualdieri L, Pisaturo M, Minichini C, Di Caprio G, Starace M, Onorato L, Scotto G, Macera M, Coppola N. Clinical Findings of HCV Chronic Infection in Undocumented Immigrants and Low-Income Refugees in Three Areas of Southern Italy. Ann Hepatol 2018;17:47-53. [PMID: 29311411 DOI: 10.5604/01.3001.0010.7534] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
327 Ha S, Totten S, Pogany L, Wu J, Gale-Rowe M. Hepatitis C in Canada and the importance of risk-based screening. Can Commun Dis Rep 2016;42:57-62. [PMID: 29770005 DOI: 10.14745/ccdr.v42i03a02] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
328 Chamorro-de-Vega E, Gimenez-Manzorro A, Rodriguez-Gonzalez CG, Escudero-Vilaplana V, De Lorenzo-Pinto A, Iglesias-Peinado I, Herranz-Alonso A, Sanjurjo Saez M; GRUviC Study Group. Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study. Expert Opin Drug Saf 2018;17:235-41. [PMID: 29325476 DOI: 10.1080/14740338.2018.1424829] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
329 Sohail A, Khan S, Ullah R, Qureshi SA, Bilal M, Khan A. Analysis of hepatitis C infection using Raman spectroscopy and proximity based classification in the transformed domain. Biomed Opt Express 2018;9:2041-55. [PMID: 29760968 DOI: 10.1364/BOE.9.002041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 2] [Article Influence: 3.8] [Reference Citation Analysis]
330 Karkhane M, Marzban A, Lashgarian HE, Zali MR; Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran, Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Genetic Variations in Host Factors and their Critical Role on HCV Medication. Res Mol Med (RMM) 2017;5:6-16. [DOI: 10.29252/rmm.5.1.6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
331 Davis C, Mgomella GS, da Silva Filipe A, Frost EH, Giroux G, Hughes J, Hogan C, Kaleebu P, Asiki G, McLauchlan J, Niebel M, Ocama P, Pomila C, Pybus OG, Pépin J, Simmonds P, Singer JB, Sreenu VB, Wekesa C, Young EH, Murphy DG, Sandhu M, Thomson EC. Highly Diverse Hepatitis C Strains Detected in Sub-Saharan Africa Have Unknown Susceptibility to Direct-Acting Antiviral Treatments. Hepatology 2019;69:1426-41. [PMID: 30387174 DOI: 10.1002/hep.30342] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
332 Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R, Bhagani S, Sherman KE, Shimonova T, Ruane P, Sasadeusz J, Slim J, Zhang Z, Samanta S, Ng TI, Gulati A, Kosloski MP, Shulman NS, Trinh R, Sulkowski M. Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clin Infect Dis. 2018;67:1010-1017. [PMID: 29566246 DOI: 10.1093/cid/ciy220] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 24.3] [Reference Citation Analysis]
333 Kerkerian G, Alimohammadi A, Raycraft T, Conway B. Repeated spontaneous clearance of hepatitis C virus infection in the setting of long-term non-progression of HIV infection. Infect Dis Rep 2017;9:7142. [PMID: 29071045 DOI: 10.4081/idr.2017.7142] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
334 Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, Ueno T, Hughes E, Bertz R, Garimella T, AbuTarif M. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clin Pharmacokinet 2017;56:1173-83. [PMID: 28066880 DOI: 10.1007/s40262-016-0504-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
335 Cotter TG, Jensen DM. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther 2019;13:2565-77. [PMID: 31534310 DOI: 10.2147/DDDT.S172512] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
336 Ng TI, Pilot-Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, Beyer J, Dekhtyar T, Irvin M, Lu L, Asatryan A, Campbell A, Yao B, Lovell S, Mensa F, Lawitz EJ, Kort J, Collins C. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses 2018;10:E462. [PMID: 30154359 DOI: 10.3390/v10090462] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
337 European Union HCV Collaborators. Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. Lancet Gastroenterol Hepatol 2017;2:325-36. [PMID: 28397696 DOI: 10.1016/S2468-1253(17)30045-6] [Cited by in Crossref: 145] [Cited by in F6Publishing: 60] [Article Influence: 29.0] [Reference Citation Analysis]
338 Mahmoudvand S, Shokri S, Azaran A, Seyedian SS, Makvandi M, Mirzaei H, Sheikhrobat SB. Seronegative occult hepatitis C infection among hemodialysis patients: A prevalence study. Ther Apher Dial 2021;25:218-24. [PMID: 32510846 DOI: 10.1111/1744-9987.13535] [Reference Citation Analysis]
339 Botheju WSP, Zghyer F, Mahmud S, Terlikbayeva A, El-Bassel N, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Central Asia: Systematic review, meta-analyses, and meta-regression analyses. Sci Rep 2019;9:2090. [PMID: 30765844 DOI: 10.1038/s41598-019-38853-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
340 Eslam M, George J. Is hepatitis C subtyping still relevant in the era of direct-acting antiviral therapy? Hepatol Int. 2015;9:5-8. [PMID: 25788373 DOI: 10.1007/s12072-014-9600-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
341 Chen P, Zheng Y, Cai Y, Zou P, Li N, Peng C, Gao H, Liu J, Chen Y, Tong Z, Li L. Prevalence of Hepatitis C Virus Infection in a Surgical Population of Southeast China: A Large-Scale Multicenter Study. Can J Gastroenterol Hepatol 2020;2020:8219536. [PMID: 32377514 DOI: 10.1155/2020/8219536] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
342 Navarro-de la Cruz D, Pérez-Castro S, Trigo-Daporta M, Aguilera-Guirao A. Prevalence and distribution of hepatitis C virus genotypes in Galicia during the period 2000-2015. Enferm Infecc Microbiol Clin (Engl Ed) 2019;37:256-9. [PMID: 29759421 DOI: 10.1016/j.eimc.2018.03.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
343 Spear TT, Riley TP, Lyons GE, Callender GG, Roszkowski JJ, Wang Y, Simms PE, Scurti GM, Foley KC, Murray DC, Hellman LM, McMahan RH, Iwashima M, Garrett-Mayer E, Rosen HR, Baker BM, Nishimura MI. Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability. J Leukoc Biol 2016;100:545-57. [PMID: 26921345 DOI: 10.1189/jlb.2A1215-561R] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
344 Ross PE, Young JR, O'Connor CM, Anoushiravani AA, DiCaprio MR. Perioperative Management of Hepatitis C in Patients Undergoing Total Joint Arthroplasty. JBJS Rev 2021;9. [PMID: 34757978 DOI: 10.2106/JBJS.RVW.20.00223] [Reference Citation Analysis]
345 Akiyama MJ, Cleland CM, Lizcano JA, Cherutich P, Kurth AE. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study. Lancet Infect Dis 2019;19:1255-63. [PMID: 31540840 DOI: 10.1016/S1473-3099(19)30264-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
346 Taherkhani R, Farshadpour F. Global elimination of hepatitis C virus infection: Progresses and the remaining challenges. World J Hepatol 2017; 9(33): 1239-1252 [PMID: 29312527 DOI: 10.4254/wjh.v9.i33.1239] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
347 Manomaivat T, Pongsiriwet S, Kuansuwan C, Thosaporn W, Tachasuttirut K, Iamaroon A. Association between hepatitis C infection in Thai patients with oral lichen planus: A case-control study. J Investig Clin Dent 2018;9:e12316. [PMID: 29345111 DOI: 10.1111/jicd.12316] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
348 Suthar AB, Harries AD. A public health approach to hepatitis C control in low- and middle-income countries. PLoS Med. 2015;12:e1001795. [PMID: 25757228 DOI: 10.1371/journal.pmed.1001795] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
349 Do A, Reau NS. Chronic Viral Hepatitis: Current Management and Future Directions. Hepatol Commun 2020;4:329-41. [PMID: 32140652 DOI: 10.1002/hep4.1480] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
350 Meanwell NA. 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph. J Med Chem 2016;59:7311-51. [PMID: 27501244 DOI: 10.1021/acs.jmedchem.6b00915] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
351 Lawitz E, Reau N, Hinestrosa F, Rabinovitz M, Schiff E, Sheikh A, Younes Z, Herring R, Reddy KR, Tran T, Bennett M, Nahass R, Yang JC, Lu S, Dvory-sobol H, Stamm LM, Brainard DM, Mchutchison JG, Pearlman B, Shiffman M, Hawkins T, Curry M, Jacobson I. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial. Gastroenterology 2016;151:893-901.e1. [DOI: 10.1053/j.gastro.2016.07.039] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 6.5] [Reference Citation Analysis]
352 Bhattacharjee C, Nandy SK, Das P, Mukhopadhyay A. Differential interaction strategies of hepatitis c virus genotypes during entry - An in silico investigation of envelope glycoprotein E2 - CD81 interaction. Infect Genet Evol 2019;69:48-60. [PMID: 30639544 DOI: 10.1016/j.meegid.2019.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
353 Younossi ZM. Hepatitis C Infection: A Systemic Disease. Clin Liver Dis. 2017;21:449-453. [PMID: 28689584 DOI: 10.1016/j.cld.2017.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
354 Behairy BE, El-araby HA, El-guindi MA, Basiouny HM, Fouad OA, Ayoub BA, Marei AM, Sira MM. Safety and Efficacy of 8 Weeks Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 4 in Children Aged 4-10 Years. The Journal of Pediatrics 2020;219:106-10. [DOI: 10.1016/j.jpeds.2019.12.034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
355 Grando AV, Ferreira PRA, Pessôa MG, Mazo DFC, Brandão-Mello CE, Reuter T, Martinelli ALC, Gonzalez MP, Nastri ACS, Campos AF, Lopes MIBF, Brito JDU, Mendes-Corrêa MC. Peginterferon still has a place in the treatment of hepatitis C caused by genotype 3 virus. Rev Inst Med Trop Sao Paulo 2017;59:e67. [PMID: 29116287 DOI: 10.1590/S1678-9946201759067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
356 Kantarjian HM, Paul S. Hepatitis C: When high drug prices preclude patient benefit. Cancer 2018;124:1644-6. [PMID: 29486061 DOI: 10.1002/cncr.31292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
357 Wei L, Han T, Yang D, Heo J, Shang J, Cheng J, Chen X, Xie Q, Kim JH, Kalmeijer R, Ouwerkerk-Mahadevan S, Hoeben E, Lenz O, Verbinnen T, Sinha R, Li M, Scott J, Peeters M, Witek J; TIGER team. Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea. J Gastroenterol Hepatol 2016;31:912-20. [PMID: 26777137 DOI: 10.1111/jgh.13288] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
358 Kc S, Karki N, Sharma D, Khadka S, Tiwari PS. Direct-Acting Antivirals in the Treatment of Hepatitis C Virus (HCV)/Human Immunodeficiency Virus (HIV) Co-infected Patients: Real-Life Experience From Nepal. Cureus 2021;13:e15932. [PMID: 34336433 DOI: 10.7759/cureus.15932] [Reference Citation Analysis]
359 Dikopoulos N, Backhus J, Dollinger M. [The news in hepatitis C therapy]. MMW Fortschr Med 2017;159:43-52. [PMID: 29086258 DOI: 10.1007/s15006-017-9595-4] [Reference Citation Analysis]
360 Petruzziello A, Marigliano S, Loquercio G, Cacciapuoti C. Hepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in Europe. Infect Agent Cancer. 2016;11:53. [PMID: 27752280 DOI: 10.1186/s13027-016-0099-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
361 Tung HD, Lee PL, Chen JJ, Kuo HT, Sheu MJ, Cheng CT, Chuang TW, Kao HJ, Hou CY, Tsai HH, Wu LC, Lee C. Geographic variation of genotype 6 hepatitis C virus infection in an endemic area of southern Taiwan. J Formos Med Assoc 2020;119:1876-80. [PMID: 32620462 DOI: 10.1016/j.jfma.2020.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
362 Tarragô AM, Pereira GL, Victória FDS, Marie AMA, Victória MB. Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon. Rev Soc Bras Med Trop 2017;50:861-3. [PMID: 29340469 DOI: 10.1590/0037-8682-0094-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
363 Söderholm J, Millbourn C, Büsch K, Kövamees J, Schvarcz R, Lindahl K, Bruchfeld A. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. Journal of Hepatology 2018;68:904-11. [DOI: 10.1016/j.jhep.2017.12.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
364 Brook G, Bhagani S, Kulasegaram R, Torkington A, Mutimer D, Hodges E, Hesketh L, Farnworth S, Sullivan V, Gore C, Devitt E, Sullivan AK; Clinical Effectiveness Group British Association for Sexual Health and HIV. United Kingdom National Guideline on the Management of the viral hepatitides A, B and C 2015. Int J STD AIDS 2016;27:501-25. [PMID: 26745988 DOI: 10.1177/0956462415624250] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
365 Rivero-Juárez A, Rivero A. Sustained virological response with sofosbuvir and ledipasvir for hepatitis C virus genotype 5. Lancet Infect Dis 2016;16:392-3. [PMID: 26803445 DOI: 10.1016/S1473-3099(16)00018-9] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
366 Hartlage AS, Kapoor A. Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up. Viruses 2021;13:1596. [PMID: 34452460 DOI: 10.3390/v13081596] [Reference Citation Analysis]
367 Guo M, Lu J, Gan T, Xiang X, Xu Y, Xie Q, Zhong J. Construction and characterization of Genotype-3 hepatitis C virus replicon revealed critical genotype-3-specific polymorphism for drug resistance and viral fitness. Antiviral Res 2019;171:104612. [PMID: 31542377 DOI: 10.1016/j.antiviral.2019.104612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
368 Nguyen D, Smith D, Vaughan-jackson A, Magri A, Barnes E, Simmonds P. Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub-Saharan Africa and South East Asia. Journal of Hepatology 2020;73:794-9. [DOI: 10.1016/j.jhep.2020.05.029] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
369 Schrier L, Wyder C, Del Torso S, Stiris T, von Both U, Brandenberger J, Ritz N. Medical care for migrant children in Europe: a practical recommendation for first and follow-up appointments. Eur J Pediatr 2019;178:1449-67. [PMID: 31240389 DOI: 10.1007/s00431-019-03405-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
370 Su X, Zhao X, Deng JL, Li SN, Du X, Dong JZ, Ma CS. Antiviral treatment for hepatitis C is associated with a reduced risk of atherosclerotic cardiovascular outcomes: A systematic review and meta-analysis. J Viral Hepat 2021;28:664-71. [PMID: 33452699 DOI: 10.1111/jvh.13469] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Lv DD, Wang ML, Chen EQ, Wu DB, Tao YC, Zhang DM, Tang H. A retrospective study of the efficacy of sofosbuvir plus NS5A inhibitors for patients with hepatitis C virus genotype-2 chronic infection. Eur J Gastroenterol Hepatol 2019;31:382-8. [PMID: 30383554 DOI: 10.1097/MEG.0000000000001299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
372 Rajhi M, Ghedira K, Chouikha A, Djebbi A, Cheikh I, Ben Yahia A, Sadraoui A, Hammami W, Azouz M, Ben Mami N, Triki H. Phylogenetic Analysis and Epidemic History of Hepatitis C Virus Genotype 2 in Tunisia, North Africa. PLoS One 2016;11:e0153761. [PMID: 27100294 DOI: 10.1371/journal.pone.0153761] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
373 Moustafa RI, Haddad JG, Linna L, Hanoulle X, Descamps V, Mesalam AA, Baumert TF, Duverlie G, Meuleman P, Dubuisson J, Lavie M. Functional Study of the C-Terminal Part of the Hepatitis C Virus E1 Ectodomain. J Virol 2018;92:e00939-18. [PMID: 30068644 DOI: 10.1128/JVI.00939-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
374 Ku KS, Chodavarapu RK, Martin R, Miller MD, Mo H, Svarovskaia ES. Sequencing Analysis of NS3/4A, NS5A, and NS5B Genes from Patients Infected with Hepatitis C Virus Genotypes 5 and 6. J Clin Microbiol 2016;54:1835-41. [PMID: 27147726 DOI: 10.1128/JCM.00238-16] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
375 Wahsh EA, Hussein AK, Gomaa AA, Baraka MA, Al-Deen Abead M. Real Life Egyptian Experience of Daclatasvir Plus Sofosbuvir with Ribavirin in Naïve Difficult to Treat HCV Patients. Infect Disord Drug Targets 2020;20:43-8. [PMID: 30009715 DOI: 10.2174/1871526518666180716141806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
376 Zignego AL, Monti M, Gragnani L. Sofosbuvir/Velpatasvir for the treatment of Hepatitis C Virus infection. Acta Biomed 2018;89:321-31. [PMID: 30333452 DOI: 10.23750/abm.v89i3.7718] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
377 Liu TW, Tsai PC, Huang CI, Tsai YS, Wang SC, Ko YM, Lin CC, Chen KY, Liang PC, Lin YH, Hsieh MY, Hou NJ, Huang CF, Yeh ML, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. J Formos Med Assoc 2018;117:54-62. [PMID: 28389143 DOI: 10.1016/j.jfma.2017.02.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
378 Swadling L, Halliday J, Kelly C, Brown A, Capone S, Ansari MA, Bonsall D, Richardson R, Hartnell F, Collier J, Ammendola V, Del Sorbo M, Von Delft A, Traboni C, Hill AV, Colloca S, Nicosia A, Cortese R, Klenerman P, Folgori A, Barnes E. Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel). 2016;4. [PMID: 27490575 DOI: 10.3390/vaccines4030027] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
379 De Luca A, Di Giambenedetto S, Lo Presti A, Sierra S, Prosperi M, Cella E, Giovanetti M, Torti C, Caudai C, Vicenti I, Saladini F, Almi P, Grima P, Blanc P, Fabbiani M, Rossetti B, Gagliardini R, Kaiser R, Ciccozzi M, Zazzi M. Two Distinct Hepatitis C Virus Genotype 1a Clades Have Different Geographical Distribution and Association With Natural Resistance to NS3 Protease Inhibitors. Open Forum Infect Dis 2015;2:ofv043. [PMID: 26213689 DOI: 10.1093/ofid/ofv043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
380 Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol 2016;29:282-96. [PMID: 27366028 DOI: 10.20524/aog.2016.0041] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
381 Honegger JR, Tedesco D, Kohout JA, Prasad MR, Price AA, Lindquist T, Ohmer S, Moore-Clingenpeel M, Grakoui A, Walker CM. Influence of IFNL3 and HLA-DPB1 genotype on postpartum control of hepatitis C virus replication and T-cell recovery. Proc Natl Acad Sci U S A 2016;113:10684-9. [PMID: 27601657 DOI: 10.1073/pnas.1602337113] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
382 Xie Y, Garza G, Dong J. Hepatitis C Virus Genotype and Subtype Distribution in Patient Specimens Tested at the University of Texas Medical Branch, Galveston, Between January 2011 and November 2014. Lab Med 2016;47:112-8. [PMID: 26995188 DOI: 10.1093/labmed/lmw004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
383 Rehm J, Shield KD. Global Burden of Alcohol Use Disorders and Alcohol Liver Disease. Biomedicines 2019;7:E99. [PMID: 31847084 DOI: 10.3390/biomedicines7040099] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
384 Kong L, Lee DE, Kadam RU, Liu T, Giang E, Nieusma T, Garces F, Tzarum N, Woods VL Jr, Ward AB, Li S, Wilson IA, Law M. Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A 2016;113:12768-73. [PMID: 27791120 DOI: 10.1073/pnas.1609780113] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
385 Ohya K, Akuta N, Suzuki F, Fujiyama S, Kawamura Y, Kominami Y, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2. J Med Virol 2018;90:919-25. [PMID: 29315652 DOI: 10.1002/jmv.25023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
386 Venkatesan A, Febin Prabhu Dass J. Deciphering molecular properties and docking studies of hepatitis C and non-hepatitis C antiviral inhibitors - A computational approach. Life Sci 2017;174:8-14. [PMID: 28259653 DOI: 10.1016/j.lfs.2017.02.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
387 Rodrigo C, Eltahla AA, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, Page K, Bruneau J, Morris MD, Cox AL, Osburn W, Kim AY, Shoukry NH, Lauer GM, Maher L, Schinkel J, Prins M, Hellard M, Lloyd AR; InC3 Collaborative. Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study. J Viral Hepat 2017;24:43-52. [PMID: 27808453 DOI: 10.1111/jvh.12616] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
388 Khadempour-Arani H, Shojaeian A, Mehri-Ghahfarrokhi A, Shahraki HR, Karimi A, Dehghan A, Mobini GR. Identifying genotype profile of chronic hepatitis C infection in Southwest Iran. J Res Med Sci 2020;25:85. [PMID: 33273930 DOI: 10.4103/jrms.JRMS_524_19] [Reference Citation Analysis]
389 Barth H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J Hepatol 2015; 7(5): 725-737 [PMID: 25914773 DOI: 10.4254/wjh.v7.i5.725] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
390 Asselah T, Kowdley KV, Zadeikis N, Wang S, Hassanein T, Horsmans Y, Colombo M, Calinas F, Aguilar H, de Ledinghen V, Mantry PS, Hezode C, Marinho RT, Agarwal K, Nevens F, Elkhashab M, Kort J, Liu R, Ng TI, Krishnan P, Lin CW, Mensa FJ. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417-426. [PMID: 28951228 DOI: 10.1016/j.cgh.2017.09.027] [Cited by in Crossref: 143] [Cited by in F6Publishing: 128] [Article Influence: 28.6] [Reference Citation Analysis]
391 Woode ME, Abu-Zaineh M, Perriëns J, Renaud F, Wiktor S, Moatti JP. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Viral Hepat. 2016;23:522-534. [PMID: 26924428 DOI: 10.1111/jvh.12516] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
392 Lu J, Feng Y, Chen L, Zeng Z, Liu X, Cai W, Wang H, Guo X, Zhou H, Tao W, Xie Q. Subtype-Specific Prevalence of Hepatitis C Virus NS5A Resistance Associated Substitutions in Mainland China. Front Microbiol 2019;10:535. [PMID: 30941111 DOI: 10.3389/fmicb.2019.00535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
393 Rattanavipapong W, Anothaisintawee T, Teerawattananon Y. Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis. PLoS One 2018;13:e0193112. [PMID: 29466415 DOI: 10.1371/journal.pone.0193112] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
394 Lim JK, Liapakis AM, Shiffman ML, Lok AS, Zeuzem S, Terrault NA, Park JS, Landis CS, Hassan M, Gallant J, Kuo A, Pockros PJ, Vainorius M, Akushevich L, Michael L, Fried MW, Nelson DR, Ben-Ari Z; HCV-TARGET Study Group. Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Clin Gastroenterol Hepatol 2018;16:1811-1819.e4. [PMID: 29306043 DOI: 10.1016/j.cgh.2017.12.037] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
395 Johnson SW, Thompson DK, Raccor B. Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Curr Infect Dis Rep 2017;19:22. [PMID: 28421422 DOI: 10.1007/s11908-017-0578-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
396 Wong RJ, Nguyen MT, Trinh HN, Huynh A, Ly MT, Nguyen HA, Nguyen KK, Yang J, Garcia RT, Levitt B, da Silveira E, Gish RG. Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States. J Viral Hepat 2017;24:17-21. [PMID: 27677786 DOI: 10.1111/jvh.12609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
397 Hezode C, Reau N, Svarovskaia ES, Doehle BP, Shanmugam R, Dvory-Sobol H, Hedskog C, McNally J, Osinusi A, Brainard DM, Miller MD, Mo H, Roberts SK, O'Leary JG, Shafran SD, Zeuzem S. Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. J Hepatol. 2018;68:895-903. [PMID: 29221887 DOI: 10.1016/j.jhep.2017.11.032] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 11.0] [Reference Citation Analysis]
398 Wu Q, Li Z, Liu Q. Treatment with PTEN-Long protein inhibits hepatitis C virus replication. Virology 2017;511:1-8. [PMID: 28783500 DOI: 10.1016/j.virol.2017.08.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
399 Wang X, Yan Y, Gan T, Yang X, Li D, Zhou D, Sun Q, Huang Z, Zhong J. A trivalent HCV vaccine elicits broad and synergistic polyclonal antibody response in mice and rhesus monkey. Gut 2019;68:140-9. [PMID: 29180585 DOI: 10.1136/gutjnl-2017-314870] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
400 Wyles DL, Sulkowski MS, Dieterich D. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy. Clin Infect Dis 2016;63 Suppl 1:S3-S11. [PMID: 27363438 DOI: 10.1093/cid/ciw219] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 6.6] [Reference Citation Analysis]
401 Behrendt P, Perin P, Menzel N, Banda D, Pfaender S, Alves MP, Thiel V, Meuleman P, Colpitts CC, Schang LM, Vondran FWR, Anggakusuma, Manns MP, Steinmann E, Pietschmann T. Pentagalloylglucose, a highly bioavailable polyphenolic compound present in Cortex moutan, efficiently blocks hepatitis C virus entry. Antiviral Res 2017;147:19-28. [PMID: 28923507 DOI: 10.1016/j.antiviral.2017.09.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
402 Liu CH, Huang CF, Liu CJ, Dai CY, Huang JF, Lin JW, Liang CC, Yang SS, Lin CL, Su TH, Yang HC, Chen PJ, Chen DS, Chuang WL, Kao JH, Yu ML. Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep 2015;5:11710. [PMID: 26130141 DOI: 10.1038/srep11710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
403 Oikonomopoulou M, Demetriou VL, Kostrikis LG, Paraskevis D. Re-analysis of unassigned hepatitis C virus (HCV) strain CYHCV025: Evidence of a highly divergent lineage within genotype 1. Mol Phylogenet Evol 2017;109:362-6. [PMID: 28179183 DOI: 10.1016/j.ympev.2017.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
404 Zhang LQ, Xu XM, Li XY, Guo J, Wang HZ, Sun JY, Cai JP. Urinary 8-oxo-7,8-dihydroguanosine levels are elevated in HCV-infected patients. Nucleosides Nucleotides Nucleic Acids 2021;:1-12. [PMID: 34379042 DOI: 10.1080/15257770.2021.1961272] [Reference Citation Analysis]
405 Mhalla S, Hammoud R, Frih A, Kadri Y, El Argoubi A, Elmay M, Mastouri M. Prevalence and risk factors of hepatitis B and C among hemodialysis patients in Tunisia. Med Mal Infect 2018;48:175-9. [PMID: 29249466 DOI: 10.1016/j.medmal.2017.11.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
406 Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017;166:637-648. [PMID: 28319996 DOI: 10.7326/m16-2575] [Cited by in Crossref: 327] [Cited by in F6Publishing: 148] [Article Influence: 65.4] [Reference Citation Analysis]
407 Lapumnuaypol K, Pisarcik D, Putthapiban P, Sukhumthammarat W, Wijarnpreecha K, Thongprayoon C, Ungprasert P. Direct-acting antiviral agents decrease haemoglobin A1c level in patients with diabetes infected with hepatitis C virus: A systematic review & meta-analysis. Indian J Med Res 2020;152:562-7. [PMID: 34145095 DOI: 10.4103/ijmr.IJMR_1088_18] [Reference Citation Analysis]
408 Meeprasert A, Hannongbua S, Kungwan N, Rungrotmongkol T. Effect of D168V mutation in NS3/4A HCV protease on susceptibilities of faldaprevir and danoprevir. Mol Biosyst 2016;12:3666-73. [PMID: 27731877 DOI: 10.1039/c6mb00610h] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
409 Gómez-gutiérrez C, Chávez-tapia NC, Ponciano-rodríguez G, Uribe M, Méndez-sánchez N. Prevalence of hepatitis C virus infection among patients undergoing haemodialysis in Latin America. Annals of Hepatology 2015;14:807-14. [DOI: 10.5604/16652681.1171751] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
410 Hegab DS, Sweilam MA. Cryoglobulinaemia in Egyptian Patients with Extrahepatic Cutaneous Manifestations of Chronic Hepatitis C Virus Infection. Dermatol Res Pract 2015;2015:182609. [PMID: 26839534 DOI: 10.1155/2015/182609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
411 Sato K, Chayama K, Alves K, Toyoda H, Suzuki F, Kato K, Rodrigues L, Zhang X, Setze C, Pilot-Matias T, Burroughs M, Redman R, Kumada H. Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients. Adv Ther. 2017;34:1449-1465. [PMID: 28536999 DOI: 10.1007/s12325-017-0506-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
412 Alberione MP, Moeller R, Kirui J, Ginkel C, Doepke M, Ströh LJ, Machtens JP, Pietschmann T, Gerold G. Single-nucleotide variants in human CD81 influence hepatitis C virus infection of hepatoma cells. Med Microbiol Immunol 2020;209:499-514. [PMID: 32322956 DOI: 10.1007/s00430-020-00675-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
413 Liao SH, Chen CL, Hsu CY, Chien KL, Kao JH, Chen PJ, Chen TH, Chen CH. Long-term effectiveness of population-wide multifaceted interventions for hepatocellular carcinoma in Taiwan. J Hepatol 2021;75:132-41. [PMID: 33689789 DOI: 10.1016/j.jhep.2021.02.029] [Reference Citation Analysis]
414 Ali NK, Mohamed RR, Saleh BE, Alkady MM, Farag ES. Occult hepatitis C virus infection among haemodialysis patients. Arab J Gastroenterol. 2018;19:101-105. [PMID: 30245116 DOI: 10.1016/j.ajg.2018.09.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
415 Fukuhara T, Yamamoto S, Ono C, Nakamura S, Motooka D, Mori H, Kurihara T, Sato A, Tamura T, Motomura T, Okamoto T, Imamura M, Ikegami T, Yoshizumi T, Soejima Y, Maehara Y, Chayama K, Matsuura Y. Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity. Sci Rep 2017;7:45228. [PMID: 28327559 DOI: 10.1038/srep45228] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
416 Jeong S, Lee YS, Kim K, Yoon JS, Kim S, Ha J, Kang I, Choe W. 2-O-Methylhonokiol Suppresses HCV Replication via TRAF6-Mediated NF-kB Activation. Int J Mol Sci 2021;22:6499. [PMID: 34204438 DOI: 10.3390/ijms22126499] [Reference Citation Analysis]
417 Puoti M, Rossotti R, Baiguera C, Orso M. Treatment of hepatitis C virus genotype 1-infected patients: mission accomplished? Liver Int 2016;36:181-4. [DOI: 10.1111/liv.13040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
418 Toyokuni S, Ito F, Yamashita K, Okazaki Y, Akatsuka S. Iron and thiol redox signaling in cancer: An exquisite balance to escape ferroptosis. Free Radic Biol Med. 2017;108:610-626. [PMID: 28433662 DOI: 10.1016/j.freeradbiomed.2017.04.024] [Cited by in Crossref: 86] [Cited by in F6Publishing: 85] [Article Influence: 17.2] [Reference Citation Analysis]
419 Donyavi T, Bokharaei-Salim F, Khanaliha K, Sheikh M, Bastani MN, Moradi N, Babaei R, Habib Z, Fakhim A, Esghaei M. High prevalence of occult hepatitis C virus infection in injection drug users with HIV infection. Arch Virol. 2019;164:2493-2504. [PMID: 31346769 DOI: 10.1007/s00705-019-04353-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
420 Fourati S, Rodriguez C, Soulier A, Donati F, Hamadat S, Poiteau L, Demontant V, Brillet R, Ahnou N, Gricourt G, Chevaliez S, Ahmed-Belkacem A, Pawlotsky JM. Fitness-associated substitutions following failure of direct-acting antivirals assessed by deep sequencing of full-length hepatitis C virus genomes. Aliment Pharmacol Ther 2020;52:1583-91. [PMID: 32886807 DOI: 10.1111/apt.16054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
421 Nguyen MH, Trinh H, Do S, Nguyen T, Nguyen P, Henry L. Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients. Am J Gastroenterol 2017;112:1824-31. [PMID: 29087397 DOI: 10.1038/ajg.2017.399] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
422 Ruta S, Cernescu C. Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol 2015; 21(38): 10811-10823 [PMID: 26478672 DOI: 10.3748/wjg.v21.i38.10811] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
423 Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S; PegBase Group Investigators. Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Ann Gastroenterol 2017;30:327-43. [PMID: 28469364 DOI: 10.20524/aog.2017.0136] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
424 Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734. [PMID: 26600216 DOI: 10.1016/j.gtc.2015.07.003] [Cited by in Crossref: 101] [Cited by in F6Publishing: 88] [Article Influence: 14.4] [Reference Citation Analysis]
425 Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM. Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver Int. 2018;38:443-450. [PMID: 28756625 DOI: 10.1111/liv.13534] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 6.4] [Reference Citation Analysis]
426 Ling J, Persson Vinnersten T, Hesson JC, Bohlin J, Roligheten E, Holmes EC, Pettersson JH. Identification of hepatitis C virus in the common bed bug - a potential, but uncommon route for HCV infection? Emerg Microbes Infect 2020;9:1429-31. [PMID: 32525459 DOI: 10.1080/22221751.2020.1780950] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
427 Lu J, Zhang L, Xu X, Chen Y, Zhou Y, Zhang Z, Fu G, Chen G. Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China. Drug Alcohol Depend 2019;194:101-6. [PMID: 30419403 DOI: 10.1016/j.drugalcdep.2018.09.026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
428 Fernández-Caballero JA, Alvarez M, Chueca N, Pérez AB, García F. The cobas® HCV GT is a new tool that accurately identifies Hepatitis C virus genotypes for clinical practice. PLoS One 2017;12:e0175564. [PMID: 28410425 DOI: 10.1371/journal.pone.0175564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
429 Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ. Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese. Drug Des Devel Ther 2018;12:1045-51. [PMID: 29750017 DOI: 10.2147/DDDT.S148117] [Reference Citation Analysis]
430 Zhou N, Han Z, Hartman-Neumann S, DeGray B, Ueland J, Vellucci V, Hernandez D, McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother 2016;71:3495-505. [PMID: 27605597 DOI: 10.1093/jac/dkw336] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
431 Joy JB, McCloskey RM, Nguyen T, Liang RH, Khudyakov Y, Olmstead A, Krajden M, Ward JW, Harrigan PR, Montaner JSG, Poon AFY. The spread of hepatitis C virus genotype 1a in North America: a retrospective phylogenetic study. Lancet Infect Dis 2016;16:698-702. [PMID: 27039040 DOI: 10.1016/S1473-3099(16)00124-9] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
432 Chantratita W, Song KS, Nimse SB, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Sonawane MD, Warkad SD, Kim T. 6 HCV Genotyping 9G test for HCV 1a, 1b, 2, 3, 4 and 6 (6a, 6f, 6i and 6n) with high accuracy. J Virol Methods 2017;246:95-9. [PMID: 28456667 DOI: 10.1016/j.jviromet.2017.04.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
433 Chris Krueger A, Chen HJ, Randolph JT, Brown BS, Halvorsen GT, Heyman HR, Li T, Marvin CC, Shanley JP, Voight EA, Bow DAJ, Van Handel C, Peterkin V, Carr RA, Stolarik D, Dekhtyar T, Irvin ML, Krishnan P, Henry RF, Wagner R, DeGoey DA. Synthesis and evaluation of 2'-dihalo ribonucleotide prodrugs with activity against hepatitis C virus. Bioorg Med Chem 2020;28:115208. [PMID: 31740203 DOI: 10.1016/j.bmc.2019.115208] [Reference Citation Analysis]
434 Welzel TM, Asselah T, Dumas EO, Zeuzem S, Shaw D, Hazzan R, Forns X, Pilot-matias T, Lu W, Cohen DE, Feld JJ. Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. The Lancet Gastroenterology & Hepatology 2017;2:494-500. [DOI: 10.1016/s2468-1253(17)30071-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
435 Budzko L, Marcinkowska-Swojak M, Jackowiak P, Kozlowski P, Figlerowicz M. Copy number variation of genes involved in the hepatitis C virus-human interactome. Sci Rep 2016;6:31340. [PMID: 27510840 DOI: 10.1038/srep31340] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
436 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
437 White DL, Kanwal F, Jiao L, El-serag HB. Epidemiology of Hepatocellular Carcinoma. In: Carr BI, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2016. pp. 3-24. [DOI: 10.1007/978-3-319-34214-6_1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
438 Mahassadi AK, Nguieguia JLK, Kissi HY, Awuah AA, Bangoura AD, Doffou SA, Attia AK. Systemic inflammatory response syndrome and model for end-stage liver disease score accurately predict the in-hospital mortality of black African patients with decompensated cirrhosis at initial hospitalization: a retrospective cohort study. Clin Exp Gastroenterol 2018;11:143-52. [PMID: 29670387 DOI: 10.2147/CEG.S140655] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
439 Tong YQ, Liu B, Liu H, Zheng HY, Gu J, Liu H, Song EJ, Song C, Li Y. Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population. Clin Microbiol Infect 2015;21:874.e9-874.e21. [PMID: 26055416 DOI: 10.1016/j.cmi.2015.05.034] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
440 Hézode C. Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions. J Viral Hepat 2017;24:92-101. [PMID: 27862695 DOI: 10.1111/jvh.12635] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
441 Witteveldt J, Martin-Gans M, Simmonds P. Enhancement of the Replication of Hepatitis C Virus Replicons of Genotypes 1 to 4 by Manipulation of CpG and UpA Dinucleotide Frequencies and Use of Cell Lines Expressing SECL14L2 for Antiviral Resistance Testing. Antimicrob Agents Chemother 2016;60:2981-92. [PMID: 26953209 DOI: 10.1128/AAC.02932-15] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
442 Chlibek R, Smetana J, Sosovickova R, Gal P, Dite P, Stepanova V, Pliskova L, Plisek S. Prevalence of hepatitis C virus in adult population in the Czech Republic - time for birth cohort screening. PLoS One 2017;12:e0175525. [PMID: 28406947 DOI: 10.1371/journal.pone.0175525] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
443 Ebranati E, Mancon A, Airoldi M, Renica S, Shkjezi R, Dragusha P, Della Ventura C, Ciccaglione AR, Ciccozzi M, Bino S, Tanzi E, Micheli V, Riva E, Galli M, Zehender G. Time and Mode of Epidemic HCV-2 Subtypes Spreading in Europe: Phylodynamics in Italy and Albania. Diagnostics (Basel) 2021;11:327. [PMID: 33671355 DOI: 10.3390/diagnostics11020327] [Reference Citation Analysis]
444 Owusu M, Bonney JK, Annan AA, Mawuli G, Okyere K, Mutocheluh M, Aryeequaye J, Adjei NK, Afihene M, Spangenberg K, Sylverken J, Owusu-Dabo E, Drosten C, Adu-Sarkodie Y. Aetiology of viral hepatitis among jaundiced patients presenting to a tertiary hospital in Ghana. PLoS One 2018;13:e0203699. [PMID: 30208084 DOI: 10.1371/journal.pone.0203699] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
445 Abutaleb A, Kottilil S, Wilson E. Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy. Hepatol Int 2018;12:214-22. [PMID: 29845496 DOI: 10.1007/s12072-018-9873-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
446 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Musa NI, Mohamed IE, Abohalima AS. Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence. Egypt Liver Journal 2020;10. [DOI: 10.1186/s43066-020-00035-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
448 Borba HH, Wiens A, Steimbach LM, Tonin FS, Pedroso M, Ivantes CA, Fernandez-Llimos F, Pontarolo R. Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study. Ther Clin Risk Manag 2017;13:59-64. [PMID: 28138248 DOI: 10.2147/TCRM.S124663] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
449 Moghimi M, Tavakoli F, Doosti M, Ahmadi-Vasmehjani A, Akhondi-Meybodi M. Correlation between interleukin-28 gene polymorphism with interleukin-28 cytokine levels and viral genotypes among HCV patients in Yazd, Iran. BMC Res Notes 2019;12:626. [PMID: 31551080 DOI: 10.1186/s13104-019-4651-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Gul A, Zahid N, Ahmed J, Zahir F, Khan IA, Ali I. Molecular characterization of Hepatitis C virus 3a in Peshawar. BMC Infect Dis 2016;16:163. [PMID: 27090517 DOI: 10.1186/s12879-016-1488-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
451 Lanini S, Ustianowski A, Pisapia R, Zumla A, Ippolito G. Viral Hepatitis. Infectious Disease Clinics of North America 2019;33:1045-62. [DOI: 10.1016/j.idc.2019.08.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
452 Phillips M, Abboud J, Abodunde B, Paul DP 3rd, Coustasse A. The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia. Health Care Manag (Frederick) 2020;39:2-11. [PMID: 31876587 DOI: 10.1097/HCM.0000000000000278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
453 Ullah N, Kakakhel MA, Bai Y, Xi L, Khan I, Kalra BS, Kumar T, Ahmad H, Shah M, Guanlan L, Zhang C. Prevalence of active HCV infection and genotypic distribution among the general population of district Mardan, Pakistan. Braz J Biol 2021;83:e244977. [PMID: 34287506 DOI: 10.1590/1519-6984.244977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 San SN, Matsumoto J, Saito Y, Koike M, Sakaue H, Kato Y, Fujiyoshi M, Ariyoshi N, Yamada H. Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro. Xenobiotica 2019;49:935-44. [PMID: 30227770 DOI: 10.1080/00498254.2018.1524947] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
455 Pierce BG, Keck ZY, Foung SK. Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol 2016;20:55-63. [PMID: 27657659 DOI: 10.1016/j.coviro.2016.09.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
456 Mousa AM, Aldebasi YH. L-carnosine mitigates interleukin-1α-induced dry eye disease in rabbits via its antioxidant, anti-inflammatory, antiapoptotic, and antifibrotic effects. Cutan Ocul Toxicol 2021;40:241-51. [PMID: 34056995 DOI: 10.1080/15569527.2021.1935995] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
457 Yousif MM, Ahmed H, Elsadek HM, Shendi AM, Gouda TM, Elsayed IA, Gendia MA, Magdy MM, Lbrahim NF, Sadek AMEM, Zaki AM, Shafeik H, Zahran MH. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies. J Viral Hepat 2020;27:1190-201. [PMID: 32564500 DOI: 10.1111/jvh.13349] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
458 Ridruejo E, Pereson MJ, Flichman DM, Di Lello FA. Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions. World J Hepatol 2021; 13(9): 1069-1078 [PMID: 34630875 DOI: 10.4254/wjh.v13.i9.1069] [Reference Citation Analysis]
459 Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM, Brainard DM, Subramanian MG, Mchutchison JG, Mo H, Svarovskaia E, Shafran SD. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. The Journal of Infectious Diseases 2018;218:1722-9. [DOI: 10.1093/infdis/jiy401] [Cited by in Crossref: 98] [Cited by in F6Publishing: 90] [Article Influence: 24.5] [Reference Citation Analysis]
460 Breitinger U, Farag NS, Ali NKM, Breitinger HA. Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors. Biophys J 2016;110:2419-29. [PMID: 27276260 DOI: 10.1016/j.bpj.2016.04.018] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
461 Singh AD, Maitra S, Singh N, Tyagi P, Ashraf A, Kumar R, Shalimar. Systematic review with meta-analysis: impact of baseline resistance-associated substitutions on the efficacy of glecaprevir/pibrentasvir among chronic hepatitis C patients. Aliment Pharmacol Ther 2020;51:490-504. [PMID: 31943236 DOI: 10.1111/apt.15633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
462 Mahmud S, Mumtaz GR, Chemaitelly H, Al Kanaani Z, Kouyoumjian SP, Hermez JG, Abu-Raddad LJ. The status of hepatitis C virus infection among people who inject drugs in the Middle East and North Africa. Addiction 2020;115:1244-62. [PMID: 32009283 DOI: 10.1111/add.14944] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
463 AlMalki WH, Shahid I, Abdalla AN, Johargy AK, Ahmed M, Hassan S. Virological surveillance, molecular phylogeny, and evolutionary dynamics of hepatitis C virus subtypes 1a and 4a isolates in patients from Saudi Arabia. Saudi J Biol Sci 2021;28:1664-77. [PMID: 33732052 DOI: 10.1016/j.sjbs.2020.11.089] [Reference Citation Analysis]
464 Suzuki S, Mori K, Higashino A, Iwasaki Y, Yasutomi Y, Maki N, Akari H. Persistent replication of a hepatitis C virus genotype 1b-based chimeric clone carrying E1, E2 and p6 regions from GB virus B in a New World monkey. Microbiol Immunol 2016;60:26-34. [PMID: 26634303 DOI: 10.1111/1348-0421.12349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
465 Luo A, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis. Medicine (Baltimore) 2019;98:e15626. [PMID: 31096473 DOI: 10.1097/MD.0000000000015626] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
466 Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM, Massetto B, Lin M, Han B, McHutchison JG, Subramanian GM, Cooper C, Agarwal K; BOSON Study Group. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462-70. [PMID: 26248087 DOI: 10.1053/j.gastro.2015.07.043] [Cited by in Crossref: 170] [Cited by in F6Publishing: 151] [Article Influence: 24.3] [Reference Citation Analysis]
467 Rivero-Juarez A, Brieva T, Frias M, Rivero A. Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Expert Opin Drug Metab Toxicol 2018;14:901-10. [PMID: 30058394 DOI: 10.1080/17425255.2018.1506765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
468 Zhou S, Cella E, Zhou W, Kong WH, Liu MQ, Liu PL, Ciccozzi M, Salemi M, Chen X. Population dynamics of hepatitis C virus subtypes in injecting drug users on methadone maintenance treatment in China associated with economic and health reform. J Viral Hepat 2017;24:551-60. [PMID: 28092412 DOI: 10.1111/jvh.12677] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
469 Viganò M, Perno CF, Craxì A; AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party. Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. Dig Liver Dis 2017;49:731-41. [PMID: 28456519 DOI: 10.1016/j.dld.2017.03.027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
470 El Missiri AM, Rayan MM, Awad MM, El Desoky AI. Assessing the impact of a combination of sofosbuvir and daclatasvir treatment for hepatitis C virus infection on heart rate, rhythm and heart rate variability using 24-hour ECG monitoring. Egypt Heart J 2020;72:37. [PMID: 32613565 DOI: 10.1186/s43044-020-00070-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
471 Noureddin M, Wong MM, Todo T, Lu SC, Sanyal AJ, Mena EA. Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals. World J Gastroenterol 2018; 24(11): 1269-1277 [PMID: 29568207 DOI: 10.3748/wjg.v24.i11.1269] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
472 Liu X, Gao Y, Niu J. Hepatitis C Virus - Related Hepatocellular Carcinoma in the Era of Direct - Acting Antiviral Agents. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.66007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
473 Holmes JA, Thompson AJ. Interferon-free combination therapies for the treatment of hepatitis C: current insights. Hepat Med 2015;7:51-70. [PMID: 26586968 DOI: 10.2147/HMER.S55864] [Cited by in Crossref: 42] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
474 Young J, Wong S, Janjua NZ, Klein MB. Comparing direct acting antivirals for hepatitis C using observational data - Why and how? Pharmacol Res Perspect 2020;8:e00650. [PMID: 32894643 DOI: 10.1002/prp2.650] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
475 Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176. [PMID: 28404132 DOI: 10.1016/s2468-1253(16)30181-9] [Cited by in Crossref: 1051] [Cited by in F6Publishing: 472] [Article Influence: 175.2] [Reference Citation Analysis]
476 Catanese MT, Dorner M. Advances in experimental systems to study hepatitis C virus in vitro and in vivo. Virology. 2015;479-480:221-233. [PMID: 25847726 DOI: 10.1016/j.virol.2015.03.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
477 Kim HS, You Y, Mun J, Gadhe CG, Moon H, Lee JS, Pae AN, Kohara M, Keum G, Kim BM, Jang SK. Structure-activity relationships of fluorene compounds inhibiting HCV variants. Antiviral Res 2020;174:104678. [PMID: 31862501 DOI: 10.1016/j.antiviral.2019.104678] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
478 Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ 2017;20:740-8. [PMID: 28489467 DOI: 10.1080/13696998.2017.1325744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
479 Zeng N, Zou C, He Z, Ma H, Ou X, You H, Kong Y, Jia J. Systematic review on the reporting quality of randomized controlled trials in patients with hepatitis B or C in China. Int J Infect Dis 2018;67:58-64. [PMID: 29138012 DOI: 10.1016/j.ijid.2017.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
480 Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263-271. [PMID: 28412293 DOI: 10.1016/j.jhep.2017.03.039] [Cited by in Crossref: 213] [Cited by in F6Publishing: 191] [Article Influence: 42.6] [Reference Citation Analysis]
481 Janiak M, Caraballo Cortes K, Demkow U, Radkowski M. Spontaneous Elimination of Hepatitis C Virus Infection. Adv Exp Med Biol 2018;1039:45-54. [PMID: 29164488 DOI: 10.1007/5584_2017_76] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
482 von Delft A, Humphreys IS, Brown A, Pfafferott K, Lucas M, Klenerman P, Lauer GM, Cox AL, Gaudieri S, Barnes E. The broad assessment of HCV genotypes 1 and 3 antigenic targets reveals limited cross-reactivity with implications for vaccine design. Gut 2016;65:112-23. [PMID: 26092843 DOI: 10.1136/gutjnl-2014-308724] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
483 Li D, Huang Z, Zhong J. Hepatitis C virus vaccine development: old challenges and new opportunities. National Science Review 2015;2:285-95. [DOI: 10.1093/nsr/nwv040] [Cited by in Crossref: 21] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
484 Guimarães VDS, Melo TGD, Ferreira RDCD, Almeida SFD, Martins LC. Prevalence of hepatitis C virus genotypes in the State of Pará, Brazil. Rev Soc Bras Med Trop 2018;51:508-12. [DOI: 10.1590/0037-8682-0457-2017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
485 von Delft A, Donnison TA, Lourenço J, Hutchings C, Mullarkey CE, Brown A, Pybus OG, Klenerman P, Chinnakannan S, Barnes E. The generation of a simian adenoviral vectored HCV vaccine encoding genetically conserved gene segments to target multiple HCV genotypes. Vaccine 2018;36:313-21. [PMID: 29203182 DOI: 10.1016/j.vaccine.2017.10.079] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
486 Yu ML, Chuang WL. New treatments for HCV: Perspective from Asia. Clin Liver Dis. 2015;5:17-21. [PMID: 31312438 DOI: 10.1002/cld.442] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
487 Zheng BZ, D'Andrea SV, Hanumegowda U, Knipe JO, Mosure K, Zhuo X, Lemm JA, Liu M, Rigat KL, Wang YK, Fang H, Poronsky C, Cutrone J, Wu DR, Arunachalam PN, Balapragalathan TJ, Arumugam A, Mathur A, Meanwell NA, Gao M, Roberts SB, Kadow JF. Discovery of BMS-961955, an allosteric inhibitor of the hepatitis C virus NS5B polymerase. Bioorg Med Chem Lett 2017;27:3294-300. [PMID: 28633899 DOI: 10.1016/j.bmcl.2017.06.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
488 Matsumoto J, San SN, Fujiyoshi M, Kawauchi A, Chiba N, Tagai R, Sanbe R, Yanaka S, Sakaue H, Kato Y, Nakamura H, Yamada H, Ariyoshi N. Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir. J Hum Genet 2020;65:143-53. [PMID: 31645655 DOI: 10.1038/s10038-019-0685-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
489 Khan S, Soni S, Veerapu NS. HCV Replicon Systems: Workhorses of Drug Discovery and Resistance. Front Cell Infect Microbiol 2020;10:325. [PMID: 32714881 DOI: 10.3389/fcimb.2020.00325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
490 Isakov V, Gankina N, Morozov V, Kersey K, Lu S, Osinusi A, Svarovskaia E, Brainard DM, Salupere R, Orlova-Morozova E, Zhdanov K. Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection. Clin Drug Investig 2018;38:239-47. [PMID: 29177645 DOI: 10.1007/s40261-017-0606-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
491 Suleiman AA, Lin CW, Liu W, Eckert D, Mensing S, Burroughs M, Kato K, Chayama K, Kumada H, Oberoi RK. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials. J Clin Pharmacol 2020;60:331-9. [PMID: 31515816 DOI: 10.1002/jcph.1524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
492 Chamorro-de-Vega E, Gimenez-Manzorro A, Sanjurjo M; GRUVIC Study Group. Sofosbuvir/ledipasvir as treatment of hepatitis C virus genotype 5 infection: Two case reports. Med Clin (Barc) 2018;151:85-6. [PMID: 29295791 DOI: 10.1016/j.medcli.2017.10.041] [Reference Citation Analysis]
493 Skladaný L, Oltman M, Fraňková S, Dražilová S, Husa P, Šperl J, Hejda V, Urbánek P, Adamcová-Selčanová S, Janičko M, Kristian P, Kupčová V, Rác M, Schréter I, Virág L, Liptáková A, Ondrášová M, Jarčuška P. Chronic hepatitis C virus infection in the Czech Republic and Slovakia: an analysis of patient and virus characteristics. Int J Public Health 2020;65:1723-35. [PMID: 33040165 DOI: 10.1007/s00038-020-01496-y] [Reference Citation Analysis]
494 Rangel JB, Thuler LCS, Pinto JFDC. Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients. Oral Oncol 2018;87:138-43. [PMID: 30527229 DOI: 10.1016/j.oraloncology.2018.10.024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
495 El-Guindi MA. Hepatitis C Viral Infection in Children: Updated Review. Pediatr Gastroenterol Hepatol Nutr 2016;19:83-95. [PMID: 27437184 DOI: 10.5223/pghn.2016.19.2.83] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
496 Cooke GS. Scaling-up HCV treatment to achieve WHO targets by 2030. Trop Med Int Health 2017;22:372-4. [DOI: 10.1111/tmi.12837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
497 Wahid B, Rafique S, Saleem K, Ali A, Idrees M. An Increase in Expression of SOCS1 Gene with Increase in Hepatitis C Virus Viral Load. Journal of Interferon & Cytokine Research 2018;38:122-8. [DOI: 10.1089/jir.2017.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
498 Johnson KL, Hertz D, Stobbe G, Alschuler K, Kalb R, Alexander KS, Kraft GH, Scott JD. Project Extension for Community Healthcare Outcomes (ECHO) in Multiple Sclerosis: Increasing Clinician Capacity. Int J MS Care 2017;19:283-9. [PMID: 29270085 DOI: 10.7224/1537-2073.2016-099] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
499 Yu W, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Coburn CA, Selyutin O, Chen L, Rokosz L, Agrawal S, Liu R, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA. Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants. J Med Chem 2016;59:10228-43. [PMID: 27792320 DOI: 10.1021/acs.jmedchem.6b01234] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
500 Elbaz T, Elserafy M, Elakel W, Mohey MA, Abdo M, Hassany M, Mehrez M, Abouelkhair M, Yosry A, Omar A, Waked I, Elsayed MH, Mahran Z, Elshazly Y, Elgarem N, Gaballa A, Doss W, Esmat G. Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. J Interferon Cytokine Res 2017;37:348-53. [PMID: 28777714 DOI: 10.1089/jir.2016.0131] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
501 Forni D, Cagliani R, Pontremoli C, Pozzoli U, Vertemara J, De Gioia L, Clerici M, Sironi M. Evolutionary Analysis Provides Insight Into the Origin and Adaptation of HCV. Front Microbiol 2018;9:854. [PMID: 29765366 DOI: 10.3389/fmicb.2018.00854] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
502 Tarr AW, Khera T, Hueging K, Sheldon J, Steinmann E, Pietschmann T, Brown RJ. Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses 2015;7:3995-4046. [PMID: 26193307 DOI: 10.3390/v7072809] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 5.1] [Reference Citation Analysis]
503 Hopcraft SE, Damania B. Tumour viruses and innate immunity. Philos Trans R Soc Lond B Biol Sci 2017;372:20160267. [PMID: 28893934 DOI: 10.1098/rstb.2016.0267] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
504 Minme R, Holzmann I, Tovo CV, Almeida PRL. PROFILE OF PATIENTS WITH CHRONIC HEPATITIS C IN A PUBLIC HEALTH PROGRAM IN SOUTHERN BRAZIL. Arq Gastroenterol 2018;55:403-6. [PMID: 30785526 DOI: 10.1590/S0004-2803.201800000-86] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
505 Haqqi A, Munir R, Khalid M, Khurram M, Zaid M, Ali M, Shah ZH, Ahmed H, Afzal MS. Prevalence of Hepatitis C Virus Genotypes in Pakistan: Current Scenario and Review of Literature. Viral Immunol 2019;32:402-13. [PMID: 31556811 DOI: 10.1089/vim.2019.0058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
506 Gallego P, Rojas Á, Falcón G, Carbonero P, García-Lozano MR, Gil A, Grande L, Cremades O, Romero-Gómez M, Bautista JD, Del Campo JA. Water-soluble extracts from edible mushrooms (Agaricus bisporus) as inhibitors of hepatitis C viral replication. Food Funct 2019;10:3758-67. [PMID: 31179460 DOI: 10.1039/c9fo00733d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
507 Köksal İ, Yılmaz G, Parlak M, Demirdal T, Kınıklı S, Candan M, Kaya A, Akhan S, Aydoğdu Ö, Turgut H, Gürbüz Y, Dağlı Ö, Gökal AA, Güner R, Kuruüzüm Z, Tarakçı H, Beslen N, Erdoğan S, Özdener F, Study Group TCHC. Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study. Turk J Gastroenterol 2018;29:464-72. [PMID: 30249562 DOI: 10.5152/tjg.2018.16597] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
508 Mettikanont P, Bunchorntavakul C, Reddy KR. Systematic review: epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection. Aliment Pharmacol Ther 2019;49:492-505. [PMID: 30687952 DOI: 10.1111/apt.15100] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
509 Wang X, Fan X, Deng H, Zhang X, Zhang K, Li N, Han Q, Lv Y, Liu Z. Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1-6 infection: A systematic review and meta-analysis. Int J Antimicrob Agents 2019;54:780-9. [PMID: 31284039 DOI: 10.1016/j.ijantimicag.2019.07.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
510 Jung GS, Jeon JH, Choi YK, Jang SY, Park SY, Kim SW, Byun JK, Kim MK, Lee S, Shin EC, Lee IK, Kang YN, Park KG. Pyruvate dehydrogenase kinase regulates hepatitis C virus replication. Sci Rep 2016;6:30846. [PMID: 27471054 DOI: 10.1038/srep30846] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
511 He T, Lopez-Olivo MA, Hur C, Chhatwal J. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Aliment Pharmacol Ther. 2017;46:711-721. [PMID: 28836278 DOI: 10.1111/apt.14271] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
512 McCabe L, White IR, Chau NVV, Barnes E, Pett SL, Cooke GS, Walker AS; SEARCH investigators. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam. Trials 2020;21:413. [PMID: 32423467 DOI: 10.1186/s13063-020-04350-x] [Reference Citation Analysis]
513 Magri MC, Prata TV, Manchiero C, Dantas BP, Mazza CC, Tengan FM. Genetic variation in the microsomal triglyceride transfer protein (-493G/T) is associated with hepatic steatosis in patients infected with hepatitis C virus. BMC Infect Dis 2017;17:235. [PMID: 28356060 DOI: 10.1186/s12879-017-2340-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
514 Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection. J Infect Dis 2016;213:206-15. [PMID: 26170396 DOI: 10.1093/infdis/jiv379] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
515 Fan Z, Zhang Q, Chen H, He P, Li Y, Si M, Jiao X. Circulating microRNAs as a biomarker to predict therapy efficacy in hepatitis C patients with different genotypes. Microb Pathog 2017;112:320-6. [PMID: 28993299 DOI: 10.1016/j.micpath.2017.10.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
516 Harfouche M, Chemaitelly H, Mahmud S, Chaabna K, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. Epidemiol Infect. 2017;145:3243-3263. [PMID: 28988562 DOI: 10.1017/s0950268817002242] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
517 Behzadi MA, Alborzi A, Kalani M, Pouladfar G, Dianatpour M, Ziyaeyan M. Immunization with a Recombinant Expression Vector Encoding NS3/NS4A of Hepatitis C Virus Genotype 3a Elicits Cell-Mediated Immune Responses in C57BL/6 Mice. Viral Immunol 2016;29:138-47. [PMID: 26909520 DOI: 10.1089/vim.2015.0085] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
518 Han J, Lee HW, Jin Y, Khadka DB, Yang S, Li X, Kim M, Cho WJ. Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. Eur J Med Chem 2020;188:112031. [PMID: 31923861 DOI: 10.1016/j.ejmech.2019.112031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
519 Wilson JL, Cheung KWK, Lin L, Green EAE, Porrás AI, Zou L, Mukanga D, Akpa PA, Darko DM, Yuan R, Ding S, Johnson WCN, Lee HA, Cooke E, Peck CC, Kern SE, Hartman D, Hayashi Y, Marks PW, Altman RB, Lumpkin MM, Giacomini KM, Blaschke TF. Scientific considerations for global drug development. Sci Transl Med 2020;12:eaax2550. [PMID: 32727913 DOI: 10.1126/scitranslmed.aax2550] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
520 Damavandi F, Wang W, Shen WZ, Cetinel S, Jordan T, Jovel J, Montemagno C, Wong GK. Enrichment of low abundance DNA/RNA by oligonucleotide-clicked iron oxide nanoparticles. Sci Rep 2021;11:13053. [PMID: 34158543 DOI: 10.1038/s41598-021-92376-9] [Reference Citation Analysis]
521 Al-Hamoudi WK. Management of hepatitis c genotype 4 in the liver transplant setting. Saudi J Gastroenterol 2016;22:173-82. [PMID: 27184634 DOI: 10.4103/1319-3767.182453] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
522 Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: An up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol 2016; 22(34): 7824-7840 [PMID: 27678366 DOI: 10.3748/wjg.v22.i34.7824] [Cited by in CrossRef: 394] [Cited by in F6Publishing: 334] [Article Influence: 65.7] [Reference Citation Analysis]
523 Mendes-Oliveira F, Bolina-Santos E, Salomon T, Miranda C, Cioffi J, Sabino E, Barbosa-Stancioli E, Moreno E, Carneiro-Proietti AB. Hepatitis C: Prevalence of serologic markers and risk factors in blood donors at a large blood centre in South-eastern Brazil (2007-2010). Transfus Apher Sci 2015;53:238-41. [PMID: 26138911 DOI: 10.1016/j.transci.2015.05.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
524 Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. Infect Drug Resist 2018;11:2117-27. [PMID: 30464554 DOI: 10.2147/IDR.S179158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
525 Behzadifar M, Heydarvand S, Behzadifar M, Bragazzi NL. Prevalence of Hepatitis C Virus in Tuberculosis Patients: A Systematic Review and Meta-Analysis. Ethiop J Health Sci 2019;29:945-56. [PMID: 30700963 DOI: 10.4314/ejhs.v29i1.17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
526 Wang Y, Cheng G, Lau G. Achieving WHO target of HCV control in Hong Kong: challenges and strategies. Glob Health Med 2021;3:276-82. [PMID: 34782869 DOI: 10.35772/ghm.2021.01075] [Reference Citation Analysis]
527 Donnison T, von Delft A, Brown A, Swadling L, Hutchings C, Hanke T, Chinnakannan S, Barnes E. Viral vectored hepatitis C virus vaccines generate pan-genotypic T cell responses to conserved subdominant epitopes. Vaccine 2020;38:5036-48. [PMID: 32532545 DOI: 10.1016/j.vaccine.2020.05.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
528 Dawood RM, Moustafa RI, Abdelhafez TH, El-Shenawy R, El-Abd Y, Bader El Din NG, Dubuisson J, El Awady MK. A multiepitope peptide vaccine against HCV stimulates neutralizing humoral and persistent cellular responses in mice. BMC Infect Dis 2019;19:932. [PMID: 31690267 DOI: 10.1186/s12879-019-4571-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
529 Nie B, Guo Y, Zhang K, Liu J, Yun S. Analysis of drug-resistance-associated mutations and genetic barriers in hepatitis C virus NS5B sequences in China. Arch Virol 2020;165:2013-20. [PMID: 32601956 DOI: 10.1007/s00705-020-04713-4] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
530 Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK, Fu B, Cohen E, Cohen DE, Gane E. Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). J Viral Hepat. 2018;25:118-125. [PMID: 28833938 DOI: 10.1111/jvh.12782] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
531 Jakobsen JC, Nielsen EE, Feinberg J, Katakam KK, Fobian K, Hauser G, Poropat G, Djurisic S, Weiss KH, Bjelakovic M, Bjelakovic G, Klingenberg SL, Liu JP, Nikolova D, Koretz RL, Gluud C. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 2017;6:CD012143. [PMID: 28585310 DOI: 10.1002/14651858.CD012143.pub2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
532 Hemelaar J, Loganathan S, Elangovan R, Yun J, Dickson-Tetteh L, Kirtley S; WHO-UNAIDS Network for HIV Isolation and Characterization. Country Level Diversity of the HIV-1 Pandemic between 1990 and 2015. J Virol 2020;95:e01580-20. [PMID: 33087461 DOI: 10.1128/JVI.01580-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
533 Salas JH, Urbanowicz RA, Guest JD, Frumento N, Figueroa A, Clark KE, Keck Z, Cowton VM, Cole SJ, Patel AH, Fuerst TR, Drummer HE, Major M, Tarr AW, Ball JK, Law M, Pierce BG, Foung SKH, Bailey JR. An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. Gastroenterology 2021:S0016-5085(21)03624-6. [PMID: 34655573 DOI: 10.1053/j.gastro.2021.10.005] [Reference Citation Analysis]
534 Maddur H, Flamm SL. Hepatitis C Genotype 3 Infection. Clinics in Liver Disease 2017;21:645-57. [DOI: 10.1016/j.cld.2017.06.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
535 Sukowati CH, El-Khobar KE, Ie SI, Anfuso B, Muljono DH, Tiribelli C. Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma. World J Gastroenterol 2016; 22(4): 1497-1512 [PMID: 26819517 DOI: 10.3748/wjg.v22.i4.1497] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
536 Ramamurthy N, Marchi E, Ansari MA, Pedergnana V, Mclean A, Hudson E, Bowden R, Spencer CCA, Barnes E, Klenerman P; STOP HCV consortium. Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C. Hepatology 2018;68:859-71. [PMID: 29534310 DOI: 10.1002/hep.29877] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
537 Bouacida L, Suin V, Hutse V, Boudewijns M, Cartuyvels R, Debaisieux L, De Laere E, Hallin M, Hougardy N, Lagrou K, Oris E, Padalko E, Reynders M, Roussel G, Senterre JM, Stalpaert M, Ursi D, Vael C, Vaira D, Van Acker J, Verstrepen W, Van Gucht S, Kabamba B, Quoilin S, Muyldermans G. Distribution of HCV genotypes in Belgium from 2008 to 2015. PLoS One 2018;13:e0207584. [PMID: 30517127 DOI: 10.1371/journal.pone.0207584] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
538 Sevvana M, Keck Z, Foung SK, Kuhn RJ. Structural perspectives on HCV humoral immune evasion mechanisms. Curr Opin Virol 2021;49:92-101. [PMID: 34091143 DOI: 10.1016/j.coviro.2021.05.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
539 Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clinical Gastroenterology and Hepatology 2016;14:1821-1830.e6. [DOI: 10.1016/j.cgh.2016.07.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 5.5] [Reference Citation Analysis]
540 Batista MN, Sanches PRDS, Carneiro BM, Braga ACS, Campos GRF, Cilli EM, Rahal P. GA-Hecate antiviral properties on HCV whole cycle represent a new antiviral class and open the door for the development of broad spectrum antivirals. Sci Rep 2018;8:14329. [PMID: 30254334 DOI: 10.1038/s41598-018-32176-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
541 McHugh MP, Wu AHB, Chevaliez S, Pawlotsky JM, Hallin M, Templeton KE. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay. J Clin Microbiol 2017;55:1550-6. [PMID: 28275079 DOI: 10.1128/JCM.02460-16] [Cited by in Crossref: 33] [Cited by in F6Publishing: 12] [Article Influence: 6.6] [Reference Citation Analysis]
542 Shuldiner SR, Gong L, Muir AJ, Altman RB, Klein TE. PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics 2015;25:465-74. [PMID: 26111151 DOI: 10.1097/FPC.0000000000000158] [Reference Citation Analysis]
543 Coyle JR, Goerge E, Kacynski K, Rodgers R, Raines P, Vail LS, Lowhim S. Hepatitis C Virus Infections Associated with Unsafe Injection Practices at a Pain Management Clinic, Michigan, 2014-2015. Pain Med 2017;18:322-9. [PMID: 28204717 DOI: 10.1093/pm/pnw157] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
544 Caro-Pérez N, Martínez-Rebollar M, Gregori J, Quer J, González P, Gambato M, García-González N, González-Candelas F, Costa J, Esteban JI, Mallolas J, Forns X, Laguno M, Pérez-Del-Pulgar S. Phylogenetic analysis of an epidemic outbreak of acute hepatitis C in HIV-infected patients by ultra-deep pyrosequencing. J Clin Virol 2017;92:42-7. [PMID: 28521213 DOI: 10.1016/j.jcv.2017.05.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
545 Loarec A, Carnimeo V, Molfino L, Kizito W, Muyindike W, Andrieux-Meyer I, Balkan S, Nzomukunda Y, Mwanga-Amumpaire J, Ousley J, Bygrave H, Maman D. Extremely low hepatitis C prevalence among HIV co-infected individuals in four countries in sub-Saharan Africa. AIDS 2019;33:353-5. [PMID: 30475267 DOI: 10.1097/QAD.0000000000002070] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
546 Thiagarajan P, Ryder SD. The hepatitis C revolution part 2: difficult-to-treat groups and experimental approaches. Curr Opin Infect Dis 2015;28:572-5. [PMID: 26524329 DOI: 10.1097/QCO.0000000000000204] [Reference Citation Analysis]
547 Carter W, Connelly S, Struble K. Reinventing HCV Treatment: Past and Future Perspectives. J Clin Pharmacol. 2017;57:287-296. [PMID: 27654843 DOI: 10.1002/jcph.830] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
548 Naghipour-khalkhaliani D, Behzadpour D, Mousavi Nasab SD. Distribution of Hepatitis C Virus Genotypes in Rasht, Capital City of Guilan Province, Northern Part of Iran. Hepat Mon 2018;18. [DOI: 10.5812/hepatmon.62030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
549 Ahmad S, Shahid F, Tahir Ul Qamar M, Rehman HU, Abbasi SW, Sajjad W, Ismail S, Alrumaihi F, Allemailem KS, Almatroudi A, Ullah Saeed HF. Immuno-Informatics Analysis of Pakistan-Based HCV Subtype-3a for Chimeric Polypeptide Vaccine Design. Vaccines (Basel) 2021;9:293. [PMID: 33801143 DOI: 10.3390/vaccines9030293] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
550 Ellwanger JH, Kaminski VL, Valverde-Villegas JM, Simon D, Lunge VR, Chies JAB. Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming. Infect Genet Evol 2018;66:376-91. [PMID: 28811194 DOI: 10.1016/j.meegid.2017.08.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
551 Umumararungu E, Ntaganda F, Kagira J, Maina N. Prevalence of Hepatitis C Virus Infection and Its Risk Factors among Patients Attending Rwanda Military Hospital, Rwanda. Biomed Res Int. 2017;2017:5841272. [PMID: 28246598 DOI: 10.1155/2017/5841272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
552 Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry. Aliment Pharmacol Ther 2019;49:1052-9. [PMID: 30874328 DOI: 10.1111/apt.15222] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 13.3] [Reference Citation Analysis]
553 Zhu XB, Zhuo LY, Yue M, Liu M, Zang F, Fan HZ, Wu JJ, Xia XS, Zhang AM, Yu RB, Huang P. Genetic variants in IFIH1 and DDX58 influence hepatitis C virus clearance in Chinese Han population. J Med Virol 2019;91:1097-103. [PMID: 30633820 DOI: 10.1002/jmv.25398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
554 Lionetti R, Piccolo P, Lenci I, Siciliano M, Visco-Comandini U, De Santis A, Pompili M, Milana M, Taibi C, Dell'Isola S, Montalbano M, Mastroianni C, Begini P, Garbuglia AR, Angelico M, D'Offizi G. Daclatasvir, sofosbuvir with or without ribavirin for 24 weeks in hepatitis C genotype 3 cirrhosis: A real-life study. Ann Hepatol 2019;18:434-8. [PMID: 31023614 DOI: 10.1016/j.aohep.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
555 Pozza R, Hill C, Hefner AM, Vawter B, Hassanein T. Hepatitis C infection: Updates on treatment guidelines. Nurse Pract 2017;42:14-23. [PMID: 28379888 DOI: 10.1097/01.NPR.0000515423.38284.28] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
556 Assih M, Ouattara AK, Diarra B, Yonli AT, Compaore TR, Obiri-Yeboah D, Djigma FW, Karou S, Simpore J. Genetic diversity of hepatitis viruses in West-African countries from 1996 to 2018. World J Hepatol 2018; 10(11): 807-821 [PMID: 30533182 DOI: 10.4254/wjh.v10.i11.807] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
557 Hézode C, Almasio PL, Bourgeois S, Buggisch P, Brown A, Diago M, Horsmans Y, Serfaty L, Szalay F, Gaeta GB, Planas R, Schlag M, Lonjon-Domanec I, Omoruyi E, DeMasi R, Zeuzem S. Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease. Liver Int 2017;37:1304-13. [PMID: 28135777 DOI: 10.1111/liv.13376] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
558 Ahmed A, Felmlee DJ. Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals. Viruses 2015;7:6716-29. [PMID: 26694454 DOI: 10.3390/v7122968] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 7.9] [Reference Citation Analysis]
559 Mcewan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, Gordon J. A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective: . European Journal of Gastroenterology & Hepatology 2017;29:208-14. [DOI: 10.1097/meg.0000000000000773] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
560 Sultan S, El-Mowafy M, Elgaml A, El-Mesery M, El Shabrawi A, Elegezy M, Hammami R, Mottawea W. Alterations of the Treatment-Naive Gut Microbiome in Newly Diagnosed Hepatitis C Virus Infection.ACS Infect Dis. 2021;7:1059-1068. [PMID: 33119247 DOI: 10.1021/acsinfecdis.0c00432] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
561 Cooke GS, Hill AM. Diagnostics for resource-limited settings in the era of interferon-free HCV therapy. J Viral Hepat 2015;22:459-60. [PMID: 25727262 DOI: 10.1111/jvh.12401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
562 Sridhar S, Yip CCY, Chan JFW, To KKW, Cheng VCC, Yuen KY. Impact of inter-genotypic recombination and probe cross-reactivity on the performance of the Abbott RealTime HCV Genotype II assay for hepatitis C genotyping. Diagn Microbiol Infect Dis 2018;91:34-7. [PMID: 29434000 DOI: 10.1016/j.diagmicrobio.2017.12.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
563 Bull RA, Eltahla AA, Rodrigo C, Koekkoek SM, Walker M, Pirozyan MR, Betz-Stablein B, Toepfer A, Laird M, Oh S, Heiner C, Maher L, Schinkel J, Lloyd AR, Luciani F. A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics. 2016;17:247. [PMID: 26988550 DOI: 10.1186/s12864-016-2575-8] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
564 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66:153-194. [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001] [Cited by in Crossref: 712] [Cited by in F6Publishing: 649] [Article Influence: 118.7] [Reference Citation Analysis]
565 Bell AM, Wagner JL, Barber KE, Stover KR. Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C. Int J Hepatol. 2016;2016:3852126. [PMID: 27403342 DOI: 10.1155/2016/3852126] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
566 Zarębska-Michaluk D. Genotype 3-hepatitis C virus’ last line of defense. World J Gastroenterol 2021; 27(11): 1006-1021 [PMID: 33776369 DOI: 10.3748/wjg.v27.i11.1006] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
567 Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019;105:219-28. [PMID: 29696643 DOI: 10.1002/cpt.1099] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
568 Xu H, Yu G, Sun H, Lv J, Wang M, Kong F, Zhang M, Chi X, Wang X, Wu R, Gao X, Zhong J, Sun B, Jiang J, Pan Y, Niu J. Use of parenteral caffeinum natrio-benzoicum: an underestimated risk factor for HCV transmission in China. BMC Public Health 2015;15:928. [PMID: 26386815 DOI: 10.1186/s12889-015-2299-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
569 Miyazaki R, Miyagi K. Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis: Daclatasvir Plus Asunaprevir. Ther Apher Dial 2016;20:462-7. [DOI: 10.1111/1744-9987.12407] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
570 Mahmud S, Al-Kanaani Z, Chemaitelly H, Chaabna K, Kouyoumjian SP, Abu-Raddad LJ. Hepatitis C virus genotypes in the Middle East and North Africa: Distribution, diversity, and patterns. J Med Virol. 2018;90:131-141. [PMID: 28842995 DOI: 10.1002/jmv.24921] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
571 Chahine EB, Kelley D, Childs-Kean LM. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. Ann Pharmacother. 2018;52:352-363. [PMID: 29115151 DOI: 10.1177/1060028017741508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
572 Nguyen E, Trinh S, Trinh H, Nguyen H, Nguyen K, Do A, Levitt B, Do S, Nguyen M, Purohit T, Shieh E, Nguyen MH. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir. Aliment Pharmacol Ther. 2019;49:99-106. [PMID: 30467877 DOI: 10.1111/apt.15043] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
573 Hussein NR. The Efficacy and Safety of Sofosbuvir-Containing Regimen in the Treatment of HCV Infection in Patients with Haemoglobinopathy. Mediterr J Hematol Infect Dis 2017;9:e2017005. [PMID: 28105296 DOI: 10.4084/MJHID.2017.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
574 El-baky NA, Uversky VN, Redwan EM. Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder. Cytokine & Growth Factor Reviews 2015;26:637-45. [DOI: 10.1016/j.cytogfr.2015.07.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
575 Shen C, Fan H, Ge Z, Cai W, Shao J, Dong C, Xue H, Fu Z, Li J, Zhang Y, Yue M. Efficacy and Safety of Glecaprevir/Pibrentasvir in HCV Patients With Previous Direct-Acting Antiviral Therapy Failures: A Meta-Analysis. Front Med (Lausanne) 2020;7:592472. [PMID: 33425940 DOI: 10.3389/fmed.2020.592472] [Reference Citation Analysis]
576 Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, Pan Q. Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis 2019;21:e13047. [PMID: 30615227 DOI: 10.1111/tid.13047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
577 Ren J, Ojeda I, Patel M, Johnson ME, Lee H. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease. Bioorg Med Chem Lett 2019;29:2349-53. [PMID: 31201062 DOI: 10.1016/j.bmcl.2019.06.009] [Reference Citation Analysis]
578 Ye M, Chen X, Wang Y, Duo L, Zhang C, Zheng YT. Identification of a New HCV Subtype 6xg Among Injection Drug Users in Kachin, Myanmar. Front Microbiol 2019;10:814. [PMID: 31057519 DOI: 10.3389/fmicb.2019.00814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
579 Ferreira PM, Guimarães RA, Souza CM, Guimarães LC, Barros CV, Caetano KA, Rezza G, Spadoni L, Brunini SM. Exposure to hepatitis C virus in homeless men in Central Brazil: a cross-sectional study. BMC Public Health 2017;17:90. [PMID: 28100196 DOI: 10.1186/s12889-016-3952-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
580 Chen Y, Yu C, Yin X, Guo X, Wu S, Hou J. Hepatitis C virus genotypes and subtypes circulating in Mainland China. Emerg Microbes Infect 2017;6:e95. [PMID: 29089588 DOI: 10.1038/emi.2017.77] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
581 Lin C, Dutta S, Ding B, Wang T, Zadeikis N, Asatryan A, Kort J, Campbell A, Podsadecki T, Liu W. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects. The Journal of Clinical Pharmacology 2017;57:1616-24. [DOI: 10.1002/jcph.959] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
582 Henquell C, Yameogo S, Sangaré L. First genome characterization of a novel hepatitis C virus genotype 5 variant. Infect Genet Evol 2016;39:173-5. [PMID: 26807921 DOI: 10.1016/j.meegid.2016.01.016] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
583 Roudot-Thoraval F. Epidemiology of hepatitis C virus infection. Clin Res Hepatol Gastroenterol 2021;45:101596. [PMID: 33610022 DOI: 10.1016/j.clinre.2020.101596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
584 Li HC, Lo SY. Hepatitis C virus: Virology, diagnosis and treatment. World J Hepatol 2015; 7(10): 1377-1389 [PMID: 26052383 DOI: 10.4254/wjh.v7.i10.1377] [Cited by in Crossref: 76] [Cited by in F6Publishing: 52] [Article Influence: 10.9] [Reference Citation Analysis]
585 Breitinger U, Farag NS, Ali NKM, Ahmed M, El-Azizi MA, Breitinger HG. Cell viability assay as a tool to study activity and inhibition of hepatitis C p7 channels. J Gen Virol 2021;102. [PMID: 33709903 DOI: 10.1099/jgv.0.001571] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
586 Charlton MR, Gane EJ, Shukla A, Dashtseren B, Duger D, Muljono DH, Payawal DA, Jargalsaikhan G, Purnomo HD, Cua IH, Hasan I, Sollano J Jr, Win KM, Lesmana LA, Salih M, Thi Thu Thuy P, Shankar R, Saraswat VA. International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. Transplantation 2019;103:733-46. [PMID: 30335692 DOI: 10.1097/TP.0000000000002453] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
587 Esmat S, Garem NE, Raslan H, Elfekki M, Sleem GA. Critical flicker frequency is diagnostic of minimal hepatic encephalopathy. J Investig Med 2017;65:1131-5. [PMID: 28743700 DOI: 10.1136/jim-2017-000428] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
588 Warkad SD, Nimse SB, Song KS, Chantratita W, Pongthanapisith V, Nawale LU, Kim T. Performance of 6 HCV genotyping 9G test for HCV genotyping in clinical samples. Virol J 2018;15:107. [PMID: 29996859 DOI: 10.1186/s12985-018-1017-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
589 El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol 2016;9:1413-21. [PMID: 27603877 DOI: 10.1080/17512433.2016.1233813] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
590 Morales JM, Sawinski D. New insights into the rational use of HCV+ organs worldwide. Clin Transplant 2019;33:e13739. [PMID: 31648391 DOI: 10.1111/ctr.13739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
591 Afsheen Z, Ahmad B, Bashir S. Hospital-visiting pregnant women signal an increased spread of hepatitis C infection in Khyber Pakhtunkhwa region of Pakistan. Virol J 2017;14:195. [PMID: 29017555 DOI: 10.1186/s12985-017-0861-y] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
592 Nakamura H, Fujioka S, Terui T, Okuda S, Kondo K, Tamatani Y, Akagi Y, Komoda Y, Kinoshita W, Ito S, Maeda K, Ukaji Y, Inaba T. Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class. Bioorg Med Chem Lett 2020;30:127361. [PMID: 32738974 DOI: 10.1016/j.bmcl.2020.127361] [Reference Citation Analysis]
593 Wang B, Krüger L, Machnowska P, Eshetu A, Gunsenheimer-Bartmeyer B, Bremer V, Hauser A, Bannert N, Bock CT. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o. Virol J 2019;16:28. [PMID: 30832687 DOI: 10.1186/s12985-019-1135-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
594 Momose H, Matsuoka S, Murayama A, Yamada N, Okuma K, Ikebe E, Hoshi Y, Muramatsu M, Wakita T, Toyota K, Kato T, Hamaguchi I. Evaluation of in vitro screening and diagnostic kits for hepatitis C virus infection. J Clin Virol 2018;105:97-102. [PMID: 29940422 DOI: 10.1016/j.jcv.2018.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
595 Kyuregyan KK, Kichatova VS, Karlsen AA, Isaeva OV, Solonin SA, Petkov S, Nielsen M, Isaguliants MG, Mikhailov MI. Factors Influencing the Prevalence of Resistance-Associated Substitutions in NS5A Protein in Treatment-Naive Patients with Chronic Hepatitis C. Biomedicines 2020;8:E80. [PMID: 32272736 DOI: 10.3390/biomedicines8040080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
596 Chantratita W, Song KS, GunHo C, Pongthanapisith V, Thongbaiphet N, Wongtabtim G, Pasomsub E, Angkanavin K, Nimse SB, Sonawane MD, Warkad SD, Kim T. 6 HCV genotyping 9G test and its comparison with VERSANT HCV genotype 2.0 assay (LiPA) for the hepatitis C virus genotyping. J Virol Methods 2017;239:1-8. [PMID: 27793646 DOI: 10.1016/j.jviromet.2016.10.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
597 He QF, Zhang QF, Zhang DZ. Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. Dig Dis Sci 2016;61:3108-17. [PMID: 27619394 DOI: 10.1007/s10620-016-4291-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
598 Prabdial-Sing N, Chirwa T, Thaver J, Smuts H, Vermeulen M, Suchard M, Puren AJ. Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012. J Viral Hepat 2016;23:881-8. [PMID: 27545625 DOI: 10.1111/jvh.12571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
599 Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J. Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors. Antimicrob Agents Chemother 2017;61:e00037-17. [PMID: 28348150 DOI: 10.1128/AAC.00037-17] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
600 Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. Expert Rev Anti Infect Ther 2018;16:625-39. [PMID: 30067107 DOI: 10.1080/14787210.2018.1505503] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
601 Kawabata H, Miyake R, Asada K, Dekishima Y, Miyaike M, Kato R. Asymmetric synthesis of intermediate for (1R,2S)-ethyl 1-amino-2-vinylcyclopropanecarboxylate by desymmetrization using engineered esterase from Bacillus subtilis. J Biosci Bioeng 2021;131:599-604. [PMID: 33744099 DOI: 10.1016/j.jbiosc.2021.02.004] [Reference Citation Analysis]
602 Dietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer KH, Graf C, Discher T, Trauth J, Schattenberg JM, Piecha F, Mauss S, Niederau C, Müller T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions. Liver Int 2020. [PMID: 32640072 DOI: 10.1111/liv.14591] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
603 Polepally AR, Mensing S, Khatri A, Beck D, Liu W, Awni WM, Menon RM, Dutta S. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Clin Pharmacokinet 2016;55:1091-101. [PMID: 27000758 DOI: 10.1007/s40262-016-0385-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
604 Soria ME, Gregori J, Chen Q, García-Cehic D, Llorens M, de Ávila AI, Beach NM, Domingo E, Rodríguez-Frías F, Buti M, Esteban R, Esteban JI, Quer J, Perales C. Pipeline for specific subtype amplification and drug resistance detection in hepatitis C virus. BMC Infect Dis 2018;18:446. [PMID: 30176817 DOI: 10.1186/s12879-018-3356-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
605 Forde KA, Bhattacharya D. Treatment of Hepatitis C Virus (HCV) Genotype 1 Disease. Curr Treat Options Infect Dis 2017;9:262-76. [PMID: 29805320 DOI: 10.1007/s40506-017-0124-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
606 Li H, Yang Z, Zhang S, Xu L, Wei Y, Jiang J, Caro L, Feng HP, McCrea JB, Li M, Xie S, Wang J, Zhao XM, Mu S. A Single- and Multiple-Dose Study to Evaluate the Pharmacokinetics of Fixed-Dose Grazoprevir/Elbasvir in Healthy Chinese Participants. Clin Pharmacol 2020;12:1-11. [PMID: 32104104 DOI: 10.2147/CPAA.S224662] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
607 Boyd SD, Tracy L, Komatsu TE, Harrington PR, Viswanathan P, Murray J, Sherwat A. US FDA Perspective on Elbasvir/Grazoprevir Treatment for Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection. Clin Drug Investig 2017;37:317-26. [PMID: 28102520 DOI: 10.1007/s40261-017-0492-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
608 Siddique MS, Shoaib S, Saad A, Iqbal HJ, Durrani N. Rapid virological&End treatment response of patients treated with Sofosbuvir in Chronic Hepatitis C. Pak J Med Sci 2017;33:813-7. [PMID: 29067045 DOI: 10.12669/pjms.334.12785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
609 Filomena A, Göpfert JC, Duffy D, Pol S, Abdel-Hamid M, Esmat G, Fontanet A, Albert ML, Joos TO, Schneiderhan-Marra N. Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. High Throughput 2017;6:E15. [PMID: 29855459 DOI: 10.3390/ht6040015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
610 Singh S, Muir AJ, Dieterich DT, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. Gastroenterology 2017;152:1544-77. [PMID: 28442120 DOI: 10.1053/j.gastro.2017.03.016] [Cited by in Crossref: 135] [Cited by in F6Publishing: 137] [Article Influence: 27.0] [Reference Citation Analysis]
611 Gonçalves D, Lima C, Ferreira P, Costa P, Costa A, Figueiredo W, Cesar T. Orange juice as dietary source of antioxidants for patients with hepatitis C under antiviral therapy. Food Nutr Res 2017;61:1296675. [PMID: 28469541 DOI: 10.1080/16546628.2017.1296675] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
612 Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O’rear JJ, Harrington PR. Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir. Gastroenterology 2017;152:586-97. [DOI: 10.1053/j.gastro.2016.10.017] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
613 Lu J, Xiang X, Cao Z, Wang W, Zhao G, Tang W, Chen L, Guo S, Zhuang Y, Shi D, Chen L, Bao S, Cai W, Wang H, Zhou H, Xie Q. Younger trend of cirrhosis incidence in genotype 3 HCV infected patients in Eastern China. J Med Virol. 2017;89:1973-1980. [PMID: 28671305 DOI: 10.1002/jmv.24894] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
614 Nyan DC, Swinson KL. A method for rapid detection and genotype identification of hepatitis C virus 1-6 by one-step reverse transcription loop-mediated isothermal amplification. Int J Infect Dis 2016;43:30-6. [PMID: 26686938 DOI: 10.1016/j.ijid.2015.12.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
615 Schwabl P, Mandorfer M, Steiner S, Scheiner B, Chromy D, Herac M, Bucsics T, Hayden H, Grabmeier-Pfistershammer K, Ferlitsch A, Oberhuber G, Trauner M, Peck-Radosavljevic M, Reiberger T. Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease. Aliment Pharmacol Ther. 2017;45:139-149. [PMID: 27910154 DOI: 10.1111/apt.13844] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 10.2] [Reference Citation Analysis]
616 Permanasari AA, Aoki-Utsubo C, Wahyuni TS, Tumewu L, Adianti M, Widyawaruyanti A, Hotta H, Hafid AF. An in vitro study of an Artocarpus heterophyllus substance as a hepatitis C antiviral and its combination with current anti-HCV drugs. BMC Complement Med Ther 2021;21:260. [PMID: 34641875 DOI: 10.1186/s12906-021-03408-w] [Reference Citation Analysis]
617 Amougou-Atsama M, Jean Adrien Atangana P, Noah Noah D, Fewou Moundipa P, Pineau P, Njouom R. The role of hepatitis C virus genotypes and core mutations in hepatocellular carcinoma in Cameroon. J Viral Hepat 2020;27:880-5. [PMID: 32301239 DOI: 10.1111/jvh.13303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
618 Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR. Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. Clin Gastroenterol Hepatol 2016;14:1035-43. [PMID: 27062903 DOI: 10.1016/j.cgh.2016.03.040] [Cited by in Crossref: 91] [Cited by in F6Publishing: 86] [Article Influence: 15.2] [Reference Citation Analysis]
619 Manee N, Thongbaiphet N, Pasomsub E, Chantratita W. Clinical evaluation of a newly developed automated massively parallel sequencing assay for hepatitis C virus genotyping and detection of resistance-association variants. Comparison with a line probe assay. J Virol Methods 2017;249:31-7. [PMID: 28851606 DOI: 10.1016/j.jviromet.2017.08.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
620 Mota Pereira F, Neves Santos FL, da Conceição Almeida Chagas M, Perez Carreiro R, Kalabric Silva L, Galvão Castro B, Rios Grassi MF. Seroprevalence and Spatial Distribution of Hepatitis C Virus in Bahia, Brazil. Am J Trop Med Hyg 2021:tpmd201615. [PMID: 34424863 DOI: 10.4269/ajtmh.20-1615] [Reference Citation Analysis]
621 Gane EJ, Kowdley KV, Pound D, Stedman CA, Davis M, Etzkorn K, Gordon SC, Bernstein D, Everson G, Rodriguez-Torres M, Tsai N, Khalid O, Yang JC, Lu S, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Tong M, Chung RT, Beavers K, Poulos JE, Kwo PY, Nguyen MH. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial. Gastroenterology. 2016;151:902-909. [PMID: 27486033 DOI: 10.1053/j.gastro.2016.07.038] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
622 Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM. Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis. Ann Intern Med 2016;165:345-55. [PMID: 27322622 DOI: 10.7326/M16-0065] [Cited by in Crossref: 94] [Cited by in F6Publishing: 42] [Article Influence: 15.7] [Reference Citation Analysis]
623 Aziz B, Nazar T, Akhlaq S. The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients. Pak J Med Sci 2019;35:101-5. [PMID: 30881405 DOI: 10.12669/pjms.35.1.109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
624 Carrion AF, Martin P. Glecaprevir + pibrentasvir for treatment of hepatitis C. Expert Opin Pharmacother 2018;19:413-9. [PMID: 29465262 DOI: 10.1080/14656566.2018.1444030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
625 Gondeau C, Pageaux GP, Larrey D. Hepatitis C virus infection: Are there still specific problems with genotype 3? World J Gastroenterol 2015; 21(42): 12101-12113 [PMID: 26576095 DOI: 10.3748/wjg.v21.i42.12101] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
626 De Conto F, Medici MC, Ferraglia F, Pinardi F, Fazzi A, Arcangeletti MC, Chezzi C, Calderaro A. Temporal dynamics of hepatitis C genotypes in a five-year hospital-based surveillance in Northern Italy. Arch Virol 2016;161:2727-37. [DOI: 10.1007/s00705-016-2975-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
627 Walter S, Rasche A, Moreira-Soto A, Pfaender S, Bletsa M, Corman VM, Aguilar-Setien A, García-Lacy F, Hans A, Todt D, Schuler G, Shnaiderman-Torban A, Steinman A, Roncoroni C, Veneziano V, Rusenova N, Sandev N, Rusenov A, Zapryanova D, García-Bocanegra I, Jores J, Carluccio A, Veronesi MC, Cavalleri JMV, Drosten C, Lemey P, Steinmann E, Drexler JF. Differential Infection Patterns and Recent Evolutionary Origins of Equine Hepaciviruses in Donkeys. J Virol 2017;91:e01711-16. [PMID: 27795428 DOI: 10.1128/JVI.01711-16] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
628 Mesalam AA, Vercauteren K, Meuleman P. Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance. Viruses 2016;8:E176. [PMID: 27338446 DOI: 10.3390/v8060176] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
629 Lee H, Jarhad DB, Yu J, Lee C, Jeong LS. Asymmetric Synthesis of 2'-C-Methyl-4'-selenonucleosides as Anti-Hepatitis C Virus Agents. J Org Chem 2019;84:14414-26. [PMID: 31608633 DOI: 10.1021/acs.joc.9b01462] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
630 Raza MN, Sughra K, Zeeshan N, Anwar MZ, Shahzad MA, Rashid U, Afroz A, Munir H. Recurrence of hepatitis C virus after treatment with pegylated interferon and direct acting antivirals in Punjab Pakistan. Braz J Biol 2021;83:e252610. [PMID: 34909837 DOI: 10.1590/1519-6984.252610] [Reference Citation Analysis]
631 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
632 Stone D, Niyonzima N, Jerome KR. Genome editing and the next generation of antiviral therapy. Hum Genet 2016;135:1071-82. [PMID: 27272125 DOI: 10.1007/s00439-016-1686-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
633 Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, Page KA. Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. J Viral Hepat 2017;24:117-27. [PMID: 27790803 DOI: 10.1111/jvh.12628] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
634 Mahmud S, Al Kanaani Z, Abu-Raddad LJ. Characterization of the hepatitis C virus epidemic in Pakistan. BMC Infect Dis 2019;19:809. [PMID: 31521121 DOI: 10.1186/s12879-019-4403-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
635 Chin-Yee B, Subramanian SV, Verma AA, Laupacis A, Razak F. Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy. Milbank Q 2018;96:369-401. [PMID: 29870114 DOI: 10.1111/1468-0009.12328] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
636 Karadağ Ö, Kaşifoğlu T, Özer B, Kaymakoğlu S, Kuş Y, İnanç M, Keser G, Kiraz S. Viral hepatitis screening guideline before biological drug use in rheumatic patients. Eur J Rheumatol 2016;3:25-8. [PMID: 27708965 DOI: 10.5152/eurjrheum.2015.150072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
637 Morales-Arraez D, Alonso-Larruga A, Diaz-Flores F, García Dopico JA, de Vera A, Quintero E, Hernández-Guerra M. Predictive factors for not undergoing RNA testing in patients found to have hepatitis C serology and impact of an automatic alert. J Viral Hepat 2019;26:1117-23. [PMID: 31077515 DOI: 10.1111/jvh.13122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
638 Zhu F, Wang Y, Xu Z, Qu H, Zhang H, Niu L, Xue H, Jing D, He H. Novel adeno‑associated virus‑based genetic vaccines encoding hepatitis C virus E2 glycoprotein elicit humoral immune responses in mice. Mol Med Rep 2019;19:1016-23. [PMID: 30569131 DOI: 10.3892/mmr.2018.9739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
639 Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015;8:298-312. [PMID: 26327920 DOI: 10.1177/1756283X15587481] [Cited by in Crossref: 73] [Cited by in F6Publishing: 23] [Article Influence: 10.4] [Reference Citation Analysis]
640 Serdari D, Kostaki EG, Paraskevis D, Stamatakis A, Kapli P. Automated, phylogeny-based genotype delimitation of the Hepatitis Viruses HBV and HCV. PeerJ 2019;7:e7754. [PMID: 31667012 DOI: 10.7717/peerj.7754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
641 Sedeno-Monge V, Vallejo-Ruiz V, Sosa-Jurado F, Santos-Lopez G. Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma. J Biosci 2017;42:509-21. [PMID: 29358564 DOI: 10.1007/s12038-017-9695-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
642 Chen M, Zheng F, Yuan G, Duan X, Rong L, Liu J, Feng S, Wang Z, Wang M, Feng Y, Zhou Q, Li J, Deng K, Li C, Xia J, Rao G, Zhou Y, Fu Y, Li YP. Development of an Infectious Cell Culture System for Hepatitis C Virus Genotype 6a Clinical Isolate Using a Novel Strategy and Its Sensitivity to Direct-Acting Antivirals. Front Microbiol 2018;9:2950. [PMID: 30564209 DOI: 10.3389/fmicb.2018.02950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
643 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS One. 2018;13:e0199760. [PMID: 29953518 DOI: 10.1371/journal.pone.0199760] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
644 Pérez AB, Chueca N, Macías J, Pineda JA, Salmerón J, Rivero-Juárez A, Hidalgo-Tenorio C, Espinosa MD, Téllez F, Von-Wichmann MÁ, Omar M, Santos J, Hernández-Quero J, Antón JJ, Collado A, Lozano AB, García-Deltoro M, Casado M, Pascasio JM, Selfa A, Rosales JM, De la Iglesia A, Arenas JI, García-Bujalance S, Ríos MJ, Bernal E, Martínez O, García-Herola A, Vélez M, Rincón P, García F. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort. PLoS One 2019;14:e0221231. [PMID: 31469856 DOI: 10.1371/journal.pone.0221231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
645 Gao Y, Nepal N, Jin SZ. Toll-like receptors and hepatitis C virus infection. Hepatobiliary Pancreat Dis Int 2021:S1499-3872(21)00155-7. [PMID: 34419367 DOI: 10.1016/j.hbpd.2021.07.011] [Reference Citation Analysis]
646 Yin P, Hong Z, Zhang L, Ke Y. Retromer localizes to autophagosomes during HCV replication. Virol Sin 2017;32:245-8. [PMID: 28429274 DOI: 10.1007/s12250-016-3914-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
647 Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses 2015;7:5018-39. [PMID: 26389941 DOI: 10.3390/v7092857] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 6.9] [Reference Citation Analysis]
648 Jacobson I, Zeuzem S, Flisiak R, Knysz B, Lueth S, Zarebska-Michaluk D, Janczewska E, Ferenci P, Diago M, Zignego AL, Safadi R, Baruch Y, Abdurakhmanov D, Shafran S, Thabut D, Bruck R, Gadano A, Thompson AJ, Kopit J, McPhee F, Michener T, Hughes EA, Yin PD, Noviello S. Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. World J Gastroenterol 2016; 22(12): 3418-3431 [PMID: 27022224 DOI: 10.3748/wjg.v22.i12.3418] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
649 Abdelkawy KS, El-Haggar SM, Ziada DH, Ebaid NF, El-Magd MA, Elbarbry FA. The effect of genetic variations on ribavirin pharmacokinetics and treatment response in HCV-4 Egyptian patients receiving sofosbuvir/daclatasvir and ribavirin. Biomed Pharmacother 2020;121:109657. [PMID: 31810127 DOI: 10.1016/j.biopha.2019.109657] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
650 Sahuc ME, Sahli R, Rivière C, Pène V, Lavie M, Vandeputte A, Brodin P, Rosenberg AR, Dubuisson J, Ksouri R, Rouillé Y, Sahpaz S, Séron K. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication. J Virol 2019;93:e02009-18. [PMID: 30842319 DOI: 10.1128/JVI.02009-18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
651 Agbowuro AA, Huston WM, Gamble AB, Tyndall JDA. Proteases and protease inhibitors in infectious diseases. Med Res Rev 2018;38:1295-331. [PMID: 29149530 DOI: 10.1002/med.21475] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 10.6] [Reference Citation Analysis]
652 Kumar A, Rajput MK, Paliwal D, Yadav A, Chhabra R, Singh S. Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries. Indian J Med Res 2018;147:445-55. [PMID: 30082568 DOI: 10.4103/ijmr.IJMR_1850_16] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
653 Barman B, Bora K, Lynrah KG, Lyngdoh WV, Jamil M. Hepatitis C virus and its genotypes in chronic liver disease patients from Meghalaya, Northeast India. Indian J Med Microbiol 2018;36:376-80. [PMID: 30429390 DOI: 10.4103/ijmm.IJMM_17_371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
654 Liu CH, Liu CJ, Su TH, Yang HC, Hong CM, Tseng TC, Chen PJ, Chen DS, Kao JH. Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. PLoS One 2018;13:e0209299. [PMID: 30576344 DOI: 10.1371/journal.pone.0209299] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
655 Carnero E, Fortes P. HCV infection, IFN response and the coding and non-coding host cell genome. Virus Res 2016;212:85-102. [PMID: 26454190 DOI: 10.1016/j.virusres.2015.10.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
656 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
657 Abdurakhmanov E, Øie Solbak S, Danielson UH. Biophysical Mode-of-Action and Selectivity Analysis of Allosteric Inhibitors of Hepatitis C Virus (HCV) Polymerase. Viruses 2017;9:E151. [PMID: 28621755 DOI: 10.3390/v9060151] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
658 Ji D, Chen GF, Wang C, Wang YD, Shao Q, Li B, Zhao J, You SL, Hu JH, Liu JL, Niu XX, Chen J, Lu L, Wu V, Lau G. Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients. Hepatol Int. 2016;10:789-798. [PMID: 27443347 DOI: 10.1007/s12072-016-9755-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
659 Mahmud S, Chemaitelly HS, Kouyoumjian SP, Al Kanaani Z, Abu-Raddad LJ. Key associations for hepatitis C virus genotypes in the Middle East and North Africa. J Med Virol 2020;92:386-93. [PMID: 31663611 DOI: 10.1002/jmv.25614] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
660 Tran AN, Lim JK. Hepatitis C: How Good Are Real-Life Data and Do Generics Work. Gastroenterol Clin North Am 2020;49:279-99. [PMID: 32389363 DOI: 10.1016/j.gtc.2020.01.006] [Reference Citation Analysis]
661 Pybus OG, Tatem AJ, Lemey P. Virus evolution and transmission in an ever more connected world. Proc Biol Sci 2015;282:20142878. [PMID: 26702033 DOI: 10.1098/rspb.2014.2878] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 14.0] [Reference Citation Analysis]
662 Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. Springerplus 2016;5:1557. [PMID: 27652130 DOI: 10.1186/s40064-016-3224-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
663 Weil C, Nwankwo C, Friedman M, Kenet G, Chodick G, Shalev V. Epidemiology of hepatitis C virus infection in a large Israeli health maintenance organization: Epidemiology of Hepatitis C in a large Israeli HMO. J Med Virol 2016;88:1044-50. [DOI: 10.1002/jmv.24426] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
664 Weil C, Mehta D, Koren G, Pinsky B, Samp JC, Chodick G, Shalev V. Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider. J Viral Hepat 2018;25:144-51. [PMID: 28984012 DOI: 10.1111/jvh.12800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
665 Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 2016;36:971-6. [PMID: 26786792 DOI: 10.1111/liv.13069] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
666 El-Shabrawi M, Hassanin F. Paediatric hepatitis C virus infection and its treatment: Present, past, and future. Arab J Gastroenterol 2019;20:163-74. [PMID: 31585703 DOI: 10.1016/j.ajg.2019.09.003] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
667 Chen M, Xu Y, Li N, Yin P, Zhou Q, Feng S, Wu T, Wei L, Wang H, Fu Y, Li Y. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus. Journal of General Virology 2021;102. [DOI: 10.1099/jgv.0.001704] [Reference Citation Analysis]
668 Bien J, Davulcu A, Delmonte AJ, Fraunhoffer KJ, Gao Z, Hang C, Hsiao Y, Hu W, Katipally K, Littke A, Pedro A, Qiu Y, Sandoval M, Schild R, Soltani M, Tedesco A, Vanyo D, Vemishetti P, Waltermire RE. The First Kilogram Synthesis of Beclabuvir, an HCV NS5B Polymerase Inhibitor. Org Process Res Dev 2018;22:1393-408. [DOI: 10.1021/acs.oprd.8b00214] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
669 Rowan PJ. What psychiatric screening and monitoring might be needed with the new generation of hepatitis C treatments? World J Virology 2015; 4(1): 13-16 [PMID: 25674513 DOI: 10.5501/wjv.v4.i1.13] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
670 Hull MW, Yoshida EM, Montaner JS. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients. Curr Infect Dis Rep 2016;18:22. [PMID: 27357277 DOI: 10.1007/s11908-016-0527-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
671 Youngberg S, Brandt E, Barve A, Machineni S, Jones CT, Dabovic K, Jones CL, Colvin RA. A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers. J Drug Assess 2018;7:66-74. [PMID: 30370176 DOI: 10.1080/21556660.2018.1535438] [Reference Citation Analysis]
672 Kartashev V, Döring M, Nieto L, Coletta E, Kaiser R, Sierra S, Guerrero A, Stoiber H, Paar C, Vandamme A, Nevens F, Ranst MV, Cuypers L, Braun P, Ehret R, Obermeier M, Schneeweiss S, Scholten S, Römer K, Isernhagen K, Qurashi N, Heger E, Knops E, Neumann-fraune M, Timm J, Walker A, Lübke N, Wedemeyer H, Wiesch JSZ, Lütgehetmann M, Polywka S, Däumer M, Hoffmann D, Protzer U, Marascio N, Foca A, Liberto M, Barreca G, Galati L, Torti C, Pisani V, Perno C, Ceccherini-silberstein F, Cento V, Ciotti M, Zazzi M, Rossetti B, Luca A, Caudai C, Mor O, Devaux C, Staub T, Araujo F, Gomes P, Cabanas J, Markin N, Khomenko I, Govorukhina M, Lugovskaya G, Dontsov D, Mas A, Martró E, Saludes V, Rodríguez-frías F, García F, Casas P, Iglesia ADL, Alados J, Pena-lópez M, Rodríguez M, Galán J, Suárez A, Cardeñoso L, Guerrero M, Vegas-dominguez C, Blas-espada J, García R, García-bujalance S, Benítez-gutiérrez L, Mendoza CD, Montiel N, Santos J, Viciana I, Delgado A, Martínez-sanchez P, Fernández-alonso M, Reina G, Trigo M, Echeverría M, Aguilera A, Navarro D, Bernal S, Lozano M, Fernández-cuenca F, Orduña A, Eiros J, Lejarazu ROD, Martínez-sapiña A, García-díaz A, Haque T. New findings in HCV genotype distribution in selected West European, Russian and Israeli regions. Journal of Clinical Virology 2016;81:82-9. [DOI: 10.1016/j.jcv.2016.05.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
673 Ohya K, Kawaoka T, Imamura M, Morio K, Nakahara T, Murakami E, Yamauchi M, Hiramatsu A, Tsuge M, Aikata H, Chayama K. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection. Intern Med. 2020;59:941-944. [PMID: 31813916 DOI: 10.2169/internalmedicine.3824-19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
674 Cha RR, Lee SS, Lee CM, Ji SB, Jung HC, Cho HC, Kim JJ, Lee JM, Kim HJ, Ha CY, Kim HJ, Kim TH, Jung WT, Lee OJ. Clinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study. Medicine (Baltimore) 2016;95:e2755. [PMID: 26871824 DOI: 10.1097/MD.0000000000002755] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
675 Hussein NR, Tunjel I, Basharat Z, Taha A, Irving W. The treatment of HCV in patients with haemoglobinopathy in Kurdistan Region, Iraq: a single centre experience. Epidemiol Infect 2016;144:1634-40. [PMID: 27125573 DOI: 10.1017/S0950268815003064] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
676 de Souza SL, Vidal LL, Ramos J, Cardoso CC, Coelho HSM, Villela-Nogueira CA, Perez RM, Soares MA, Santos AF. Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles of IL28B and IL10 Single Nucleotide Polymorphisms. Biomed Res Int 2018;2018:2931486. [PMID: 29888255 DOI: 10.1155/2018/2931486] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
677 Te H, Doucette K. Viral hepatitis: Guidelines by the American Society of Transplantation Infectious Disease Community of Practice. Clin Transplant 2019;33. [DOI: 10.1111/ctr.13514] [Cited by in Crossref: 23] [